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Abstract 
Naringenin and nobiletin are naturally-derived citrus flavonoids that have significant lipid-
lowering and insulin sensitizing effects in vitro and in vivo. In murine models of obesity, 
metabolic dysfunction and atherogenesis, these flavonoids protect against the development of 
cardiometabolic disease. However, the ability of naringenin and nobiletin to reverse existing 
metabolic dysfunction and atherosclerosis has not been investigated.  
The purpose of this thesis was to investigate the ability of the citrus flavonoids, naringenin 
and nobiletin, to reverse obesity, metabolic syndrome and atherosclerosis in two different 
mouse models of atherosclerosis regression. The first chapter demonstrates in Ldlr-/- mice 
with diet-induced obesity, metabolic syndrome and atherosclerosis, that the addition of either 
naringenin or nobiletin to the high-fat diet completely reverses obesity and insulin resistance, 
and improves hyperlipidemia, hepatic steatosis and monocytosis. This leads to an 
improvement in lesion morphology, consistent with regression but no attenuation in plaque 
size. The second chapter built upon these studies by looking at the effects of naringenin in a 
more aggressive mouse model of atherosclerosis regression. Ldlr-/- mice with diet-induced 
metabolic dysfunction and atherosclerosis were intervened with chow diet supplemented with 
naringenin. Naringenin enhanced the reversal of obesity, hyperlipidemia, insulin resistance 
and monocytosis compared to intervention with chow alone. Lesions in the naringenin-
treated mice were smaller, comprised of less macrophages and had more characteristics of 
increased lesion stability compared to lesions in mice intervened with chow alone. The third 
chapter further investigated the effects of naringenin in the absence of high-fat feeding. In 
lean, pair-fed Ldlr-/- mice, naringenin supplementation reduced adiposity, enhanced insulin 
sensitivity and lowered plasma lipids. Mechanistically, these metabolic improvements were 
due in part to enhanced energy expenditure and increased hepatic fatty acid oxidation, in the 
absence of obesity or high-fat feeding. 
In summary, the studies in this thesis provide evidence and molecular insight into how 
treatment with citrus flavonoids can reverse metabolic dysfunction and contribute to the 
regression of atherosclerosis in a mouse model. Furthermore, this thesis highlights the 
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therapeutic utility of naringenin and nobiletin, and further underscores their importance in 
future therapeutic development for metabolic syndrome and atherosclerosis.  
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Chapter 1 * 
1 Thesis Topics Review 
1.1 General Introduction 
Cardiovascular disease represents the leading cause of morbidity and mortality in 
Western society (Roth et al., 2015). The most prevalent underlying cause of 
cardiovascular disease events such as stroke and myocardial infarction is atherosclerosis. 
The majority of patients with atherosclerosis present without overt clinical symptoms for 
many decades. Furthermore, 50% of patients have a life-ending event without prior 
knowledge of their disease (Go et al., 2014). Atherosclerosis is a progressive, lipid and 
inflammatory-driven disease characterized by growth of fat-engorged plaques in the 
vessel wall of medium-sized arteries (Moore and Tabas, 2011). As these plaques grow 
into the arterial lumen, they can occlude blood flow, or rupture resulting in thrombi 
formation, both resulting in acute myocardial infarction or stroke (Libby et al., 2011). 
Major risk factors for the development of atherosclerosis include age, hypertension, 
smoking, obesity, diabetes and increased blood concentrations of cholesterol and 
triglycerides (Libby et al., 2011). Despite the success of pharmacological treatments, 
most notably statin drugs, the prevalence of cardiovascular disease in Canadians 
continues to rise (Lee et al., 2009). Many patients are unable to reach lipid-lowering 
targets with statin therapy alone and there are a number of patients who are statin-
intolerant, or who experience significant side effects with statin therapy. Furthermore, 
statins have no effects on other atherogenic dyslipidemias such as elevated triglyceride-
rich lipoproteins and reduced high-density lipoproteins (Musunuru, 2010). Some 
complimentary drugs to statin therapy have been developed including ezetimibe, fibrates, 
niacin, bile acid sequestrants and antibodies to proprotein convertase subtilisin/kexin type 
                                                
*a version of the atherosclerosis regression section of this chapter is published: 
Burke, A.C., and Huff, M.W. (2018). Regression of atherosclerosis: lessons learned from genetically 
modified mouse models. Curr Opin Lipidol 29, 87-94. 
No copyright license required for reprint for dissertation/thesis  
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9 (PCSK9), but only ezetimibe is routinely prescribed. This may be due to negative side 
effects or little additive effect on top of statin therapy. Additionally, cardiovascular 
disease drug trials have one of the lowest success rates of the major medical fields (Hay 
et al., 2014). Furthermore, current therapeutic strategies do little to improve other 
cardiometabolic risk factors such as obesity, insulin resistance to type 2 diabetes, and 
hypertriglyceridemia. Consequently, novel treatment strategies are highly sought after.  
The majority of pre-clinical drug development for metabolic syndrome and 
atherosclerosis has focused on animal models of progression where treatment is initiated 
at the same time as the disease, especially in atherosclerosis studies (Baylis et al., 2017). 
We have learned a lot about how therapeutics affect disease progression and development 
from these prevention style studies. However, many therapeutic strategies that were 
developed using this model failed in clinical trials. Furthermore, when humans are treated 
for these diseases, the majority are treated after disease onset. This suggests that it would 
be advantageous to pursue pre-clinical therapeutic studies using an intervention-style 
model, after disease has been established. 
This thesis focuses on the therapeutic potential of two citrus-derived flavonoids, 
naringenin (from grapefruit) and nobiletin (from tangerines) and their ability to regulate 
lipid metabolism, insulin signaling and energy metabolism, to reverse pre-existing 
obesity, metabolic syndrome and atherosclerosis in an intervention model.  
1.2 Dyslipidemia and Cardiovascular Disease 
It has been over a hundred years since Anitschkow and Chalatow showed that dietary 
cholesterol induced atherosclerosis in rabbits, the first experimental link between 
cholesterol and cardiovascular disease (Goldstein and Brown, 2015). Clinical studies 
confirmed this finding in humans many years later, showing that a 2-fold increase in 
serum cholesterol levels correlated with a 7-fold increase in death due to cardiovascular 
disease (Neaton and Wentworth, 1992). Cholesterol is an essential steroid molecule that 
is required for the synthesis of steroid hormones and bile acids, and is an essential 
component of myelin sheaths that surround nerve axons (Goldstein and Brown, 2009). 
Cholesterol is also an important component of the plasma membrane, where it maintains 
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a barrier and serves to interact between cells and the environment, affects fluidity, and is 
a component of lipid rafts within the membrane, structures which are important in 
organizing signaling molecules.  
Cells acquire cholesterol from a number of sources including de novo cholesterol 
biosynthesis and uptake of cholesteryl ester-rich low-density lipoproteins (LDL) in the 
peripheral tissues and cholesteryl ester rich high-density lipoproteins (HDL) in the liver. 
One of the earliest studies investigating cholesterol biosynthesis showed that in mice 
sealed in bottles, the cholesterol content of mice fed a cholesterol-free diet increased, and 
when mice under the same conditions were fed cholesterol, there was no longer an 
increase in cholesterol (Goldstein and Brown, 2015). This showed that not only can 
animals synthesize cholesterol, but that cholesterol biosynthesis is inhibited by dietary 
cholesterol, the first description of cholesterol feedback.  
The development of ultracentrifugation drove the discovery of cholesterol-carrying 
lipoproteins in the plasma and contributed to the evidence that elevated LDL-cholesterol 
caused cardiovascular disease. Specifically that heart attack patients had significantly 
elevated plasma LDL compared to healthy controls (Gofman et al., 1954). The 
pathogenicity of LDL and the variation in plasma levels, as well as the fact that 
cholesterol biosynthesis was a regulated process motivated studies into investigating 
cholesterol biosynthesis inhibitors as a treatment. 3-hydroxy-3-methyl-glutaryl-coenzyme 
A (HMG-CoA) reductase is the first, rate-limiting enzyme in cholesterol biosynthesis and 
is responsible for the conversion of HMG-CoA to mevalonate. It is early in the 
cholesterol biosynthetic pathway, making it an attractive target. The first HMG-CoA 
reductase inhibitor discovered was a natural compound isolated from Penicillium 
citrinum called compactin (Tobert, 2003). This discovery eventually led to the discovery 
of lovastatin, the first HMG-CoA reductase inhibitor to be delivered clinically and the 
first of a class of drugs called statins. The discovery of statins has been essential in 
demonstrating the relationship between cholesterol-lowering and cardiovascular disease 
protection (Mills et al., 2011). Despite overwhelming evidence from large-scale clinical 
trials that statins reduce morbidity and mortality from cardiovascular disease, many 
people with normal LDL-cholesterol levels still develop cardiovascular disease 
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(Musunuru, 2010). In addition to high plasma LDL-cholesterol, atherogenic 
dyslipidemias can be characterized by increased plasma triglyceride-rich very low-
density lipoproteins (VLDL), and reduced HDL, neither of which are strongly affected by 
statin therapy. Therefore, additional therapeutic strategies are needed to mitigate these 
additional risk factors. 
Elevated LDL-cholesterol is a well-known and undebated risk factor for cardiovascular 
disease. However, the role for triglycerides in cardiovascular disease is still debated and 
not fully understood (Reiner, 2017; Talayero and Sacks, 2011). Hypertriglyceridemia is 
associated with high rates of VLDL production and reduced clearance, resulting in an 
accumulation of VLDL remnants and intermediate density lipoproteins (IDL) in the 
circulation (Reiner, 2017). Hypertriglyceridemia most commonly occurs in patients with 
metabolic syndrome or type 2 diabetes, and these patients have an increased risk of 
cardiovascular disease, even if they have met plasma LDL-cholesterol lowering targets 
(Ginsberg and MacCallum, 2009). Each of these atherogenic lipoproteins, VLDL, IDL 
and LDL, harbor one apoB100 molecule, which suggests apoB levels in the circulation 
might make a better metric of cardiovascular disease risk. Consequently, Canadian 
guidelines have included apoB measurements in cardiovascular disease risk assessment 
(Anderson et al., 2016). Furthermore, mipomersen, an antisense oligonucleotide that 
targets apoB mRNA for degradation resulting in no protein translation, reduced VLDL 
cholesterol, LDL cholesterol and triglycerides in patients with the difficult-to-treat 
hyperlipidemic disease, familial hypercholesterolemia (Raal et al., 2010). Unfortunately, 
a significant side effect of mipomersen treatment is hepatic fat accumulation resulting in 
liver damage, limiting the usage of this drug to patient populations with severe 
hyperlipidemia. This further strengthens the hypothesis that reducing apoB-containing 
lipoproteins represents a promising therapeutic strategy. 
HDL levels have also been correlated with cardiovascular disease risk. Repeatedly, 
evidence shows that HDL-cholesterol is cardio-protective (Rader and Hovingh, 2014). 
However, the causal properties of HDL consistent with atheroprotection have remained 
somewhat elusive. In one clinical trial increasing HDL-cholesterol through inhibition of 
cholesterol ester transfer protein (CETP) reduced cardiovascular disease (Bowman et al., 
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2017). However, in other clinical trials, CETP inhibition resulted in increased 
cardiovascular disease events and mortality, suggesting that the cardio-protective effects 
of HDL may not be as simple as increasing HDL-cholesterol (Barter et al., 2007). This 
fueled a shift in the HDL field to enhancing HDL function as a therapeutic target, which 
cannot be assessed through measuring HDL-cholesterol content (Rader and Hovingh, 
2014). Therefore, HDL-targeted therapeutic strategies have turned to enhancing 
cholesterol efflux from macrophages and promoting reverse cholesterol transport. 
In summary, therapeutic interventions that lower plasma LDL, decrease the production of 
apoB-containing lipoproteins, increase the uptake or catabolism of apoB-containing 
lipoproteins or increase the capacity of high density lipoproteins to promote reverse 
cholesterol transport may prove effective in further reducing cardiovascular disease. 
1.3 Lipoprotein Metabolism 
Whole body lipid homeostasis is maintained through a balance of uptake of exogenous 
fatty acid and cholesterol, and endogenous synthesis of these molecules, as well as the 
trafficking of these lipids through the body in macromolecular complexes within the 
circulation called lipoproteins.  
1.3.1 Classes of Lipoproteins 
Lipoproteins are soluble macromolecules made up of protein and lipid constituents to 
facilitate the transport of insoluble lipids throughout the body (Hegele, 2009). 
Lipoproteins are classified by density and each lipoprotein is made up of different lipids, 
and apolipoproteins, which are proteins that bind lipids (Table 1.1). Fundamentally, 
lipoproteins are comprised of a hydrophobic core containing triglycerides and cholesteryl 
esters, encased in a hydrophilic phospholipid monolayer containing free cholesterol and 
associated apolipoproteins. Apolipoproteins help provide structural support, but are also 
important in mediating the interaction of lipoproteins with cell surface receptors and in 
determining the rate of lipoprotein catabolism within the circulation. 
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Table 1.1 Lipoprotein Classifications  
Nature Reviews | Drug Discovery 
Apoprotein
Apoprotein 
Phospholipid 
Unesterified 
cholesterol 
Polar 
surface coat 
Apoprotein 
Cholesterol
ester
Triacylglyceride
Nonpolar
lipid core
composed primarily of cholesterol and cholesteryl esters. 
High density lipoproteins (HDLs) are the smallest of the 
lipoprotein particles and have the highest protein content. 
The main physiological role of HDL is in the transport 
of unesterified cholesterol from the peripheral tissues to 
the liver (FIG. 2).
Dyslipidaemias
In a normolipidaemic plasma profile, the distribution of 
triglycerides, cholesterol and proteins is optimal for the 
dissemination of hydrophobic lipids through the aque-
ous milieu. When this profile is perturbed, the resulting 
changes are not only detrimental to the health of an 
individual, but also provide an altered environment for 
drug transport and delivery. A disruption in the normal 
distribution of lipoprotein classes within the plasma 
is referred to as dyslipidaemia. In Western societies, 
a sedentary lifestyle contributes significantly to the 
growing incidence of hyperlipidaemia, a diagnostic 
criterion of metabolic disease. The relationship between 
dyslipidaemia and a comorbid disease state is not always 
clearly delineated; in many cases, it is thought that the 
plasma lipoprotein components might be a contributing 
factor rather than a result of the primary disease. For the 
purpose of this discussion we can distinguish two types of 
dyslipidaemias: disease-associated dyslipidaemias, which 
cover a broad range of diverse disease states that exhibit 
co-morbidity with altered plasma lipid levels, and drug-
induced dyslipidaemias that are associated with pharma-
ceutical therapies eliciting an unwanted secondary effect 
on the plasma lipoprotein levels (TABLE 3).
Disease-associated dyslipidaemia. Elevated plasma 
triglycerides and low HDL cholesterol are diagnostic 
markers for metabolic syndrome, which affects 25% of 
the North American population (a percentage that con-
tinues to increase). In addition to the concern over cardio-
vascular health, there is significant evidence indicating 
that metabolic syndrome confers a greater risk for other 
disease states. For example, patients with schizophrenia 
are four times more likely to have metabolic syndrome 
than the general population3. In bipolar disorder and 
schizophrenia, the estimated prevalence of dyslipidaemia 
is 23 to 25% respectively4. World-wide, the prevalence of 
metabolic syndrome is increasing in parallel with the inci-
dence of breast cancer, and low serum HDL-C levels have 
been recognized as an independent predictor of increased 
breast cancer risk in overweight or obese postmenopausal 
Figure 1 | General structure of a lipoprotein. The core is primarily composed of 
triacylglycerides and cholesterol esters. They are encased by a phospholipid monolayer. 
Apolipoproteins embedded in the phospholipid layer confer structural and functi nal 
properties to the molecule. Figure modified, with permission, from REF. 173  (1990) 
Gower Medical Publishing. 
Table 1 | Characteristics of apolipoproteins found in human plasma 
Apolipo-
protein
Plasma 
concentration 
(mg per dL)
Present on 
chylomicrons
Distribution into 
lipoproteins during 
fasted state (%)
Molecular 
weight 
(kDa)
Function
VLDL LDL HDL
ApoA1 130 Transiently 0 0 100 29.0 LCAT activator; substrate for 
SRB1
ApoA2 40 No 0 0 100 17.4 Structure; hepatic lipase 
inhibitor; substrate for SRB1
ApoA4 15 Yes 0 0 0 44.5 LCAT activator
ApoB48 Transient Exclusively 0 0 0 241 Chylomicron structure
ApoB100 80–250 No 6–12 88–94 0 512 Structure; receptor ligand
ApoC1 3–6 No 3 0 97 6.6 LCAT activator
ApoC2 3–12 No 40 0 60 9.0 Lipoprotein lipase activator
ApoC3 12 No 30 10 60 9.0 Hepatic lipase inhibitor
ApoD 10–12 No 0 0 100 19.0 Many postulated
ApoE 5–7 Yes 40 10 50 34.0 Substrate for LDLr; chylomicron 
remnant receptor
Qualitative data concerning chylomicrons has been included, but all quantitative data concerning distribution is from fasted 
plasma analyses123–126. HDL, high density lipoproteins; LCAT, lecithin–cholesterol acyltransferase; LDL, low density lipoprotein; 
LDLr, low density lipoprotein receptor; SRB1, scavenger receptor B1; VLDL, very low density lipoprotein. 
R E V I E W S
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Wasan, K.M., Brocks, D.R., Lee, S.D., Sachs-Barrable, K., and Thornton, S.J. (2008). Impact of 
lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for 
drug discovery. Nat Rev Drug D cov 7, 84-99.
(Permission to reproduce obtained)
Lipoprotein 
Class
Composition (% 
by weight)
Source of 
Production
Associated 
Apolipoproteins
Primary 
Function
Chylomicrons
80-95% TG
3-6% PL
1-3% FC
2-4% CE
1-2% Protein
Intestine
AI, AII, AIV, AV, 
B48, CI, CII, CIII, 
E
Delivery of 
dietary 
triglycerides
Very Low Density 
Lipoproteins 
(VLDL)
45-65% TG
15-20% PL
4-8% FC
16-22% CE
6-10% Protein
Liver AV, B100, CI, CII, CIII, E
Delivery of 
endogenous 
triglycerides
Intermediate 
Density 
Lipoproteins 
(IDL)
24-30% TG
25-27% PL
8-10% FC
32-35% CE
10-12% Protein
VLDL Catabolism B100, CI, CII, CIII, E
Delivery of 
endogenous 
triglycerides and 
cholesterol
Low Density 
Lipoproteins 
(LDL)
4-8% TG
18-24% PL
6-8% FC
45-50% CE
18-22% Protein
VLDL/IDL 
Catabolism B100
Delivery of 
Cholesterol
Lipoprotein(a)
4-8% TG
18-24% PL
6-8% FC
45-50% CE
18-22% Protein
Modification of 
LDL B100, (a) Unknown
High Density 
Lipoproteins 
(HDL)
2-7% TG
26-32% PL
3-5% FC
15-20% CE
45-55% Protein
Liver and 
intestine 
secretion of 
apoA1
AI, AII, AIV, AV, 
CI, CII, CIII, E, M
Reverse 
cholesterol 
transport from the 
periphery to the 
liver
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Chylomicrons are the largest lipoprotein and are produced by the intestinal enterocyte to 
transport dietary lipids. They are comprised of one apoB48 backbone and predominantly 
carry triglycerides (Table 1.1). VLDL are next largest and are produced by the liver. 
They are made up of one apoB100 molecule and predominantly carry triglycerides.  
Catabolism of triglycerides within VLDL particles results in the formation of 
intermediate IDL, which carries approximately equal parts triglyceride and cholesteryl 
ester. Upon further triglyceride catabolism, and protein and lipid exchange with other 
lipoproteins, IDL particles form cholesteryl ester-rich LDL. Cholesteryl ester is also 
carried by HDL, which are the smallest lipoproteins and are important in the process of 
reverse cholesterol transport.  
1.3.2 Exogenous Lipoprotein Metabolism 
Lipoprotein metabolism can be classified into exogenous or endogenous pathways 
depending on whether the lipids are derived from dietary sources (exogenous) or from the 
liver through de novo lipogenesis (endogenous) (Figure 1.1). In the exogenous pathway, 
dietary lipids are absorbed in the small intestine. Within the duodenum, dietary 
triglycerides are hydrolyzed to monoglycerides and free fatty acids by pancreatic lipase 
and emulsified with cholesterol, plant sterols, fat soluble vitamins and bile acids to form 
mixed micelles. Lipid absorption occurs at the brush border of the intestinal villi in the 
jejunum. Cholesterol is absorbed into the intestinal enterocyte via the apically located 
sterol transporter protein, Niemann-Pick C1-Like1 (NPC1L1) (Huff et al., 2006) whereas, 
free fatty acids and monoglycerides are absorbed via passive diffusion. Upon 
internalization, these molecules are re-esterified into triglycerides by the enzymes, 
monoacyglycerol acyltransferase (MGAT) and diacylglycerol acyltransferase (DGAT). 
The apoB48 backbone of the chylomicron is derived from editing the full length APOB 
mRNA by the apoB mRNA editing enzyme (ABOBEC1), which deaminates cytosine at 
position 6666 to an uracil resulting in the insertion of a stop codon in the apoB100 
protein. This truncates the apoB100 protein, resulting in a protein that is 48% of the 550 
kDa apoB100 protein (Chen et al., 1987). In humans, APOBEC1 is exclusively expressed 
in the intestine, whereas in mice it is expressed in both the intestine and liver (Greeve et 
al., 1993). ApoB48 is cotranslationally lipidated with mostly triglycerides, and some  
8 
 
 
 
 
In exogenous lipoprotein metabolism, dietary triglycerides and cholesterol are packaged 
onto apoB48 within the intestinal enterocyte to form chylomicrons that are released into 
the lymphatics, which subsequently enter the circulation. ApoC-II on the chylomicron 
activates lipoprotein lipase (LPL), which hydrolyzes triglycerides to free fatty acids 
(FFA), allowing for their uptake into peripheral tissues (adipose/muscle). The remnant 
chylomicron, depleted of triglycerides, is removed from the circulation by hepatic LDLR 
or LRP-mediated endocytosis. The remnant chylomicron is pro-atherogenic. In 
endogenous lipoprotein metabolism, newly synthesized and dietary lipids are packaged 
onto apoB100 within the hepatocyte to form very low-density lipoproteins (VLDL). 
These particles also undergo hydrolysis by LPL, forming IDL. The IDL particle is pro-
atherogenic, but also participates in lipid exchange with HDL, exchanging triglycerides 
for cholesteryl ester, thereby becoming LDL. LDL can be taken up by the liver or 
peripheral tissue via the LDLR. LDL can also be modified by lipoprotein(a). Both LDL 
and lipoprotein(a) are pro-atherogenic. HDL is intrinsic to reverse cholesterol transport, 
in which cholesterol from peripheral tissue is removed via efflux to HDL. HDL is cleared 
by scavenger receptor B1 (SR-B1) in the liver, where cholesterol is converted to bile 
acids for excretion. 
  
Figure 1.1 Exogenous and Endogenous Lipoprotein Metabolism 
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the intima of susceptible arteries (Figure 2). LDL then aggregates and/or is 
readily oxidised, resulting in an inflammatory response as well as foam cell 
formation in both macrophages and smooth muscle cells. This process leads 
to premature atherosclerosis in patients with hypercholesterolaemia, particu-
larly those with FH.
2.2  Very-Low-Density Lipoprotein
Another dyslipidaemia that predisposes to premature atherosclerosis is famil-
ial combined hyperlipidaemia (FCH) (Sahebkar and Watts, 2013a). FCH is the 
most common form of inherited dyslipidaemia and is genetically heteroge-
neous, resulting from variations in multiple genes involved in the metabolism 
and clearance of plasma lipoproteins (Chapter 15). Combined hyperlipidaemia 
is often accompanied by additional metabolic abnormalities, including adipose 
tissue dysfunction, increased fatty acid flux to the liver and insulin resistance 
(Chapter 19). The metabolic phenotype of this dyslipidaemia is hepatic overpro-
duction of very-low-density lipoprotein (VLDL), elevated plasma VLDL tria-
cylglycerol (TAG), apoB and small dense LDL (Figure 2). These lipoproteins 
also readily accumulate within the arterial intima, eliciting inflammatory and 
other cellular responses linked to atherogenesis.
Intestine
LDLR
Peripheral Tissues
IDL
Capillaries
Lipolysis (LPL)
suonegodnEsuonegoxE
TAG/CE
LDL
CE
CE
CE
cholesterol
CETP
Diet
cholesterol
triglycerides
apoB-48
apoE
apoC-III
Chylomicron
TAG/CE
apoC-II
cholesterol
bile acids
Bile
Chylo-
Remnant
TAG/CE
apoE
apoB-48
Artery
Plaque
Artery
Plaque
apoE
apoB-100
apoC-III
Capillaries
Lipolysis (LPL)
apoC-II
apoE
apoB-100
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LDLR
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HTGL
SR-B1
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FIGURE 2 A schematic of exogenous and endogenous lipoproteins involved in atherogen-
esis. Elevated low-density lipoproteins (LDL) promote atherosclerosis as typified by patients with 
familial hypercholesterolaemia. Very-low-density lipoproteins (VLDL), their remnants (IDL) and 
chylomicron remnants also amplify atherogenesis. Lp(a) readily enters the arterial intima and pro-
motes atherosclerosis. Low levels of HDL or dysfunctional HDL are unable to promote reverse 
cholesterol transport from lesion macrophages, contributing to the formation of foam cells.
Huff, M.W., Daugherty, A. and Lu, H. (2016). Chapter 18 – Atherosclerosis. In Biochemistry of Lipids, 
Lipoproteins and Membranes. (Waltham: Elsevier), p  520-548.
(Permission to reproduce obtained)
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cholesteryl ester and phospholipids by microsomal transfer protein (MTP) within the 
endoplasmic reticulum (ER), forming the nascent chylomicron, which are secreted into 
the lymphatics and subsequently the circulation. Within the lymphatics and circulation, 
nascent chylomicrons acquire additional apolipoproteins, apoE, apoC-II, and apoC-III 
from HDL, which are required for appropriate catabolism of chylomicron particles. 
ApoC-III prevents premature catabolism of the nascent chylomicron by interfering with 
binding of apoB or apoE to hepatic receptors, and through inhibition of lipoprotein lipase 
(Norata et al., 2015). ApoC-II is a cofactor required for activity of lipoprotein lipase, an 
enzyme secreted by parenchymal cells in the adipose, heart and skeletal muscle and is 
active on the luminal surfaces of capillary endothelial cells. Lipoprotein lipase hydrolyzes 
chylomicron-derived triglycerides to free fatty acids for uptake into tissues for re-
esterification and storage. The remnant particle, depleted of triglycerides, is removed 
from the circulation by hepatic LDL-receptors (LDLR) and LDLR related protein (LRP), 
both of which recognize ApoE as a ligand (Cooper, 1997).   
1.3.3 Endogenous Lipoprotein Metabolism 
Endogenous lipoprotein metabolism encompasses the recycling of dietary lipids and de 
novo cholesterol and triglyceride synthesis in the liver. The majority of circulating 
cholesterol is produced de novo in hepatocytes, making the liver central to cholesterol 
homeostasis and endogenous lipoprotein metabolism (Figure 1.1).  
1.3.3.1 Secretion of ApoB100 Lipoproteins 
Hepatic triglyceride and cholesterol are required for the formation and secretion of VLDL 
particles. Each VLDL particle contains one apoB100. Similar to chylomicron biogenesis, 
apoB100 is cotranslationally lipidated with triglycerides, cholesteryl ester and 
phospholipids by MTP within the ER of hepatocytes, with triglycerides being the major 
lipid core constituent of the nascent VLDL particle. These triglycerides are 
predominantly derived from de novo synthesis or cytoplasmic lipid droplet stores. 
Following translation, the particle is bulk-loaded with more lipids, again via MTP in the 
smooth ER. The lipid-loaded particle then exits the ER and is trafficked to the cis Golgi 
apparatus via VLDL-transport vesicles, where it undergoes further maturation (Tiwari 
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and Siddiqi, 2012). The mature VLDL particle is then secreted, via COPII-coated 
secretory vesicles, into the circulation, where it picks up apoC-II, apoC-III and apoE. 
1.3.3.2 Uptake and Clearance of ApoB-Containing Lipoproteins 
Following secretion, VLDL particles undergo lipolysis by lipoprotein lipase, in a similar 
manner to chylomicron lipolysis. The triglyceride-rich core of the particle is depleted, 
resulting in the formation of VLDL remnant particles. Within the circulation, CETP 
facilitates the transfer of cholesteryl ester from HDL particles to the VLDL particle in 
exchange for triglycerides from the VLDL particle. In mice, CETP is not expressed and 
therefore, mice carry the majority of their plasma cholesterol in HDL particles (Guyard-
Dangremont et al., 1998). Following enrichment of cholesteryl esters, the VLDL remnant 
is known as IDL. IDL is further depleted in triglyceride through lipolysis by the enzyme, 
hepatic lipase, and undergoes one of two metabolic fates. IDL can be cleared by hepatic 
LDLR binding of associated apoE. Further depletion of triglycerides results in 
dissociation of apoE and this cholesteryl ester-enriched lipoprotein is known as LDL. 
LDL carries the majority of cholesterol in the circulation and is the major atherogenic 
lipoprotein in humans. It contains one associated apolipoprotein, apoB100, which allows 
it to be cleared by the LDLR. 
1.3.3.3 The LDL-Receptor (LDLR) 
The LDLR is a cell surface receptor that mediates the endocytosis of apoB and apoE-
containing lipoproteins including LDL, VLDL, IDL and chylomicron remnants. The 
LDLR is a glycoprotein that is 839 residues consisting of five domains. These are: the 
ligand binding domain, the epidermal growth factor domain, the O-linked sugar domain, 
the membrane-spanning domain and the cytoplasmic tail domain. Lipoprotein clearance 
mediated by the LDLR involves receptor-mediated endocytosis (Goldstein and Brown, 
2009). The bound lipoprotein and receptor are internalized by invagination of the cell 
membrane into the cytoplasm that are coated by clathrin, forming coated vesicles. These 
vesicles are acidified and lose their coat, and fuse with other uncoated vesicles called 
endosomes. The acidification results in the dissociation of the lipoprotein from the LDLR 
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and the lipoprotein is delivered to the lysosome, while the LDLR can either be recycled 
to the cell surface or targeted for degradation in the lysosome.  
The LDLR gene is transcriptionally regulated by sterol response element binding proteins 
(SREBPs) (See section 1.4.3.1), which are transcription factors that are regulated by 
cellular cholesterol levels. SREBPs bind to sterol response elements (SRE) in the 
promotor region of specific genes. In cells with low sterol, or cholesterol levels, mature 
SREBP2 is translocated to the nucleus, where it upregulates genes containing SREs 
within in their promotors. This includes the LDLR, but also other genes involved in 
regulating cellular cholesterol levels, including HMG-CoA reductase, the rate limiting 
enzyme in cholesterol biosynthesis, and PCSK9, a protein that targets the LDLR for 
degradation. High cellular cholesterol, blocks the maturation of SREBP2, resulting in the 
downregulation of these targets.  
Mutations within LDLR gene cause the disease familial hypercholesterolemia, an 
autosomal dominant disorder that is characterized by elevated plasma cholesterol, tendon 
xanthomas and increased risk for cardiovascular disease. There have been >2000 
mutations discovered in all five domains of the LDLR that affect a number of functions 
including ligand binding, internalization, receptor recycling, and synthesis (Defesche et 
al., 2017).  
1.3.3.4 Reverse Cholesterol Transport 
Reverse cholesterol transport is the process of transporting excess cholesterol from the 
peripheral tissues to the liver for excretion in the bile. HDL is the major lipoprotein 
involved in the transportation of this cholesterol. The protein backbone of HDL is apoAI, 
which is synthesized by both intestinal enterocytes and hepatocytes, and is secreted in a 
lipid-poor state, containing some phospholipids (Rader, 2006). The nascent HDL particle 
immediately recruits additional phospholipids and free cholesterol via ATP binding 
cassette transporter A1 (ABCA1) from the liver and intestine. Free cholesterol is 
esterified by lecithin-cholesterol acyltransferase to form the hydrophobic lipid core of the 
HDL particle. HDL particles continue to mature in the circulation, acquiring more 
cholesterol from the peripheral tissues for removal. Once a particle has become 
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cholesteryl ester rich, CETP facilitates the transfer of cholesteryl ester from HDL to 
VLDL particles, which upon catabolism are cleared by the liver. The increase in 
triglyceride makes HDL a better substrate for hepatic lipase, which helps to facilitate 
selective hepatic cholesterol uptake via hepatic scavenger receptor class BI (SR-BI) for 
excretion into the bile. This frees a smaller HDL particle, which can take up peripheral 
cholesterol again. In the liver, the newly acquired cholesteryl ester is hydrolyzed to free 
cholesterol, transferred to the ER and used by hepatocytes for bile synthesis, integration 
into cellular membranes, excreted into bile, stored in neutral lipid droplets as cholesteryl 
ester or repackaged into VLDL particles for secretion into the plasma. 
1.4 Fatty Acid and Cholesterol Metabolism 
1.4.1 Fatty Acid and Triglyceride Synthesis 
In the fasted state, the majority of VLDL-triglycerides are derived from fatty acids that 
originated from the lipolysis of adipose tissue triglyceride stores (>70%), with the 
remainder being derived from de novo lipogenesis and fatty acids from chylomicron 
lipolysis (Barrows and Parks, 2006). However, during the fed state, adipose tissue 
lipolysis is suppressed and de novo lipogenesis is increased in response to insulin 
stimulation. Moreover, in states of metabolic dysfunction, rates of de novo lipogenesis 
are increased (Postic and Girard, 2008). This dynamic nature requires that fatty acid and 
triglyceride synthesis be tightly regulated. 
Fatty acid synthesis begins with the carboxylation of acetyl-coenzyme A (CoA), mostly 
derived from carbohydrates from glycolysis, to malonyl-CoA by acetyl-CoA carboxylase 
(ACC) within the cytoplasm (Sanders and Griffin, 2016). At this point, the molecule is 
committed to fatty acid biosynthesis, although malonyl-CoA suppresses fatty acid beta 
oxidation. Malonyl-CoA provides two carbon units to fatty acid synthase, a multi-enzyme 
protein that performs the subsequent elongation reactions, producing 16- and 18- carbon 
saturated fatty acids. These resultant fatty acids must be activated by long chain fatty 
acyl-CoA synthetase, before they can become substrates for subsequent processing or 
partitioning. The activated fatty acyl-CoAs are desaturated by stearoyl-CoA desaturase 
before they can be used in mitochondrial fatty acid oxidation or used to for cholesterol 
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esterification. Fatty acids can also be re-esterified to a glycerol backbone for storage as 
triglycerides. 
Fatty acids from de novo lipogenesis, as well as those from dietary sources and the 
lipolysis of adipose tissue, can be packaged into triglyceride molecules for storage in 
lipid droplets as well as used in the production of chylomicrons (intestine) and VLDL 
particles (liver). The incorporation of fatty acids into triglycerides occurs through the 
glycerol phosphate pathway in most tissues and the monoacylglycerol pathway in adipose 
tissue, liver and intestine (Farese et al., 2000). Fatty acyl-CoAs are used in both 
pathways. The glycerol phosphate pathway begins with the acylation of glycerol-3-
phosphate by glycerol-3-phosphate acyltransferase to yield lysophosphatidic acid. 
Subsequently, lysophosphatidic acid is acylated to form phosphatidic acid, and 
dephosphorylated to produce diacylglycerol. In the monoacylgycerol pathway, fatty acyl-
CoAs are esterified to 2-monoacylglycerols by acyl-CoA: monoglycerol acyltransferase 
to produce diacylglycerol. A final fatty acyl-CoA is used to acylate diacylcerol to 
triglycerides by diacylglycerol acyl transferase. Newly synthesized triglycerides are 
formed into lipid droplets or incorporated into newly synthesized apoB-containing 
lipoproteins via MTP in the liver or intestine for secretion.  
1.4.2 Cholesterol Synthesis and Esterification 
Cholesterol is required by cells for the proper maintenance of cellular membranes as well 
for the production of steroid hormones, bile acids and some vitamins. Cholesterol 
synthesis starts in the cytosol with acetyl-CoA, which is used to synthesize HMG-CoA. 
The next steps all take place in the smooth ER. HMG-CoA is reduced to mevanolate by 
HMG-CoA reductase, which is the rate limiting step in cholesterol biosynthesis and the 
drug target for statin therapy for cholesterol lowering. Similar to the LDLR, HMG-CoA 
reductase is regulated by sterol levels through a SRE and SREBPs (Sections 1.3.3.3 and 
1.4.3.1). Through a series of phosphorylation and condensation reactions, mevanolate is 
converted to various isoprenoid intermediates and finally converted to squalene. 
Cyclization of squalene results in the formation of lanosterol, which upon further 
modification forms one cholesterol molecule.  
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Excess free cholesterol within the cell can be toxic, causing loss of membrane fluidity, 
intracellular cholesterol crystal formation, formation of toxic oxysterols and the induction 
of apoptosis (Tabas, 2002). One mechanism through which cells combat excess free 
cholesterol is through cholesterol esterification. Free cholesterol within the cell is 
esterified by acyl-coenzyme A:cholesterol acyltransferase (ACAT). Two forms of this 
enzyme exist, which differ in their tissue distribution with ACAT1 expressed 
ubiquitously and ACAT2 exclusively expressed in the liver and intestine. Both forms 
preferentially use oleoyl-CoA as the fatty acid for the esterification reaction. Cholesteryl 
ester can be stored in cytoplasmic lipid droplets or can be packaged onto apoB-containing 
lipoproteins for secretion. Additionally, excess free cholesterol can be removed from the 
cell by cholesterol efflux (Section 1.3.3.4) or through the biosynthesis of steroids or bile 
acids. 
1.4.3 Regulation of Triglyceride and Cholesterol Synthesis 
The biosynthesis of cholesterol and triglycerides is tightly regulated by a variety of 
transcription factors that respond to changes in nutrient and hormone signaling. 
1.4.3.1 Sterol Regulatory Element Binding Proteins 
SREBPs are a family of transcription factors that regulate fatty acid, triglyceride and 
cholesterol metabolism. Three members regulate the production of lipids for export in 
lipoproteins and bile, SREBP1a, SREBP1c, and SREBP2, which are encoded by two 
genes, SREBP1 and SREBP2 (Horton et al., 2002). SREBP1a and SREBP1c are two 
different isoforms, and result from different splicing variants in exon 1 of SREBP1. 
SREBP1a and SREBP2 are expressed ubiquitously, whereas SREBP1c is predominantly 
expressed in hepatocytes. SREBP1a is involved in global lipid synthesis and growth, 
SREBP2 regulates genes involved in cholesterol synthesis or its metabolism and 
SREBP1c regulates genes involved in fatty acid synthesis (Shimano and Sato, 2017). 
SREBP2 responds to cellular sterol levels and SREBP1c responds to cellular sterol 
levels, liver-x-activated receptors (LXRs), insulin and glucagon.  
SREBPs belong to the basic helix-loop-helix-leucine zipper family of transcription 
factors, but they differ from other family members in that they are synthesized as inactive 
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ER membrane bound precursors (Horton et al., 2002; Shimano and Sato, 2017). The 
SREBPs are approximately 1150 amino acids long comprised of three domains, the N-
terminal domain that contains the basic helix-loop-helix-leucine zipper for binding DNA, 
two hydrophobic transmembrane domains, and a regulatory C-terminal domain. In order 
to function as a transcription factor in the nucleus, the N-terminal domain must be 
released from the ER membrane. Three proteins are involved in the processing and 
release of nuclear SREBPs, SREBP-cleavage activating protein (SCAP), S1P and S2P. 
SCAP is located in the ER membrane where its C-terminal domain is bound to the C-
terminal domain of SREBP. Insulin-induced gene protein (INSIG) 1 and INSIG2 are 
responsible for retaining the SCAP-SREBP complex at the ER membrane (Shimano and 
Sato, 2017). When there are abundant oxysterols in the ER membrane, INSIG retains the 
SCAP-SREBP complex at the ER membrane. Conversely, in low oxysterol conditions, 
INSIGs are ubiquitinylated targeting them for degradation and allowing SCAP to escort 
SREBP to the Golgi apparatus. In the Golgi, S1P, a serine protease, and S2P, a 
metalloproteinase, cleave SREBP releasing the basic helix-loop-helix leucine zipper 
domain, which becomes nuclear SREBP (nSREBP). nSREBP translocates to the nucleus, 
where it can bind SREs in promotor/enhancer regions of multiple target genes. SREBP1a 
and SREBP2 activate the transcription of genes involved in cholesterol uptake and 
synthesis, such as the LDLR, HMG-CoA reductase and PCSK9 to restore cellular sterol 
balance (Horton et al., 2002). On the other hand, SREBP1c activates the transcription of 
genes involved in fatty acid synthesis and elongation, including acetyl-CoA carboxylase, 
fatty acid synthase, glycerol-3-phosphate acyltransferase and stearoyl-CoA desaturase. 
SREBPs can also be regulated transcriptionally. SREBP1c can be regulated by insulin, 
glucagon, LXRs, and hepatocyte nuclear factor 4 (HNF4). Unlike SREBP1a and 
SREBP2, SREBP1c is nutritionally regulated by energy status with the major regulator 
being insulin (Shimano and Sato, 2017). During fasting, insulin is low and the expression 
of SREBP1c target genes remains low. Upon feeding, insulin increases, as does the 
expression of SREBP1c target genes. Many molecular mechanisms by which insulin 
leads to SREBP1c activation have been described. First, the Akt (protein kinase B)-
mediated phosphorylation of glycogen synthase kinase 3ß (GSK3ß), resulting in its 
inhibition, prevents SREBP degradation. Second, phosphorylated Akt phosphorylates and 
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inhibits INSIG2A, which liberates the SREBP-SCAP complex, allowing for its 
translocation to the Golgi. Third, mTORC1 activation by phosphorylated Akt results in 
increased transcription, translocation from the ER to Golgi and nuclear transport. Which 
of these mechanisms predominates, or is most important, is currently unknown. In states 
of insulin resistance, hyperinsulinemia persists during fasting, which can result in 
hyperactivity of any of these pathways and hyperactivity of SREBP1c. 
1.4.3.2 Other Regulators of Triglyceride and Cholesterol Synthesis 
SREBPs are not the only transcription factors that have a role in regulating the 
biosynthesis of triglycerides and cholesterol. Transcription factors such as upstream 
stimulatory factors (USFs), LXRs and carbohydrate responsive element binding protein 
(ChREBP) also have crucial roles (Wang et al., 2015). These transcription factors have 
been shown to increase the expression of lipogenic genes directly but also play a role in 
recruiting SREBPs to promoter elements promoting a feed forward mechanism of 
lipogenesis. LXR is a nuclear hormone receptor that responds to oxysterol levels. It 
heterodimerizes with retinoid x receptor (RXR) to bind to LXR-response elements within 
the promotors of genes including FAS, ACC and SCD1. ChREBP is activated in response 
to increased glucose and binds to elements within the promotors of genes including FAS, 
ACC, SCD1 and PKM.  
1.4.4 Fatty Acid Oxidation 
Fatty acid oxidation is an important metabolic process that allows for the production of 
energy when glucose levels are low. In the liver, stimulation of fatty acid oxidation also 
limits the availability of triglycerides for VLDL production and secretion, thereby 
lowering plasma lipids and reducing hepatic lipid content. Within the cell, the major site 
of fatty acid oxidation is the mitochondria. 
The rate limiting enzyme in fatty acid oxidation is carnitine palmitoyltransferase 1 
(CPT1), which resides at the outer mitochondrial membrane and mediates the entry of 
fatty acids into the mitochondria (Houten and Wanders, 2010). Mitochondria are 
impermeable to activated long-chain fatty acids so the activated acyl-CoA is transferred 
to carnitine to form acylcarnitine. The acylcarnitine can then be shuttled through a 
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translocase across the inner mitochondrial membrane where it is converted back to acyl-
CoA by carnitine palmitoyltransferase 2 (CPT2). The liberated carnitine is shuttled back 
to the cytosol for subsequent CPT1-mediated reactions. Within the mitochondrial matrix, 
four enzymatic steps are involved in processing the fatty acid into acetyl-CoA, which can 
enter the Kreb’s cycle and the generated NADH enters the oxidative phosphorylation 
pathway to produce ATP, CO2 and water. In the majority of tissues, the liver isoform, 
CPT1A, is expressed except in skeletal muscle, cardiac muscle and brown adipose tissue, 
where the muscle isoform (CPT1B) is highly expressed (Calderon-Dominguez et al., 
2016). 
Fatty acid oxidation also occurs in the peroxisome when the fatty acid chain is too long 
for mitochondrial fatty acid oxidation. Many of the steps are similar to mitochondrial 
fatty acid oxidation, but there are some distinct differences (Lodhi and Semenkovich, 
2014). Carnitine is not required for the translocation of acyl-CoAs into the peroxisome 
and therefore CPT1 is not involved. Instead, uptake is mediated by three ATP cassette 
transporter D subfamily proteins. Additionally, the first, and rate limiting step, is carried 
out by acyl-CoA oxidase (ACOX1), and because peroxisomes lack a respiratory chain, 
energy is released as heat instead of being used to generate ATP.  
1.4.4.1 Regulation of Fatty Acid Oxidation 
The regulation of fatty acid oxidation occurs by a number of mechanisms. CPT1A is 
transcriptionally regulated by a complex of transcription factors including peroxisome 
proliferator-activated receptor (PPAR)γ-coactivator 1α (PGC1α), PPARα and PPAR ß/δ 
(Schreurs et al., 2010). Additionally, lipolysis and the liberation of fatty acids can act as 
PPARα ligands, activating fatty oxidation. Alternatively, CPT1A is also allosterically 
negatively regulated by malonyl-CoA, which is produced from acetyl-CoA by ACC 
during de novo lipogenesis. During the fed state when malonyl-CoA levels are high, fatty 
acids are prioritized to storage as triglycerides. Conversely, during the fasted states, ACC 
is inhibited and malonyl-CoA levels are reduced, relieving CPT1 inhibition and 
promoting fatty acid oxidation.  
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1.4.4.2 PPARs 
The PPARs are a subgroup of a class of ligand-dependant transcription factors that 
regulate whole-body lipid homeostasis and include three members: PPARα, PPARß/δ 
and PPARγ. PPARs heterodimerize with RXRs, which subsequently bind peroxisome 
proliferator response elements (PPREs), and recruit co-activator complexes including 
PGC1α (Section 1.4.4.3) to promote the expression of target genes (Harmon et al., 2011; 
Wang, 2010). Different isoforms are expressed in different tissues with PPARα expressed 
in metabolic tissues, most notably the liver, PPAR ß/δ expressed ubiquitously and PPARγ 
primarily expressed in adipose tissue. PPARs are unique in that they have a large ligand 
binding domain that can accommodate a variety of endogenous lipids and fatty acids, 
although lipid binding is not required for activity. PPARα and PPARß/δ are involved in 
the regulation of fatty acid oxidation while PPARγ regulates fat cell differentiation and 
lipid storage. Genes regulated by PPARα and PPARß/δ include CPT1 and ACOX1, both 
of which are involved in mitochondrial and peroxisomal fatty acid oxidation, 
respectively. Fibrates are a class of drugs that are synthetic PPARα ligands, promoting 
increased fatty acid oxidation and are used to treat hypertriglyceridemia and insulin 
resistance. 
1.4.4.3 PGC-1α 
In order to promote gene transcription, co-activator molecules fine-tune the regulation of 
transcription factors. These molecules interact with transcription factors to either repress 
or activate the transcription of downstream gene targets. An important co-activator 
molecule involved in the regulation of hepatic PPARα-mediated fatty acid oxidation is 
PGC-1α. PGC-1α is upregulated in response to fasting, which in turn upregulates fatty 
acid oxidation and gluconeogenesis (Finck and Kelly, 2006). Pgc1a-/- mice show a 
delayed response to fasting, are hypoglycemic and develop severe hepatic steatosis, 
similar to Ppara-/- mice (Leone et al., 2005; Leone et al., 1999). Additionally, PGC-1α 
has been shown to play a role in the upregulation of mitochondrial biogenesis, cellular 
respiration rates and energy substrate uptake and utilization (Wu et al., 1999). 
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1.4.4.4 ATGL 
Adipose triglyceride lipase (ATGL) performs the first and rate-limiting step in the 
intracellular hydrolysis of triglycerides to diacylglycerides (Lass et al., 2011). In addition 
to this, hepatic ATGL activity has been shown to enhance fatty acid oxidation through 
increased expression of Ppara and its target genes (Ong et al., 2011). In mice with 
hepatic knockdown of ATGL, hepatic fatty acid oxidation is reduced. However, hepatic 
fatty acid oxidation was not rescued by treatment with a PPARα-agonist, suggesting that 
the mechanism through which ATGL enhances fatty acid oxidation was not through 
liberated fatty acids acting as PPARα ligands. Furthermore, ATGL activates PGC-1α 
through SIRT1 (Khan et al., 2015), suggesting an alternative regulator of fatty acid 
oxidation.  
1.5 Hepatic Steatosis 
The development of hepatic steatosis is linked with other metabolic disorders including 
obesity, dyslipidemia, and insulin resistance or type 2 diabetes, and is associated with an 
increased risk for cardiovascular disease (Than and Newsome, 2015). Hepatic steatosis 
develops as the accumulation of lipids, mostly stored as cholesteryl ester and 
triglycerides in lipid droplets, when the delivery and biosynthesis of lipids is greater than 
the secretion and metabolism. It is associated with increased hepatic inflammation and 
impaired hepatic function. Excessive hepatic lipid accumulation can deteriorate into non-
alcoholic fatty liver disease (NAFLD).  
NAFLD develops via a “two-hit hypothesis” (Than and Newsome, 2015). The “first hit” 
involves an increase in free fatty acid flux to the liver during insulin resistance, enhanced 
dietary influx and increased hepatic lipogenesis resulting in an accumulation of hepatic 
fatty acids and triglycerides. The “second hit” involves lipid peroxidation, mitochondrial 
dysfunction and inflammation. Lipid peroxidation promotes the proliferation of a non-
hepatocyte liver cell, stellate cells, which contribute to liver fibrosis. Pro-inflammatory 
signalling via nuclear factor-κß and c-Jun N-terminal kinase signalling increases 
transcription of inflammatory genes and enhances insulin resistance via degradation of 
the insulin receptor substrate (Hirosumi et al., 2002). The combination of these features 
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results in oxidative stress, mitochondrial dysfunction and can result in necrosis (Than and 
Newsome, 2015).  
1.6 Insulin 
Insulin is a peptide hormone secreted by the β-cells of pancreatic islets that plays an 
important role in regulating lipid and carbohydrate metabolism by promoting the 
absorption of blood glucose and subsequent synthesis of lipids, glycogen and proteins 
(Wilcox, 2005).  
1.6.1 Function and Signaling 
In response to a meal, increased blood glucose and amino acids promote the secretion of 
insulin. Insulin has different effects on a wide variety of insulin-responsive tissues. The 
major sites of insulin action are the liver, muscle and white adipose tissue. In liver, 
insulin suppresses gluconeogenesis and VLDL production, while promoting lipogenesis 
and glycogenesis. In the muscle, insulin stimulates the uptake of glucose and 
glycogenesis and suppresses gluconeogenesis. In the white adipose tissue, insulin 
stimulates glucose uptake and lipogenesis and inhibits lipolysis, promoting the storage of 
triglycerides.  
The effects of insulin are mediated through the insulin receptor (IR) and insulin receptor 
substrate (IRS) proteins. The insulin receptor is a tetramer comprised to two extracellular 
α-subunits and two transmembrane ß-subunits (Boucher et al., 2014). Insulin binding to 
the α-subunits promotes a conformational change and kinase activity of the ß-subunits, 
which facilitates the recruitment and phosphorylation of IRS proteins. This elicits a 
phosphorylation cascade, which results in the activation of the mitogen-activated protein 
kinase (MAPK) pathway and the phosphatidylinositol 3-kinase (PI3K) pathway. The 
MAPK pathway elicits the proliferative effects on insulin and is involved cell 
differentiation and proliferation. 
The PI3K pathway evokes the metabolic effects of insulin signaling. PI3K 
phosphorylates and activates Akt. Akt is the bifurcation point in the insulin signalling 
pathway, where each branch of the pathway responds differently during insulin 
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stimulation or insulin resistance (Li et al., 2010). Akt has numerous phosphorylation 
targets. Phosphorylation of GSK3ß results in inhibition of the enzyme allowing glycogen 
synthase to convert glucose into glycogen (Haeusler et al., 2018). Another target of Akt is 
forkhead family box O (FOXO) proteins, which act as transcription factors that promotes 
the transcription of genes involved in gluconeogenesis, PEPCK and G6PC. 
Phosphorylation by Akt results in inhibition of FOXO, resulting in reduced 
gluconeogenesis. Another target of Akt is the phosphorylation and activation of 
mammalian target of rapamycin complex 1 (mTORC1), which enhances the transcription 
of SREBP-1c. SREBP-1c is a transcription factor that promotes lipogenesis (Section 
1.4.3.1). Thus, insulin inhibits gluconeogenesis and promotes lipogenesis. 
1.6.2 Insulin Resistance 
Insulin resistance occurs when normal physiological levels of insulin can no longer elicit 
anabolic effects on gluconeogenesis and is characterized by elevated blood glucose. The 
pancreas responds by increasing insulin secretion to compensate for the lack of sensitivity 
by peripheral tissues, leading to hyperinsulinemia. Insulin resistance is closely linked to 
obesity, NAFLD, dyslipidemia and cardiovascular disease risk. Furthermore, insulin 
resistance is an intrinsic characteristic of type 2 diabetes. Type 2 diabetes is characterized 
by fasting hyperglycemia due to the pancreatic β-cells becoming unable to provide 
sufficient insulin and/or reduced insulin sensitivity in the liver and peripheral tissues to 
maintain glucose homeostasis (Boucher et al., 2014). 
The effects of insulin resistance and hyperinsulinemia differs depending on the insulin-
responsive tissue. The major sites that contribute to the features of insulin resistance are 
the liver (Section 1.6.2.1), adipose tissue and skeletal muscle (Boucher et al., 2014). In 
the adipose tissue, insulin resistance is characterized by an impaired ability of insulin to 
inhibit hormone sensitive lipase. This results in increased triglyceride lipolysis, 
increasing plasma free fatty acids and the hepatic free fatty acid pool for hepatic 
triglyceride and VLDL synthesis. In insulin resistant skeletal muscle, insulin fails to 
stimulate the expression of the glucose transporter, GLUT4. This results in less glucose 
uptake into the muscle, which perpetuates hyperglycemia.  
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1.6.2.1 Hepatic Insulin Resistance 
In the liver, insulin resistance results in an impaired ability of insulin to suppress hepatic 
gluconeogenesis, while continuing to stimulate lipogenesis. This results in the patient 
phenotype of hyperglycemia, hyperinsulinemia and hyperlipidemia. One hypothesis is 
that this effect is related to the bifurcation of the insulin signaling pathway. Insulin 
mediated activation of Akt continues to stimulate one arm of insulin signalling 
(lipogenesis via mTORC1) but fails to inhibit the other arm (gluconeogenesis via 
repression of FOXO) (Li et al., 2010). Recent work has demonstrated that hepatic lipid 
accumulation also plays an intrinsic role in promoting hepatic insulin resistance (Perry et 
al., 2014; Petersen et al., 2017). Hepatic diacylglycerides, the penultimate intermediate in 
triglyceride synthesis, activate protein kinase Cε (PKCε), which impairs tyrosine 
phosphorylation of the IR, impeding insulin action. This results in an inability of insulin 
to inactivate FOXO and hepatic gluconeogenesis. Continued supply of glycerol and fatty 
acids from insulin resistant adipose tissue and chylomicrons continues to fuel hepatic de 
novo lipogenesis (Perry et al., 2014; Vatner et al., 2015). This results in the phenotype of 
hepatic insulin resistance where hepatic gluconeogenesis and lipogenesis continue despite 
classical insulin signaling. 
Hyperlipidemia is also associated with hepatic insulin resistance. Increased free fatty acid 
availability from adipose tissue and continued stimulation of lipogenesis results in 
hepatic lipid accumulation. Furthermore, insulin has been implicated in promoting the 
degradation of apoB (Taghibiglou et al., 2000). Therefore, during insulin resistance there 
may be an increase in apoB production. Increased apoB synthesis and triglyceride 
availability increases the production and secretion of triglyceride-rich VLDL particles 
(Section 1.3.3.1), which characterize diabetic dyslipidemia (Goldberg, 2001). 
1.7 Adipose Tissue and Obesity 
1.7.1 White Adipose Tissue 
Obesity, or excess adiposity, is an intrinsic feature of the metabolic syndrome, and is 
associated with increased tissue inflammation, contributing to an increased risk for 
cardiovascular disease. Adiposity increases both viscerally and subcutaneously, with 
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visceral adipose tissue being significantly associated with increased metabolic risk 
(Ibrahim, 2010). The major function of white adipose tissue, or fat, is to store lipid for 
energy, predominantly in form of triglycerides. This does not mean that adipose tissue is 
inert. It is a metabolically active tissue that has important endocrine functions, producing 
the hormones leptin, adiponectin and other cytokines (Kershaw and Flier, 2004). These 
functions become dysregulated during the process of adipose excess, or obesity and are 
related to the development of insulin resistance and dyslipidemia.  
During the development of obesity, adipose tissue is characterized by rapid adipocyte 
hypertrophy and hyperplasia, driven by excess triglyceride substrate (Rutkowski et al., 
2015). Increase in size and abundance of adipocytes has also been correlated with the 
infiltration of macrophages, potentiating the production of cytokines (Kershaw and Flier, 
2004; Weisberg et al., 2003). This increase in inflammatory status of adipose tissue has 
been shown to play a crucial role in the development of insulin resistance (Section 1.6.2) 
during obesity (Xu et al., 2003). Furthermore, unregulated lipolysis of adipose tissue 
during insulin resistance has been implicated in hepatic insulin resistance (Section 
1.6.2.1). 
Several factors are important in the development of obesity-associated adipose tissue 
inflammation. Two mechanisms for increased macrophage content and inflammation 
have been proposed. Firstly, macrophages are recruited into the adipose tissue via 
chemokine such as monocyte chemoattractant protein 1 (MCP1), and adipokines such as 
leptin and tumor necrosis factor-α from the circulation (Bai and Sun, 2015; Weisberg et 
al., 2003) and secondly, local proliferation of resident macrophages (Amano et al., 2014). 
The precise trigger of obesity-associated inflammation remains elusive, but several 
potential mechanisms have been described (Reilly and Saltiel, 2017). They could arise 
through exogenous signals such as gut-derived antigens, or dietary components or 
metabolites. Alternatively, they could arise from adipose-intrinsic stimuli such as 
adipocyte death, hypoxia or mechanical stress. Crown-like structures (CLS), consisting of 
macrophages surrounding dead adipocytes, have been found in both obese rodents and 
humans and may be related to increased inflammation in obese adipose tissue (Bai and 
Sun, 2015). 
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1.7.2 Brown Adipose Tissue 
Brown adipose tissue is the major site of non-shivering thermogenesis in mammals 
(Giralt and Villarroya, 2013). It is located in discrete anatomical depots and differs in 
function and morphology. Brown adipocytes are characterized by multilocular lipid 
droplets as opposed to the unilocular lipid droplets that characterize white adipocytes. 
Brown adipose tissue is involved in energy expenditure in contrast to energy storage. 
Thermogenesis is induced in response to cold or beta-adrenergic signaling through 
uncoupling protein-1 (UCP-1). Numerous uncoupled mitochondria actively oxidize 
metabolic substrates and dissipate energy as heat, leading to protection from obesity. This 
makes brown adipose tissue an attractive anti-obesity target.  
Thermogenic stimuli can result in the browning of white adipose tissue, a process where 
white adipose tissue takes on characteristics of brown adipose tissue (Abdullahi and 
Jeschke, 2016). Beige, or brite adipocytes are multilocular and enriched in mitochondria, 
facilitating an increased oxidative capacity. This has been mediated through an increase 
in UCP-1, and more recently through an increase in SERCA2b-calcium cycling 
thermogenesis (Ikeda et al., 2017; Nedergaard and Cannon, 2014). These represent 
potential anti-obesity therapeutic targets. 
1.8 Monocytes 
Monocytes are a large type of leukocyte that can differentiate into macrophage or 
myeloid-lineage dendritic cells, and are an important cell type in the adaptive immune 
system. Monocytes have three roles in the human body including, replenishing resident 
macrophages in different tissues under normal conditions, responding to sites of 
inflammation in response to infection, or differentiation into macrophages or dendritic 
cells as an immune response (Dutta and Nahrendorf, 2014). The majority of monocytes in 
the adult are stored in the spleen. They are derived from hematopoiesis in the bone 
marrow or extramedullary hematopoiesis in the spleen (Dutta and Nahrendorf, 2014; 
Robbins et al., 2012). 
All blood monocytes are produced through myelopoiesis in the bone marrow and spleen 
(Dutta and Nahrendorf, 2014). An increase in blood monocytes, or monocytosis, can 
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result from many pathological states including infections, obesity, hyperglycemia and 
atherosclerosis (Nagareddy et al., 2014; Nagareddy et al., 2013; Swirski et al., 2014). 
This is further discussed in Sections 1.8.1, and 1.8.2 of this thesis. Myelopoiesis is the 
proliferation and differentiation of hematopoietic stem cells to propagate leukocyte 
populations. Hematopoietic stem progenitor cells are multipotent and self-renewing; they 
can differentiate into three lineages: common lymphoid progenitors (CLPs), common 
myeloid progenitors (CMPs) and common megakaryocyte erythroid progenitors (MEPs), 
(Figure 1.2) (Seita and Weissman, 2010). CLPs can differentiate into B cells, T cells and 
natural killer (NK) cells. MEPs can differentiate into megakaryocytes (which become 
platelets) and erythrocytes. Finally, CMPs can differentiate into monocytes or common 
granulocyte precursor cells, which become neutrophils, basophils and eosinophils. 
1.8.1 Hypercholesterolemia and Monocytosis 
Hypercholesterolemia is an irrefutable risk for cardiovascular disease. Studies have also 
shown that hyperlipidemia is correlated with increased monocytosis and neutrophilia, 
which may impart some of the risk (Soehnlein and Swirski, 2013). Specifically, in mice, 
hypercholesterolemia has been shown to increase the Ly6Chi subset (CD14hiCD16lo 
subset in humans) of monocytes, which are preferentially recruited to growing 
atherosclerotic plaques (Mosig et al., 2009; Rahman et al., 2017b; Swirski et al., 2007). 
The mechanisms through which hypercholesterolemia elicits monocytosis are currently 
being investigated. Recent work has identified a few mechanisms including 
hematopoietic intracellular cholesterol homeostasis and efflux, hematopoietic ApoE, and 
extramedullary myelopoiesis linking hypercholesterolemia and monocytosis. 
Intracellular cholesterol homeostasis is important to maintaining cellular function, and 
preventing cholesterol overloading. In hematopoietic cells, intracellular cholesterol 
homeostasis is regulated by two transporters, ABCA1 and ATP binding cassette 
transporter G1 (ABCG1), which transport cholesterol to nascent and mature HDL, 
respectively. In mice, deletion of both these receptors results in increased bone marrow 
hematopoietic stem and progenitor cells, CMPs and GMPs (Yvan-Charvet et al., 2010). 
This was associated with increased membrane lipid-rafts and downstream proliferative 
signaling, which upon disruption markedly reduced proliferation in vitro  
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Hematopoiesis is the process by which stem cells give rise to different blood cells. 
Hematopoietic stem and progenitor cells (HSPCs) are self-renewing and multi-potent. 
They give rise to multi-potent progenitor (MPP) cells, which are multi-potent but not 
self-renewing. MPPs can differentiate into two lineages: common myeloid progenitor 
(CMP) cells and common lymphoid progenitor (CLP) cells. Common lymphoid 
progenitors can differentiate into natural killer (NK) cells, B-lymphocytes and T-
lymphocytes. CMPs can differentiate into megakaryocyte and erythroid progenitor 
(MEP) cells and granulocyte monocyte progenitor (GMP) cells. CMPs can also 
differentiate directly into monocyte and dendritic cells. MEPs differentiate into 
erythrocytes and megakaryocytes, which also form platelets. GMPs can form monocytes 
or granulocytes including neutrophils, eosinophils, and basophils. Elevated monocytes 
and neutrophils are a risk for atherosclerosis.   
Figure 1.2 Hematopoietic Stem Cell Differentiation 
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(Yvan-Charvet et al., 2010). The addition of HDL, or transgenic apoA1, promoted 
cholesterol efflux and reduced myelopoiesis. ApoE has been implicated in 
atheroprotection, primarily through its role in the clearance of apoB-containing 
lipoproteins. ApoE may also play a role in hematopoietic stem cell proliferation and 
myelopoiesis (Soehnlein and Swirski, 2013). Apoe-/- mice fed a high-fat diet develop 
more pronounced monocytosis, neutrophilia and proliferation of hematopoietic stem cells 
than Ldlr-/- mice with similar hyperlipidemia (Murphy et al., 2011). This suggests an 
additive effect. Mechanistically, ApoE in hematopoietic cells is secreted, and anchors and 
interacts with ABCA1 and ABG1 facilitating cholesterol efflux as described above. 
Again, this links hematopoietic intracellular cholesterol homeostasis and myelopoiesis 
(Yvan-Charvet et al., 2010).  
The majority of studies have investigated myelopoiesis in the bone marrow. 
Extramedullary myelopoiesis occurs outside the bone marrow and in adults, a major 
reservoir of undifferentiated monocytes resides in the spleen (Swirski et al., 2009). In 
mice, it has been shown that during atherogenesis, a large percentage of these splenic 
monocytes become Ly6Chi monocytes, which are recruited to the growing atherosclerotic 
plaque, and this seems to be dependent on the hypercholesteraemic milieu (Robbins et al., 
2012). Again, this implicates hypercholesterolemia in eliciting monocytosis, contributing 
to increased cardiovascular disease risk. 
1.8.2 Obesity, Insulin Resistance and Monocytosis 
Other metabolic disorders have been implicated in enhancing myelopoiesis and inducing 
monocytosis. Two studies show that diet-induced obesity contributes to increased 
myelopoiesis in hematopoietic stem cells in the bone marrow (Nagareddy et al., 2014; 
Singer et al., 2014). These effects are mediated through toll-like receptor 4 (TLR4)/ 
Myeloid differentiation primary response 88 (Myd88) signaling in adipose tissue 
macrophages, which activate inflammasome signaling and propagate a proliferative 
signal to the bone marrow. Another study has connected hyperglycemia to enhanced 
myelopoiesis in a model of type 1 diabetes (Nagareddy et al., 2013). Increased neutrophil 
production of calprotectin (S100A8/S100A9) signals through RAGE on myeloid 
progenitor cells, promoting increased proliferation. These two mechanisms, obesity and 
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hyperglycemia, may be linked in the setting of type 2 diabetes and may explain some of 
the increased cardiovascular disease risk in this setting.  
1.9 Atherosclerosis Progression 
Many of the metabolic abnormalities discussed in this thesis contribute to the 
development of arterial atherosclerotic plaques (Grundy, 2012). Atherosclerosis occurs 
predominantly at sites of disturbed laminar flow, more specifically arterial branch points 
and bifurcations of the medium and large-sized arteries (Moore and Tabas, 2011). These 
arteries are comprised of three layers (Figure 1.3). The innermost, or luminal layer, is the 
intima, which is made up of a single layer of endothelial cells and subendothelial 
connective tissue that mediates vascular tone. It is bordered by the internal elastic lamina. 
The medial layer is defined by both the internal and external elastic lamina and comprises 
smooth muscle cells that are also responsible for mediating vascular tone, but also secrete 
elastin, collagen and glycosaminoglycans. The outermost layer is the adventitia and is 
comprised of connective tissue with sporadic fibroblasts, smooth muscle cells and 
progenitor cells.  
Healthy vasculature endothelium maintains a semi-permeable barrier. However, in 
response to injury this barrier loses confluence and becomes compromised. This allows 
for the accumulation of apoB-containing lipoproteins, which are retained via binding of 
the negatively charged apoB backbone to exposed proteoglycans (Moore and Tabas, 
2011; Weber and Noels, 2011). Lipoprotein trapping within the subendothelial space 
increases their susceptibility to modification by reactive oxygen species or enzymes such 
as myeloperoxidases or lipoxygenases (Weber and Noels, 2011). This results in the 
initiation of an inflammatory response. Activated endothelium secrete chemoattractants 
that interact with receptors on monocytes promoting their migration into the intima 
(Moore and Tabas, 2011). 
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Arteries are comprised of three layers: 1. the intima, which is comprised of an endothelial 
cell monolayer on the luminal side, and subendothelial connective tissue that maintains 
vascular tone, 2. the media, which is defined by both the internal and external elastic 
lamina and is comprised of vascular smooth muscle cells, which function to maintain 
vascular tone but also synthesize and secrete elastin, collagen and glycosaminoglycans, 3. 
the adventitia, which is the outermost layer and is comprised of connective tissue, and 
sporadic fibroblasts, smooth muscle cells and progenitor cells. 
  
Figure 1.3 Composition of the Arterial Wall 
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Recruited monocytes (Section 1.8), more specifically Ly6Chi monocytes, become 
tethered by endothelial selectins, vascular cell adhesion molecule (VCAM-1) and 
intercellular adhesion molecule-1 (ICAM-1), and roll over the endothelium overlying 
retained lipoproteins (Moore and Tabas, 2011). The adhesion of monocytes is followed 
by their intravasation into the subendothelial space. Within the subendothelial space, the 
monocytes differentiate predominantly into macrophages under stimulation of 
macrophage colony stimulating factor (M-CSF). These macrophages take up lipoproteins 
and become foam cells (Section 1.9.2).  
As the atherogenic milieu persists, foam cells accumulate in the subendothelial space, 
causing thickening of the arterial intima (Figure 1.4). As foam cells accumulate, the 
lesion progresses to a fatty streak. The plaque continues to grow, and smooth muscle cells 
are recruited. Inflammation, lipoproteins and endothelial activation can stimulate the 
activation or phenotypic switching of smooth muscle cells. Differentiation and contractile 
genes are downregulated and the smooth muscle cells proliferate and migrate into the 
atherosclerotic plaque. They increase the secretion of matrix and proteoglycans, thought 
to stabilize the plaque, forming a fibrous cap (Smooth muscle are reviewed in Section 
1.9.3) (Bennett et al., 2016; Tabas et al., 2015). Monocytes continue to be recruited, but 
local proliferation becomes a major contributor to plaque growth (Robbins et al., 2013). 
As the plaque progresses into the advanced stages, it becomes more vulnerable and 
susceptible to rupture. This is due to a multitude of factors. Excess cholesterol can 
become deposited extracellularly forming cholesterol crystals, which can amplify 
inflammatory signaling and disrupt the extracellular matrix within the plaque (Moore and 
Tabas, 2011). Additionally, the recruited smooth muscle cells take up lipoproteins, 
becoming foam cells themselves and lose their reparative function (Discussed further in 
Section 1.9.3) (Frontini et al., 2009). Furthermore, increased matrix metalloproteinases, 
derived from macrophages, can degrade matrix proteins in the fibrous cap, thereby 
thinning it (Moore and Tabas, 2011). Increased intracellular cholesterol induces ER-
stress, which when prolonged results in apoptotic cell death (Discussed Further in Section 
1.9.2.2) (Moore et al., 2013). Lipid-loaded macrophages have impaired efferocytosis and  
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Endothelial dysfunction and the accumulation of lipoproteins within the subendothelial 
space results in the recruitment of monocytes, which become tethered by endothelial 
selectins (A). Following adhesion, monocytes intravasate into the intima, where they 
differentiate into macrophages and take up lipoproteins, becoming foam cells. As the 
atherogenic milieu persists, foam cells accumulate and the lesion progresses to a fatty 
streak. The plaque continues to grow and smooth muscle cells are recruited (B). Smooth 
muscle cells synthesize and secrete a collagen matrix, which stabilizes the plaque. As the 
plaque continues to progress into the advanced stages, it is characterized by an enlarged 
necrotic core, extracellular cholesterol deposition and matrix breakdown, increasing its 
susceptibility to rupture (C). Upon rupture, plaque debris is exposed to the blood 
triggering coagulation and thrombus formation, increasing the likelihood of arterial 
occlusion and subsequent myocardial infarction or stroke.  
  
Figure 1.4 Progression of Atherosclerosis 
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this coupled with increased apoptosis can lead to secondary necrosis. All of these features 
contribute to a more vulnerable plaque, which upon rupture releases debris triggering 
coagulation and thrombus formation, thereby increasing the likelihood of arterial 
occlusion and subsequent myocardial infarction or stroke. Therefore, stabilization or 
inducing regression of these plaques is an important clinical objective. (Regression is 
reviewed in Section 1.10 of this thesis).  
1.9.1 Macrophages 
Monocyte-derived macrophages engulf lipoprotein-derived lipids resulting in the 
formation of foam cells, which are a quintessential cell type of atherosclerotic plaques. 
Lipoprotein-derived lipids can be taken up by the macrophage via multiple mechanisms. 
Macrophages can clear apoB-containing lipoproteins by the LDLR, but the expression is 
downregulated upon foam cell formation due to intracellular cholesterol levels (Moore et 
al., 2013). Scavenger receptors including scavenger receptor A1 (SR-A1), CD36, SR-B1 
and others can bind oxidized LDL and promote foam cell formation. After 
internalization, cholesteryl esters are hydrolyzed in the late endosomal compartment into 
free cholesterol and fatty acids. The free cholesterol is trafficked to the ER, where it is 
esterified by ACAT, allowing it to be stored in lipid droplets, contributing to the ‘foamy’ 
appearance of foam cells. Native LDL can be taken up by macrophages via pinocytosis, a 
type of bulk-phase phagocytosis. Finally, aggregated lipoproteins can be taken up my 
phagocytosis. 
The accumulation of lipids within the macrophage can overwhelm normal cellular 
cholesterol homeostasis. In response to excess lipid accumulation, macrophages efflux 
excess lipid via ABCA1, and ABCG1 to nascent and mature HDL, respectively. In the 
foam cell, this process is upregulated via LXR activation by cholesterol derivatives 
(Moore et al., 2013). During atherogenesis, this process is overwhelmed and this can lead 
to the accumulation of excess free cholesterol, promoting ER stress, which can lead to 
apoptosis and cell death (Section 1.9.2.2). 
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1.9.1.1 Macrophage Polarization 
Macrophages are a heterogeneous and plastic population of immune cells (Moore et al., 
2013). Studies in cell culture have resulted in a classification system of two major types 
of macrophages, M1 and M2 (Moore et al., 2013; Peled and Fisher, 2014). In vivo, it is 
more realistic that macrophages exist across a spectrum of phenotypes between M1 and 
M2 (Peled and Fisher, 2014). Furthermore, there are macrophages within the plaque that 
are outside this spectrum including Mox macrophages, which are induced by oxidized 
phospholipids and characterized by a distinct molecular signature (Moore et al., 2013). 
Polarization towards the M1 state is induced in vitro by toll-like receptor ligands and 
interferon gamma. M1 macrophages secrete pro-inflammatory mediators and contribute 
to perpetuated inflammation in the plaque and degradation of extracellular matrix, 
promoting atherosclerotic plaque progression. On the other side of the spectrum, M2 
macrophages are induced by Th2-type cytokines and are anti-inflammatory. They are 
thought to be involved in tissue repair and play an important role in atherosclerotic 
plaque regression and resolution.  
1.9.1.2 Plaque Cell Apoptosis, Efferocytosis and Necrosis 
Macrophages are phagocytic cells of the immune system that function to clear debris, 
microbes and foreign substances. In atherosclerosis, they are important in ‘clearing’ 
lipoproteins, but they also play an important role in plaque apoptosis and the clearance of 
these apoptotic cells in a process called efferocytosis. As the plaque progresses, excess 
intracellular free cholesterol integrates itself into cellular membranes, including in the 
ER. This can lead to increased ER-stress, which can activate pathways in the unfolded 
protein response (UPR), and  ultimately lead to apoptosis, a type of cell death (Tabas, 
2009). Apoptosis is a physiological program facilitated by a series of cysteine aspartate-
specific proteases called caspases, which are involved in a cell death signaling cascade 
(Van Vre et al., 2012). Apoptosis results in rounding of the cell, chromatin condensation, 
nuclear fragmentation and blebbing of the plasma membrane into apoptotic bodies, which 
can be cleared by efferocytosis. In advanced atherosclerosis, the process of efferocytosis 
becomes defective (Kojima et al., 2017).  
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Defective efferocytosis is not completely understood, but does not seem to be related to 
an overwhelming increase in apoptosis (Kojima et al., 2017). It may be related to a 
macrophage subtype that predominates in advanced atherosclerotic lesions (Macrophage 
polarization reviewed in Section 1.9.2.1). M1 macrophages have lower phagocytic 
capacity than M2 macrophages. Additionally, competing phagocytic substrates may play 
a role, with lipoproteins outcompeting apoptotic bodies for phagocytosis (Van Vre et al., 
2012). Furthermore, although lipid-loaded macrophages retain phagocytic capacity, lipid-
loaded smooth muscle cells cannot function as phagocytes, and together with a 
preponderance for M1 macrophages, this results in less functional efferocytes (Bennett et 
al., 2016; Clarke et al., 2010). If apoptotic cell clearance is delayed, the apoptotic bodies 
undergo breakdown of their membranes, releasing cellular contents into the extracellular 
space, promoting a non-resolving inflammatory response and secondary necrosis within 
the plaque (Kojima et al., 2017). 
In addition to apoptosis, cell death in atherosclerosis can be mediated through autophagy 
and necroptosis, and both play a role in advanced atherosclerosis (Kavurma et al., 2017). 
Autophagy is a protective mechanism through which a cell ‘eats oneself’. In early 
atherosclerosis lipophagy plays an important role in the management and hydrolysis of 
lipid droplets. During atherosclerosis, cytokines and other signals can induce macro-
autophagy, and when overstimulated, this can result in autophagic cell death. During 
advanced atherosclerosis, this process becomes deregulated and cells can no longer 
undergo this protective mechanism, therefore shuttling more cells towards apoptosis, 
where defective efferocytosis cannot keep up (Martinet and De Meyer, 2009). 
Necroptosis, or programmed cell necrosis, may play a role in necrotic core formation. 
Blocking necroptosis is protective in murine atherosclerosis development, although the 
exact role it plays in lesion development is still under investigation (Karunakaran et al., 
2016; Kavurma et al., 2017). 
1.9.2 Smooth Muscle Cells and Collagen 
For many years, vascular smooth muscle cells were characterized as having a reparative 
role in atherogenesis (Bennett et al., 2016). Increased vascular smooth muscle cells 
would increase elaboration of collagen matrix and fortify the fibrous cap. Recent lineage-
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tracing studies have expanded on this role showing that a large number of smooth muscle 
derived cells in atherosclerotic plaques lose traditional markers (smooth muscle α-actin) 
and gain macrophage markers (CD68) (Shankman et al., 2015). This suggests that 
smooth muscle cell content may be underestimated in plaques. Furthermore, lipid-loaded 
smooth muscle cells have impaired ability to lay down matrix and cannot act as 
efferocytes (See Section 1.9.2.2 of this thesis), suggesting a larger role in the 
pathogenesis of advanced lesions (Bennett et al., 2016; Frontini et al., 2009). 
1.10 Atherosclerosis Regression 
Lesion regression has been described in several animal models of atherosclerosis 
including rabbits, swine and non-human primates, but the mechanisms were not explored 
until the turn of the millennium. The advent of atherosclerosis regression models in 
genetically modified mice has greatly accelerated this field of research.  
Atherosclerosis regression does not involve the same mechanisms as progression in 
reverse order. There are distinct cellular and molecular processes that mobilize plaque 
elements to resolve the plaque. A complete understanding of these processes required 
development of suitable mouse models and selection of appropriate study protocols.  
Most atherosclerosis studies have been designed to investigate molecular mechanisms 
that govern the development, or progression of atherosclerosis. In this way, studies have 
examined the knockout or overexpression of a gene or the effect of a drug at the same 
time disease is initiated, before lesions have been established. This approach has provided 
tremendous insight into the roles of different molecules and cell types in disease 
development and factors that govern disease initiation. The majority of murine 
progression studies have used Ldlr-/- mice or Apoe-/- mice, in which diets high in fat and 
cholesterol increase atherogenic plasma lipoproteins (chylomicron remnants, VLDL 
remnants or LDL) and lower HDL-cholesterol that in turn potentiate plaque formation 
(Ishibashi et al., 1993; Veniant et al., 2001; Zhang et al., 1992).  
Within the last 17 years, groups have capitalized on both Ldlr-/- and Apoe-/- mice to 
establish models where regression of lesions can be achieved. Typically, mice are fed fat 
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and cholesterol-rich diets for a time period that varies depending upon the type or 
complexity of lesion to be established. Following this induction period, a subset of mice 
is sacrificed and lesion assessment is performed for size and pathological characteristics. 
This step is critical as it provides the baseline to which regression can be assessed. The 
remaining mice are subjected to an intervention, which often consists of a low-fat diet, a 
genetic manipulation and/or a drug treatment, for a variable period of time that is 
dependent on factors such as complexity or strength of the intervention. At the 
completion of the intervention phase, atherosclerotic lesions are assessed for size, 
composition and histologically defined characteristics. By definition, regression can only 
be determined by direct comparison to the baseline data. Unfortunately, a number of 
otherwise well-designed intervention studies have not included baseline data, thereby 
preventing any conclusions with respect to regression.  
1.10.1 Mouse Models of Atherosclerosis Regression 
In order to establish atherosclerosis, mice require manipulation of their lipoprotein 
profiles such that apoB-containing lipoproteins are elevated and HDL is suppressed 
(Veniant et al., 2001). In this milieu, even chow-fed mice have elevated plasma 
cholesterol and therefore, it is difficult to drive lesion regression. A number of groups 
have found ways to circumvent this difficulty. The most common murine models of 
regression are aortic transplant, the Reversa mouse, Apoe or Ldlr complementation in 
their respective knockout mice, and Ldlr-/- or Apoe-/- mice with dietary intervention (Feig 
et al., 2011a; Kassim et al., 2010; Potteaux et al., 2011; Reis et al., 2001; Van Craeyveld 
et al., 2011). These models are reviewed below. 
1.10.1.1 Transplant Model 
The first consistent murine model of regression utilized aortic transplantation (Reis et al., 
2001). Diet-induced atherosclerosis in Apoe-/- mice provides baseline lesions for analysis. 
Subsequently, the aortic arch from the atherogenic mouse, including lesions, is dissected 
and anastomosed to the abdominal aorta of a wildtype, chow-fed recipient mouse. The 
normolipidemia in recipient mice drives atherosclerosis regression in the transplanted 
plaques, which can occur as early as 3 days post-transplant (Feig et al., 2012; Trogan et 
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al., 2006). This model has shown extensive utility in elucidating mechanisms that 
contribute to regression (reviewed below) and understanding how specific gene 
knockouts or therapeutics influence atherosclerosis regression (Bradfield et al., 2016; 
Feig et al., 2010; Feig et al., 2011b; Rahman et al., 2017a; Trogan et al., 2006).  
1.10.1.2 Reversa Mouse 
The sophisticated surgery required for the transplant model of regression and the 
abnormal location of the transplanted lesions have hindered its broad utility. The Reversa 
mouse is a model in which Ldlr-/- Apob100/100Mx1-Cre+/+ mice harboring a floxed 
microsomal transfer protein (Mttp) gene are fed a high fat diet (Lieu et al., 2003). 
Following the induction phase, the Mttp gene is deleted (Mx1-Cre activation) and mice 
are transferred to a chow diet (low-fat), resulting in very low plasma VLDL- and LDL-C. 
Rapid regression occurs as early as 6 days post-Mttp deletion (Feig et al., 2011a).  
1.10.1.3 ApoE or LDLR Gene Complementation 
Mice require a mutation to develop diet-induced atherosclerosis, which limits the 
potential for regression even following transfer of mice to a chow (low-fat) diet because 
mild hypercholesterolemia persists. Following diet-induction of atherosclerosis in Apoe-/- 
or Ldlr-/- mice, reintroduction of the Apoe and Ldlr genes, respectively, via adenoviral 
delivery to the liver, together with transfer of mice to a chow diet results in very low 
plasma cholesterol and regression of established atherosclerosis (Kassim et al., 2010; 
Potteaux et al., 2011; Van Craeyveld et al., 2011). 
1.10.1.4 PCSK9 AAV Mice 
A new model of atherosclerosis progression has been developed that does not require 
germ-line mutations. A single injection of a recombinant adeno-associated virus (AAV) 
containing a PCSK9 gain-of-function mutation that targets the LDL receptor for 
degradation in combination with a high fat diet was sufficient to increase LDL-
cholesterol and induce atherosclerosis in C57BL/6 mice (Bjorklund et al., 2014). 
Following atherosclerosis induction, simply switching these mice to a chow diet for six 
weeks was sufficient to induce lesion regression (Peled et al., 2017). 
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1.10.1.5 Dietary Switch 
A number of studies have started to focus on models to examine lesion pathogenesis as 
well as therapeutic interventions in Apoe-/- or Ldlr-/- mice in which the intervention phase 
is initiated with a switch to chow (low-fat) diet alone (Hans et al., 2009; Hewing et al., 
2013; Huang et al., 2017; Karunakaran et al., 2016; Rayner et al., 2011). 
1.10.2 Molecular Events in Atherosclerosis Regression 
Mouse models of regression have been key for revealing the molecular characteristics of 
the so-called “regressive plaque”. These models have been critical for understanding 
advanced plaque morphology, including size, monocyte recruitment, proliferation and 
efferocytosis, smooth muscle cell recruitment, and extracellular matrix deposition. 
Regression models have been especially informative with respect to the necrotic core, 
fibrous cap, apoptosis and necroptosis, features of lesions that do not exist in early fatty 
streak lesions.  
Regressive plaques are characterized by reduced overall macrophage content and 
remaining macrophages are located at the luminal periphery. Additionally, regressive 
plaques have increased fibrotic material, less apoptosis, and smaller necrotic cores 
(Figure 1.5). Overall, the combination of these features is suggestive of plaques of 
increased stability and less susceptibility to rupture and subsequent thrombosis formation.  
1.10.3 Macrophages and Regression 
The most well characterized cell type in atherosclerosis regression is the macrophage 
(Moore et al., 2013; Moore and Tabas, 2011; Peled and Fisher, 2014; Tabas and 
Bornfeldt, 2016). A number of studies have characterized the role of 
monocyte/macrophage kinetics and macrophage phenotype during plaque resolution 
(Peled and Fisher, 2014). Logistically, lesion macrophage content can be reduced in three 
ways: 1) reduced recruitment into the plaque, 2) reduced proliferation within the plaque 
with stable apoptosis, and 3) emigration out of the plaque. 
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In atherosclerosis-susceptible mice (Ldlr-/- or Apoe-/-) fed a high-fat diet, progressing 
plaques (A) rapidly grow because of continued elevation of apoB-containing lipoproteins. 
Progressing plaques are larger, and the predominant cell type is the M1, pro-
inflammatory macrophage, engorged with many lipid droplets (foam cells). Smooth 
muscle cells also become foamy and the collagen cap is smaller and less organized. Due 
to increased apoptosis and defective efferocytosis, progressing plaques are characterized 
by an enlarged necrotic core, also contributing to a less stable, more vulnerable plaque. 
During regression in mice (B), plaques can shrink in size. They are characterized by 
reduced lipid, fewer total macrophages, but more M2, anti-inflammatory macrophages. 
These plaques are more stable, characterized by increased amount and more organized 
collagen in the cap, less apoptosis and smaller necrotic cores, contributing to a less 
vulnerable plaque. 
  
Figure 1.5 Plaque Composition in Progressing and Regressing Atherosclerotic 
Plaques 
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1.10.3.1 Egress of Macrophages 
Using the transplant model, macrophage depletion through emigration was one of the 
first processes identified contributing to the regressing plaque (Llodra et al., 2004; Reis et 
al., 2001). This feature was subsequently observed in the Reversa mouse (Feig et al., 
2011a). Emigration in the transplant model was associated with distinct changes in 
molecular signature, including upregulation of dendritic and M2 markers, and reduction 
of adhesion molecules (Feig et al., 2012). Upregulation of Ccr7, a marker of dendritic 
cell migration, was found to be essential for macrophage depletion (Trogan et al., 2006). 
The first cell trafficking studies in the Apoe-/- transplant model revealed that decreased 
plaque size was linked to emigration of monocyte-derived macrophages (Llodra et al., 
2004). The increase in Ccr7 expression has been observed in other models of 
atherosclerosis regression associated with macrophage emigration from plaques and 
reduced plaque macrophage content and size (Feig et al., 2011a; Feig et al., 2010; Feig et 
al., 2011c; Feig et al., 2012).  
1.10.3.2 Recruitment of M2 Macrophages 
The atherogenic milieu is characterized by elevated monocytes in the circulation, which 
perpetuates atherosclerosis (Barrett et al., 2017; Murphy et al., 2011; Nagareddy et al., 
2014; Nagareddy et al., 2013; Rahman et al., 2017b; Swirski et al., 2007; Tabas and 
Bornfeldt, 2016). Therefore, reducing monocyte recruitment would likely contribute to 
reduced lesion macrophage content during regression. Reduced monocyte recruitment 
into plaques was first observed in trafficking studies performed in the Apoe-/- mouse 
using the Apoe complementation model of regression (Potteaux et al., 2011) and 
confirmed by others (Distel et al., 2014; Nagareddy et al., 2013). The dogma until 
recently was that Ly6Chi monocytes were preferentially recruited to growing 
atherosclerotic plaques becoming pro-inflammatory M1 macrophages, whereas Ly6Clo 
monocytes were thought to be precursors of M2 pro-resolving macrophages in regressing 
plaques. The precursor of lesion M2 cells was revealed in recent studies using a 
combination of the Apoe-/- transplant model and normolipidemic recipient mice deficient 
in chemokine receptors necessary to recruit Ly6Chi (Ccr2-/- or Cx3cr1-/-) or patrolling 
Ly6Clo (Ccr5-/-) monocytes (Rahman et al., 2017a). As anticipated, reduced plaque 
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macrophage content and increased M2 markers were associated with regression. 
However, continued recruitment of Ly6Chi monocytes and their polarization to the M2 
state were required for resolution of atherosclerotic inflammation and plaque regression 
(Rahman et al., 2017a). 
1.10.3.3 Reduced Intraplaque Macrophage Proliferation 
The Swirski lab demonstrated that growth and maintenance of advanced plaques is not 
dominated by the recruitment of monocytes, but by the propagation of local macrophages 
within the plaque (Robbins et al., 2013). This raises the possibility that halting 
macrophage proliferation may be an important player in the transition between advanced 
plaque progression and regression. Recently, macrophage proliferation was targeted in 
high fat fed Apoe-/- mice with an intervention consisting of simvastatin nanoparticles. 
Although plaque size did not change, the intervention attenuated macrophage 
proliferation, reduced plaque inflammation and increased markers of plaque stabilization 
(Tang et al., 2015). However, it was difficult to assess whether regression occurred 
without baseline lesion data. 
Likely, all three mechanisms of macrophage depletion, increased macrophage egress, 
reduced monocyte recruitment with a shift to M2 polarization and attenuated macrophage 
proliferation, participate in the resolution or regression of atherosclerotic lesions. The 
coordinated reduction of lesion macrophages contributes to a less inflammatory plaque. 
1.10.4 Smooth Muscle Cells and Plaque Remodeling 
The fate of SMCs in regressing plaques has received much less focus. This limitation 
likely stems from the observation that murine atherosclerosis is primarily macrophage 
foam cell-driven. In the Apoe-/- transplant model, regressing plaques were characterized 
by increased SMCs, especially in the cap, which is consistent with plaque stabilization 
(Llodra et al., 2004; Trogan et al., 2006). In the Ldlr-/- AAV Ldlr complementation 
model, plaque regression was characterized by an increased number of SMCs and a 
modest increase in collagen (Van Craeyveld et al., 2011). In the Ldlr-/- diet model, 
intervention with a PPARδ agonist resulted in preservation of lesion SMC number and 
collagen was increased and more highly organized, characteristics of lesions with a more 
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stable phenotype (Bojic et al., 2014). The exact mechanisms through which SMCs alter 
their function during regression are unknown. With a reduced lipoprotein stimulus, fewer 
SMC-foam cells are formed, which is known to result in increased SMC matrix 
production (Frontini et al., 2009). Additionally, lower M1 macrophage content would 
result in less matrix metalloproteinase production, which facilitate breakdown of collagen 
matrix and regulate cell proliferation, migration and apoptosis (Van Lint and Libert, 
2007). 
1.10.5 HDL and Cholesterol Efflux 
Mechanisms that increase HDL capacity for cholesterol efflux are the most extensively 
characterized intervention processes during regression and have been recently reviewed 
(Feig et al., 2016). For example, aortic transplant from Apoe-/- mice into Apoe-/- recipients 
transgenic for human ApoA1 and fed a chow diet, resulted in rapid lesion regression 
(Feig et al., 2011b). In Apoe-/- mice fed a high fat, high cholesterol diet with established 
atherosclerosis, intervention with injections of recombinant ApoA-I(Milano) or a 
reconstituted statin-containing HDL particle, while continuing the high fat, high 
cholesterol diet, resulted in lesions characteristic of atherosclerosis regression 
(Duivenvoorden et al., 2014; Shah et al., 2001). Additionally, in high-fat fed Ldlr-/- mice, 
intervention with a chow diet plus an antagonist of mir-33, a microRNA that 
downregulates genes in HDL generation, resulted in improved HDL function and induced 
lesion regression (Distel et al., 2014; Rayner et al., 2011). 
1.10.6 Genetic Intervention and Regression 
ApoE, Ldlr and ApoA1 complementation, as well as Mttp deletion induce regression in 
mice with established atherosclerosis and were discussed above and in (Feig et al., 2011a; 
Kassim et al., 2010; Potteaux et al., 2011; Van Craeyveld et al., 2011). 
1.10.7 Diabetes Hinders Regression 
The direct causative role of type 2 diabetes and accelerated atherosclerosis has not been 
firmly established, although a combination of hyperglycemia, insulin resistance and 
hyperlipidemia likely contribute. Studies in mice have suggested that diabetes impairs 
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atherosclerosis regression (Barrett et al., 2017; Nagareddy et al., 2013; Parathath et al., 
2011; Willecke et al., 2015). In the Reversa model, the induction of type 1 diabetes with 
STZ at the same time as the Mttp deletion and switch to a chow diet impaired the 
improvement of plaque features associated with regression (Parathath et al., 2011). 
Although no change in plaque size occurred in either controls or STZ-treated mice, 
lesions of diabetic mice showed attenuated increases in collagen and M2 macrophages. 
Furthermore, reductions in plaque cholesterol, macrophage content and inflammatory 
gene expression were impaired. Similar findings were reported in Ldlr-/- mice fed a 
Western diet for six months and with STZ-induction of type 1 diabetes at the time of 
intervention with a chow diet (Nagareddy et al., 2013). The reductions in lesion area, 
lipid content, macrophage number and inflammatory markers were significantly 
attenuated in diabetic mice, an effect attributed to persistent recruitment of Ly6Chi 
monocytes into lesions. In a recent study, Ldlr-/- mice fed a high-fat diet were injected 
with STZ at week 14 (Willecke et al., 2015). At week 16, intervention consisted of a 
chow diet, with or without injection of adenovirus Ldlr. Regression was only observed 
with Ldlr expression, and lesion size and macrophage content decreased similarly in both 
diabetic and non-diabetic mice. However, lesion size and complexity was greater in 
diabetic mice at baseline. The impact of type 2 diabetes on regression has not been 
explored in mice likely because the interventions used to resolve features of type 2 
diabetes, including hyperinsulinemia, insulin resistance, glucose intolerance and obesity, 
also lower plasma lipids, making it difficult to dissect the specific role of type 2 diabetes 
during regression.  
1.10.8 Therapeutic Interventions Combined with Plasma Lipid 
Lowering 
Although mouse models of regression have extensively employed genetic interventions to 
characterize features of plaque regression, the impact of therapeutic strategies on 
regression have also been reported. Most therapeutic interventions have been performed 
on the background of aggressive lipid lowering. This approach is rationalized because the 
majority of patients would be treated on the background of statin therapy as well as diet 
and lifestyle modifications. Many therapeutic strategies have focused on cholesterol 
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efflux and HDL raising strategies (reviewed in (Feig et al., 2016) and above). Other 
studies have successfully achieved regression with different therapeutic interventions. In 
the Ldlr-/- model, intervention with the addition of an MTP inhibitor to a chow diet did 
not change plaque size, but induced several characteristics of regression, including 
reduced macrophages and increased collagen (Hewing et al., 2013). In Apoe-/- mice, 
intervention with the addition of the LXR agonist TO901317 to a chow diet in the Apoe 
complementation model, induced plaque regression, but also caused hepatic steatosis 
(van der Stoep et al., 2013). Using the Reversa model, the addition of the PPARγ agonist, 
pioglitazone to the intervention, had no additive effect on regressing lesions (Feig et al., 
2011a). In the Ldlr-/- model, intervention with small molecule inhibitors of ER stress 
signaling did not affect lesion area, but reduced necrotic core size and increased SMC 
and collagen content, features consistent with more stable plaques (Huang et al., 2017). 
Similarly, intervention by the addition of a PARP inhibitor to a chow diet in Apoe-/- mice 
resulted in a trend to smaller lesion sizes, with features of regression (Hans et al., 2009).  
1.10.9 Therapeutic Interventions in the Absence of Dietary Change  
Some regression studies have examined therapeutic interventions while maintaining the 
high-fat diet, in order to determine whether the therapeutic could overcome or compete 
favorably with the lesion-inducing high-fat diet. In Apoe-/- mice with high-fat diet 
induced atherosclerosis, pharmacological inhibition of ACAT, while maintaining the 
high-fat diet, slowed progression of lesion size, but did not induce regression (Rong et al., 
2013). Apoe−/− mice fed a Western diet for 6 weeks subsequently received an 
intervention with the necroptosis inhibitor necrostatin-1, while maintaining the Western 
diet (Karunakaran et al., 2016). Although lesion size and features of plaque instability 
were decreased relative to controls, regression could not be assessed because no baseline 
data was provided. A recent report examined intervention with cyclodextrin in diet-
induced Apoe-/- mice and demonstrated significant regression of plaques not only when 
combined with lipid-lowering, but also in the background of severe hypercholesterolemia 
(Zimmer et al., 2016). The effect was attributed to LXR activation and improved 
cholesterol efflux.  
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1.11 Flavonoids 
In the search for new targets and therapeutic strategies for the metabolic syndrome and 
atherosclerosis, attention has turned to alternative therapies including a group of naturally 
occurring compounds called flavonoids. Flavonoids are a large class of secondary plant 
metabolites. They are widely distributed in plants and are important to plant pigmentation 
as well as have function in UV filtration, nitrogen fixation and anti-microbial properties 
(Heim et al., 2002). They are also present in our daily diet, in plant-derived foods such as 
fruits, vegetables, seeds, nuts, wine, and tea. Flavonoids are 15-carbon compounds 
composed of two phenyl rings connected by a three-carbon unit (Croft, 1998). They 
frequently occur attached to a sugar, or as O-glycosides, which makes them water 
soluble, although this reduces their bioavailability (Thilakarathna and Rupasinghe, 2013). 
The intestinal microflora breaks down the flavonoid glycosides to their aglycone form, 
which allows them to be absorbed. Therefore, the microbial population of the intestine 
could have a significant effect on absorption and bioavailability (Heim et al., 2002). 
Following absorption, there is evidence of modification in the liver or intestine, including 
glucuronidation, methylation and hydroxylation. There are several classes of flavonoids 
that are grouped based on structure and level of oxidation (Heim et al., 2002). These 
include flavanones, flavonols, flavones, flavan-3-ols, anthocyanins and isoflavones.  
1.11.1 Epidemiological Evidence  
The health properties of flavonoids have been demonstrated in numerous epidemiological 
studies investigating the inverse correlation between flavonoid consumption and coronary 
heart disease, stroke and type 2 diabetes (Mulvihill et al., 2016; Peterson et al., 2012). In 
a meta-analysis of 95 prospective studies, increased consumption of fruits and vegetables 
has been correlated with reduced relative risk for coronary heart disease, cardiovascular 
disease, stroke and all-cause mortality (Aune et al., 2017). In a study of Finnish men, 
those in the highest quartile of flavonol and flavan-3-ols intake had reduced relative risk 
for ischemic stroked compared to men in the lowest quartile of consumption (Mursu et 
al., 2008). In the same study, consumption of flavonones and flavones was associated 
with a reduced relative risk in cardiovascular disease death. In a separate study in post-
menopausal women, there was an inverse correlation between flavonone consumption 
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and coronary heart disease (Mink et al., 2007). No association was found between 
flavonoid consumption and stroke mortality. This discrepancy between cohorts raises an 
important caveat in assessing the effects of flavonoids; when measuring flavonoid 
consumption, many studies estimate intake based on food sources, and biomarkers of 
consumption are not used (Assini et al., 2013a; Peterson et al., 2012). Therefore, research 
has started to focus on assessing the effects of purified flavonoids to assess their disease 
fighting properties.  
1.11.2 Flavonoids and Metabolic Disease 
A number of studies have shown that purified flavonoids have lipid-lowering and insulin 
sensitizing effects in animal models of metabolic disease. Herbacetin, a flavonoid found 
in flaxseed, prevented obesity, hyperlipidemia, hyperglycemia and hepatic steatosis in 
high-fat fed C57BL/6J mice (Veeramani et al., 2018). Treatment with apigenin, a 
flavonoid found in celery and parsley, in high-fat fed C57BL/6J mice ameliorated 
hyperlipidemia, insulin resistance and hepatic steatosis but did not affect diet-induced 
obesity (Jung et al., 2016). These effects were attributed to reduced lipogenic gene 
expression and enhanced oxidative gene expression in the liver. Luteolin, a flavonoid 
found in parsley, thyme and peppermint, prevented obesity, insulin resistance and hepatic 
steatosis (Kwon et al., 2015). Luteolin enhanced lipolysis and the Kreb’s cycle in adipose 
tissue and reduced gluconeogenesis in the liver. These studies suggest that flavonoids can 
target pathways involved in lipid metabolism and glucose homeostasis resulting in 
metabolic protection in mouse models.  
1.11.3 Flavonoids and Atherosclerosis 
A number of flavonoids have been shown to have anti-atherosclerotic effects in murine 
models of atherogenesis. Far fewer of these studies have focused on the regression or 
reversal of atherosclerosis. Quercetin, a flavonoid found in apples and onions, prevents 
the progression of atherosclerosis in high-fructose fed C57BL/6 mice, which was 
associated with reduced plasma lipids and reduced vascular ROS production, 
inflammation and apoptosis (Lu et al., 2017). In Apoe-/- mice and ApoE*3Leiden mice, 
quercetin protects against atherosclerosis, enhances macrophage reverse cholesterol 
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transport and reduces systemic inflammation (Cui et al., 2017; Kleemann et al., 2011). 
Isorhamnetin, a flavonoid found in red and yellow onions, protects against atherosclerosis 
and reduces oxidized LDL-induced apoptosis in Apoe-/- mice fed a high-cholesterol diet 
(Luo et al., 2015). In a regression model, rabbits fed a cholesterol-enriched induction diet, 
intervention with apple pro-cyanidins reduced aortic plaques from baseline to a greater 
extent than intervention with a normal chow diet alone (Wang et al., 2017). These studies 
are just a few examples of the beneficial effects of flavonoids on atherosclerosis 
progression and regression. 
1.11.4 Citrus Flavonoids 
Citrus fruits represent a significant source of many types of flavonoids. The most 
common citrus flavonoids investigated for anti-atherogenic effects are hesperetin, 
eriodictyol, tangeretin, naringenin and nobiletin (Table 1.2) (Mulvihill et al., 2016). 
Hesperidin, the glycosidic form of hesperetin slowed weight gain, prevented 
hyperlipidemia, insulin resistance and hepatic steatosis, thereby preventing 
atherosclerosis in high-fat fed Ldlr-/- mice (Sun et al., 2017). In zebrafish, eriodictoyl 
ameliorates diet-induced obesity, hyperlipidemia and hepatic steatosis through enhanced 
hepatic mitochondrial biogenesis (Hiramitsu et al., 2014).  
This thesis focuses on the effects of two citrus-derived flavonoids, naringenin and 
nobiletin. Naringenin is a flavonoid, predominantly found in grapefruits. Previous studies 
from our laboratory have shown that this flavonoid has significant anti-atherogenic 
properties. In cultured hepatocytes (HepG2), naringenin inhibited ACAT1/2 and MTP 
activity, and reduced triglyceride accumulation in the ER resulting in reduced production 
of apoB-containing lipoproteins (Borradaile et al., 2003a; Wilcox et al., 2001). 
Furthermore, naringenin also enhanced the proteasomal degradation of apoB100 in 
oleate-stimulated HepG2 cells (Borradaile et al., 2002a). In additional mechanistic 
studies, naringenin reduced apoB100 production through activation of the PI3K 
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Table 1.2 Common Citrus Flavonoids 
Adapted from: Manach, C., Scalbert, A., Morand, C., Rémésy, C., and Jiménez, L. (2004). 
Polyphenols: food sources and bioavailability. Am J Clin Nutr 79, 727-47.
(Permission to reproduce obtained)
Flavonoid Structure Class Source 
Naringenin 
 
Flavanone – 
aglycone form 
Grapefruits, 
tomatoes, 
mint 
Naringin 
 
Flavanone 
Grapefruits, 
tomatoes, 
mint 
Hesperetin 
 
Flavanone – 
aglycone form 
Oranges, 
tomatoes, 
mint 
Hesperedin 
 
Flavanone 
Oranges, 
tomatoes, 
mint 
Eriodictyol 
 
Flavanone – 
aglycone form 
Lemons, 
tomatoes, 
mint 
Nobiletin 
 
Polymethoxylated 
flavone 
Tangerines, 
orange juice 
Tangeretin 
 
Polymethoxylated 
flavone 
Tangerines, 
oranges juice 
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and MAPKerk pathways, similar to insulin signaling (Allister et al., 2005; Borradaile et 
al., 2003b). Unlike insulin, this activity was independent of phosphorylation of the IR or 
IRS proteins (Allister et al., 2008). When these results were extended into an in vivo 
model of metabolic dysfunction and atherogenesis, namely the Ldlr-/- mouse fed a high-
fat diet, naringenin prevented weight gain, hyperinsulinemia and dyslipidemia in short-
term studies, and slowed progression of atherosclerosis in long-term studies (Mulvihill et 
al., 2009; Mulvihill et al., 2010). Furthermore, naringenin was also able to protect against 
cholesterol-induced metabolic dysregulation, inflammation and atherosclerosis in both 
high-fat or high-sucrose diets, further highlighting its therapeutic potential (Assini et al., 
2013b). 
Nobiletin is a polymethoxylated flavonoid derived predominantly from tangerines. 
Experiments from our laboratory in HepG2 cells demonstrated that at a dose 10 times 
lower than naringenin, nobiletin activated MAPKerk signaling to increase LDLR and 
decrease MTP expression to reduced apoB100 secretion (Mulvihill et al., 2011). Similar 
to naringenin, this effect was independent of the IR and IRS. In macrophages, nobiletin 
reduced the expression of proinflammatory cytokines and the uptake of acetylated LDL 
(Lin et al., 2003; Whitman et al., 2005). When these results were extended to an in vivo 
mouse model by our group, supplementation of nobiletin to a high-fat diet prevented diet-
induced obesity, insulin resistance, hyperlipidemia and the development of 
atherosclerosis (Mulvihill et al., 2011). These studies highlight the potential therapeutic 
use of citrus flavonoids in treating obesity, the metabolic syndrome and atherosclerosis. 
1.12 Mouse Models and Diets 
1.12.1 Ldlr-/- Mouse 
C57BL/6J mice are the most common strain used in metabolic research due to their 
amenability of developing diet-induced obesity and insulin resistance upon feeding a 
high-fat diet (Fontaine and Davis, 2016). Mice are not intrinsically susceptible to 
atherosclerosis, as they transport the majority of their plasma cholesterol in HDL 
(Guyard-Dangremont et al., 1998). Therefore, genetically modified mice are required to 
study atherosclerosis. Deletion of Ldlr in C57BL/6J mice disrupts normal murine 
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lipoprotein metabolism resulting in elevated plasma cholesterol, particularly in the LDL 
fraction because of defective LDLR-mediated clearance from plasma (Ishibashi et al., 
1993). Upon feeding these mice a cholesterol containing diet, plasma cholesterol is 
further increased in both the VLDL and LDL fractions and they develop atherosclerosis 
in the aorta and the aortic sinus (Ishibashi et al., 1994). Ldlr-/- mice, fed a high fat, high 
cholesterol (HFHC) diet for twelve weeks, develop many of the features of the metabolic 
syndrome including obesity, insulin resistance, dyslipidemia, and hepatic steatosis 
(Assini et al., 2013b). They also develop intermediate lesions that exhibit significant lipid 
accumulation, macrophage and smooth muscle cell infiltration, and extensive collagen 
deposition (Assini et al., 2013b). After 24 weeks of HFHC diet, the lesions are more 
advanced, with increased numbers of apoptotic cells and a large necrotic core. Ldlr-/- 
mice were used in Chapters 2, 3 and 4. 
1.12.2 Mouse Diets 
1.12.2.1 Chow Diet 
Laboratory chow (TD8604) was used as a control diet, which provided a reference for 
metabolic indices altered by feeding the high-fat, high cholesterol diet. The chow diet 
contains complex carbohydrates and 14% of calories as fat. One of the major ingredients 
in the chow diet is soybeans, which can contain the isoflavones daidzein and genistein. 
Typical concentrations are variable between 350 to 650 mg/kg. The caloric density of the 
chow diet is 3.0 kcal/g (Table 1.3). The chow diet was fed ad libitum to mice in studies 
described in Chapter 2. 
1.12.2.2 High Fat, Cholesterol-Containing Diet 
The high fat, cholesterol-containing diet (HFHC) (TD09268) is a modified western diet. 
The western diet is commonly used to induce metabolic abnormalities and 
atherosclerosis. The HFHC diet has an additional 0.15% cholesterol, bringing the total 
cholesterol to 0.2%. Diets with the same, or similar amounts of cholesterol have been 
shown to increase macrophage inflammation, and exacerbate the development of insulin 
resistance, dyslipidemia, hepatic steatosis and atherosclerosis (Subramanian et al., 2011; 
Subramanian et al., 2008). The HFHC diet is made up of 42% of calories derived from  
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Formula
Traditional Chow 
Diet
TD8604
Iso-Flavone Free 
Chow Diet
High-fat, Cholesterol 
Containing Diet 
(TD09268)
g/kg
Casein
*See represented 
ingredients, exact 
amounts not 
specified
†See represented 
ingredients, exact 
amounts not 
specified
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DL-Methionine 3
Sucrose 341.46
Corn Starch 150.75
Anhydrous Milk Fat 160
Lard (Pork) 50
Cellulose 35.13
Mineral Mix 50
Zinc Carbonate 0.04
Vitamin Mix 10
Choline Bitartrate 3
Ethoxyquin 0.02
Macronutrients % weight (% calories)
Protein 24.3 (32) 16.4 (22) 17.3 (15.2)
Carbohydrate 40.2 (54) 48.5 (66) 48.7 (42.8)
Fat 4.7 (14) 4 (12) 21.2 (42)
kcal/g 3.0 3.0 4.5
Cholesterol (%wt) 0.005% 0 0.2%
*Represented ingredients: Dehulled soybean meal, wheat middlings, flaked corn, ground 
corn, fish meal, cane molasses, ground wheat, dried whey, soybean oil, brewers dried 
yeast, dicalcium phosphate, calcium carbonate, iodized salt, choline chloride, kaolin, 
magnesium oxide, ferrous sulfate, vitamin E acetate, menadione sodium bisulfite complex 
(source of vitamin K activity), manganous oxide, copper sulfate, zinc oxide, niacin, thiamin 
mononitrate, vitamin A acetate, vitamin D3 supplement, calcium pantothenate, pyridoxine 
hydrochloride, riboflavin, vitamin B12 supplement, calcium iodate, folic acid, biotin, cobalt 
carbonate.
†Represented ingredients: Ground wheat, ground corn, wheat middlings, corn gluten 
meal, calcium carbonate, dicalcium phosphate, soybean oil, brewers dried yeast, iodinized
salt, L-lysine, DL-methionine, choline chloride, magnesium oxide, vitamin E acetate, 
menadione sodium bisulfite complex (source of vitamin K activity), manganous oxide, 
ferrous sulfate, zinc oxide, niacin, calcium pantothenate, copper sulfate, pyridoxine 
hydrochloride, riboflavin, thiamin mononitrate, vitamin A acetate, calcium iodate, vitamin 
B12 supplement, folic acid, biotin, vitamin D3 supplement, cobalt carbonate.
Table 1.3 Mouse Diets 
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fat, 43% of calories derived from carbohydrates and 15% calories derived from protein. 
The main sources of fat are anhydrous milk fat and lard, and the fatty acid profile is 58% 
saturated, 36% monounsaturated and 5% polyunsaturated. The carbohydrate sources are 
sucrose (30% of calories) and corn starch (13% of calories) and the protein source is 
casein (15.2% of calories). The caloric density of the HFHC diet is 4.5 kcal/g (Table 1.3). 
The HFHC diet was fed ad libitum to the mice in studies described in Chapters 2 and 3. 
1.12.2.3 Isoflavone-free Chow Diet 
An isoflavone-free chow (TD2016) was used as a control chow diet, to which flavonoids 
were supplemented in order to assess the additive effects of flavonoid supplementation. 
An isoflavone free chow was used because of the variability in flavonoid content in 
conventional soy-based chow diets, and the metabolic effects of soy-derived flavonoids 
can be similar to those of the citrus flavonoids under investigation in this thesis 
(Borradaile et al., 2002b). The major ingredients are wheat and corn and it does not 
contain soybean. Typical isoflavone concentrations range from non-detectable to 20 
mg/kg (compared to 350 to 650 mg/kg in conventional chow). The isoflavone-free diet 
contains complex carbohydrates and 12% of calories as fat. The caloric density of iso-
flavone-free chow is 3.0 kcal/g (Table 1.3). The isoflavone-free diet was fed ad libitum to 
mice in studies described in Chapter 3 and pair-fed to mice in the studies described in 
Chapter 4.  
1.13 Scope of Thesis 
Obesity, dyslipidemia and insulin resistance are major risk factors for the development of 
premature cardiovascular disease. Although statins, a class of cholesterol-lowering drugs, 
have been successful at reducing cardiovascular disease mortality, obesity, and metabolic 
syndrome, cardiovascular disease remains a leading cause of morbidity and mortality 
world-wide. Despite many promising pre-clinical therapeutic studies in animal models, 
there is often a lack of translatability into humans. The majority of pre-clinical 
therapeutic studies have been performed in animal models of disease progression, 
whereby the treatment is started at the same time as disease initiation. Recently there has 
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been an evolution towards intervention-based study designs, where the treatment is 
administered after the disease has been established. 
The studies described in this thesis were undertaken to assess the therapeutic capacity of 
citrus flavonoids, naringenin and nobiletin, to reverse existing obesity, metabolic 
dysfunction and atherosclerosis, after disease was already established. We first examined 
the ability of naringenin and nobiletin supplementation to induce weight loss, reverse 
insulin resistance, hyperlipidemia, hepatic steatosis and improve atherosclerosis in diet-
induced Ldlr-/- mice that continued to consume a high-fat, high cholesterol diet. To 
extend these studies into a model of atherosclerosis regression, we next examined the 
ability of naringenin supplementation to a chow diet at intervention, to enhance metabolic 
improvements and induce atherosclerosis regression in Ldlr-/- mice with pre-estabished 
metabolic dysfunction and intermediate atherosclerosis. Finally, to further understand the 
metabolic effects and to identify underlying mechanisms of naringenin, we investigated 
the effects of naringenin supplementation in the absence of obesity, metabolic 
dysfunction and atherosclerosis by conducting a pair-feeding study in chow-fed Ldlr-/- 
mice.  
Therefore, Chapters 2 to 4 address the following hypotheses: 
1. Intervention by supplementation of the flavonoids, naringenin and nobiletin, to a 
high-fat diet can reverse diet-induced obesity, hyperlipidemia, hepatic steatosis, 
insulin resistance and atherosclerosis in a mouse model of diet-induced obesity 
and intermediate atherosclerosis (Chapter 2). 
2. Intervention by supplementation of the flavonoid naringenin to a chow diet can 
enhance the reversal of obesity and metabolic dysfunction and induce regression 
of established atherosclerotic lesions in a mouse model of diet-induced obesity 
and intermediate atherosclerosis (Chapter 3). 
3. Supplementation of the flavonoid naringenin to a regular chow diet in lean, 
healthy mice will enhance insulin sensitivity, increase energy expenditure and 
reduce plasma lipids compared to mice fed a regular chow diet alone (Chapter 4). 
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Chapter 2  
2 Intervention with citrus flavonoids reverses obesity, and 
improves metabolic syndrome and atherosclerosis in 
obese Ldlr-/- mice 
2.1 Introduction 
Fat accumulation, as a result of an imbalance between energy input and expenditure, 
leads to obesity, type 2 diabetes, cardiovascular disease and hepatic steatosis, which 
collectively represent one of the leading causes of adult morbidity and mortality world-
wide (Hamilton et al., 2007; Olshansky et al., 2005; Saltiel, 2016). This suggests that 
restoration of functional energy homeostasis is critical for therapeutic intervention. 
Despite efforts to develop anti-obesity medications that curtail symptoms of metabolic 
dysfunction, drugs that have reached market have limited efficacy for obesity (~5-8%) 
and many have been withdrawn for negative side effects (Heymsfield and Wadden, 2017; 
Khera et al., 2016; Rodgers et al., 2012; Saltiel, 2016). Currently available therapeutics 
predominantly work by either reducing caloric intake or blocking food absorption 
(Saltiel, 2016). Additionally, patients often regain lost weight. The treatment strategy 
with the most robust and lasting improvements is gastric bypass surgery, which has 
shown up to ~25% weight loss at 12-years together with a 51% remission rate for type 2 
diabetes (Adams et al., 2017). Presently, gastric bypass surgery as an intervention for 
obesity and metabolic syndrome is limited to patients with a BMI ≥35kg/m2 (Nguyen and 
Varela, 2017), excluding patients with moderate obesity, although these patients often 
present with increased metabolic dysfunction and cardiovascular risk (Eckel et al., 2005; 
Wilson et al., 2002). Therefore, there is urgent need for safe and effective medical 
therapies for obesity and its associated complications, including the metabolic syndrome 
and cardiovascular disease.  
Epidemiological studies show an inverse correlation between flavonoid (a class of plant-
derived polyphenols) consumption and the development of type 2 diabetes, metabolic 
syndrome, and atherosclerosis (Amiot et al., 2016; Mulvihill et al., 2016). Previous 
research in our lab identified the citrus-derived flavonoids, naringenin and nobiletin, as 
77 
 
novel therapeutics for the prevention of metabolic syndrome and cardiovascular disease 
(Assini et al., 2015; Assini et al., 2013; Mulvihill et al., 2009; Mulvihill et al., 2011; 
Mulvihill et al., 2010). These flavonoids have anti-inflammatory properties, promote 
insulin sensitivity and inhibit apoB100 secretion from cultured hepatocytes (Borradaile et 
al., 2003; Lin et al., 2003; Mulvihill et al., 2011; Whitman et al., 2005). When extended 
to a mouse model of obesity, metabolic dysfunction and atherogenesis, namely the Ldlr-/- 
mouse fed a high-fat, high cholesterol (HFHC) diet, prevention studies revealed that 
supplementation of the HFHC diet with naringenin or nobiletin attenuated weight gain 
and adiposity, enhanced insulin signaling, lowered plasma lipids, prevented systemic 
inflammation and hepatic steatosis, resulting in slowed atherosclerosis progression 
(Assini et al., 2015; Assini et al., 2013; Mulvihill et al., 2009; Mulvihill et al., 2011; 
Mulvihill et al., 2010). While these studies highlight potential therapeutic utility of the 
citrus flavonoids, it would be more clinically relevant to assess the efficacy of these 
compounds in an intervention protocol, where obesity, insulin resistance, hyperlipidemia 
and atherosclerosis have been established prior to treatment. 
In the present study we show, in Ldlr-/- mice with pre-established diet-induced obesity, 
metabolic dysregulation and intermediate-stage atherosclerosis, that intervention by the 
addition of either naringenin or nobiletin to a HFHC diet not only prevented continued 
obesity and deterioration in symptoms of the metabolic syndrome, but markedly reduced 
adipose tissue mass, normalized glucose homeostasis, and attenuated both hyperlipidemia 
and hepatic steatosis. Correction of metabolic parameters was accompanied by a 
reduction in circulating blood monocytes. Collectively, these metabolic improvements 
did not resolve the size of aortic sinus atherosclerotic lesions, but plaques in flavonoid-
treated mice were characterized by reduced macrophage and cholesterol content, 
consistent with lesion regression (Basu et al., 2018; Burke and Huff, 2018). 
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2.2 Materials and Methods 
2.2.1 Animals and Diets 
Male Ldlr-/- mice on a C57BL/6 background (Jackson Laboratory, Bar Harbor, MA), 
were housed in pairs in standard cages at 23ºC on a 12 h light and dark cycle. The 
animals were cared for in accordance with the Canadian Guide for the Care and Use of 
Laboratory Animals. All experimental procedures were approved by the Animal Care 
Committee at the University of Western Ontario (protocol # AUP-2016-057). Mice 10-12 
weeks of age (n=10) were fed ad libitum, a purified rodent chow diet (14% of calories 
from fat, Teklad Rodent Diet 8604, Envigo, Madison WI) for 24 weeks. Another group of 
mice (10-12 weeks of age, n=120; 24/group) were fed a high-fat, cholesterol containing 
(HFHC; 42% of calories from fat, 0.2% cholesterol, Teklad TD09268, Envigo, Madison 
WI) diet for 12 weeks (baseline). A subgroup of these HFHC-fed mice (n=24) were 
sacrificed at 12 weeks to provide baseline data for analyses that required sacrifice. The 
remaining mice were divided amongst 4 different groups and for the subsequent 12 
weeks: one group remained on the same HFHC diet (n=24), one group remained on the 
HFHC supplemented with 3% naringenin (#N5893, Millipore-Sigma) (n=24), one group 
remained on the HFHC diet supplemented with 0.3% nobiletin (#10236-47-2, R&S 
PharmChem, Hangzhou City, China) (n=24) and one group switched to the standard 
rodent chow (n=24). Food intake and body weights were measured weekly. Caloric 
intake was calculated as weight of food eaten (g) per day multiplied by the caloric 
content of each diet (chow 3.0 kcal/g; HFHC 4.5 kcal/g). We previously observed a taste 
aversion with naringenin and nobiletin, which was mitigated by slowly increasing the 
flavonoid dose over the first week of intervention to prevent an impact on food intake 
(data not shown). 
2.2.2 Blood and Tissue Collection 
Mice were fasted for 6 hours at the start of the light cycle prior to blood taking or 
sacrifice. At sacrifice, animals were anesthetized with Ketamine-Xylazine (100µg/g 
Ketamine hydrochloride, Bioniche Animal Health Canada Inc., Belleville, ON and 
10µg/g Xylazine, Bayer Healthcare, Animal Health Division, Bayer Inc., Toronto, ON). 
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Blood was collected via cardiac puncture in syringes containing 80 µl of 7% Na2-EDTA. 
Blood was centrifuged at 12,000 rpm for 10 minutes at 4ºC to separate the plasma, which 
was stored at -20ºC for further use. Tissue dissections were performed via midline 
incision. To dissect the heart for histological analysis, the left ventricle was perfused with 
phosphate buffered saline (PBS) containing heparin (10 units/mL) and the right atrium 
was cut to drain the perfusate. The heart and full-length aorta were dissected together. 
Aortae were rinsed and cleaned using a dissecting microscope to remove any adipose 
tissue. Aortae were snap frozen in liquid N2 and stored at -80ºC for mRNA and lipid 
measurements. The top half of the heart was placed in optimum cutting temperature 
(OCT) medium, frozen on dry ice and stored at -80ºC for histological analyses. A small 
piece of epididymal and inguinal white adipose tissue was fixed in 4% paraformaldehyde 
and paraffin embedded for histological analyses. Liver, epididymal white adipose tissue 
(eWAT), inguinal white adipose tissue (iWAT), brown adipose tissue, quadriceps, 
gastrocnemii and solei muscles were removed, weighed and snap frozen in liquid N2 and 
stored at -80ºC. 
2.2.3 Metabolic Cages 
From 1 to 4 weeks prior to completion of the intervention period, energy expenditure, 
respiratory exchange ratio (RER), food consumption and locomotor activity were 
assessed using the Comprehensive Laboratory Animal Monitoring System (CLAMS; 
Columbus Instruments, Columbus, OH). Mice were housed in metabolic cages with free 
access to food and water and acclimatized for 48 hours. For the subsequent 24 hours, 
every 10 minutes, data on O2 consumption (VO2; mL/h) and CO2 production (VCO2; 
mL/h) were collected. The RER was derived from the ratio of VCO2 to VO2, and energy 
expenditure was determined as (3.815+ 1.232 X RER) X VO2 and expressed as analysis 
of covariance (ANCOVA)-adjusted energy expenditure in kcal/h. ANCOVA-adjustments 
to energy expenditure were made based on body weight, which allowed for the 
determination of differences in energy expenditure, independent of group differences in 
body weight. The ANCOVA analysis performed for this work was provided by the 
NIDDK Mouse Metabolic Phenotyping Centers (MMPC, www.mmpc.org) using their 
Energy Expenditure Analysis page (http://www.mmpc.org/shared/regression.aspx). 
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Ambulatory activity was measured as infrared beam breaks in the X, Y, and Z axis per 
hour. Accumulated food consumption was measured in grams and converted to kcal 
based on diet composition.  
2.2.4 Micro-CT 
Mice were first imaged at 12 weeks (baseline) on diet (n=8/group) and regularly 
following intervention (Week 14, 16, 18, 21, 23), as described previously (Assini et al., 
2015). Whole-body composition analysis was conducted by micro-CT imaging using a 
Locus Ultra micro-CT scanner (GE Healthcare) (Granton et al., 2010). Following a 4 
hour fast, mice were anesthetized with 1.5% isoflurane in O2. The scan protocol consisted 
of an x-ray tube voltage of 80 kVP and a current of 55.0 mA. A calibrating phantom, 
comprising air and water, was scanned concurrently as calibrators that enabled the 
conversion of the reconstructed image values into CT numbers (Hounsfield Units (HU)). 
In a scan time of 16 seconds, 1000 views were acquired in one continuous rotation. 
Images were reconstructed to an isotropic voxel size of 150 µm3. The analysis was 
conducted using MicroView software version 2.2 (GE Healthcare). Total adipose tissue 
volume was calculated by selecting all voxels with values within a window of -225 to -60 
HU and then divided into subcutaneous and visceral depots. Subcutaneous and visceral 
adipose tissue depots were differentiated using the muscular abdominal wall, which is 
readily identifiable because of its higher density (Luu et al., 2009). The subcutaneous and 
visceral adipose depots were outlined manually and the volume of each region was 
calculated by MicroView as the number of voxels falling within the threshold window 
multiplied by voxel volume (150 µm3). 
2.2.5 Glucose Tolerance and Insulin Tolerance Tests 
A glucose tolerance test was performed following a 6 hour fast by i.p. injection with 15% 
glucose in 0.9% NaCl (1g/kg body weight) (Mulvihill et al., 2009). Blood samples for 
glucose measurements (Bayer Contour Blood Glucose Monitoring System, Bayer 
Healthcare) were taken up to 120 minutes post-injection. An insulin tolerance test was 
conducted following a 5 hour fast by i.p. injection with insulin (0.6 IU/kg body weight; 
Novolin GE Toronto, Novo Nordsik, Cooksville, ON) (Mulvihill et al., 2009). Blood 
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samples for glucose measurements were obtained up to 60 minutes post-injection. 
Glucose and insulin tolerance were calculated as a percent change in blood glucose from 
baseline.  
2.2.6 Tissue Lipids 
Lipids from liver, quadriceps, gastrocnemii and solei, and full-length aortae dissected free 
of fat and connective tissue, were extracted using the method of Folch et al. from samples 
stored at -80ºC, as described previously (Assini et al., 2013; Folch et al., 1957). 
[Cholesteryl-1,2-3H(N)]Cholesteryl oleate (PerkinElmer, Guelph, Canada: #NET746L) 
was added to assess recovery. A combined 200 µg/mL triolein and 200 µg/mL 
cholesterol standard was prepared in isopropanol and aliquoted for standard curves (0-
20µg). Samples and standards were dried under N2, and a 1% Triton X-100 solution in 
chloroform added and left at room temperature for 1 hour to solubilize. Samples and 
standards were dried under N2, followed by the addition of deionized water and 
incubation at 37ºC for 15 minutes. Samples were analyzed using enzymatic reagents for 
triglyceride (Roche Diagnostics: Triglycerides/glycerol blanked, #11877771 216), total 
cholesterol (WAKO Diagnostics: Cholesterol E (CHOD-DAOS method) #439-17501) 
and free cholesterol (WAKO Diagnostics: Free cholesterol (COD-DAOS) method #435-
35801). Cholesteryl ester was determined as the difference between total cholesterol and 
free cholesterol. 
2.2.7 Plasma Measurements 
Plasma triglyceride and total cholesterol were measured on a Cobas Mira S autoanalyzer 
(Roche Diagnostics, Laval, Canada) using calibrators and controls from Roche 
Diagnostics (Mulvihill et al., 2009). Enzymatic reagents for triglyceride (Roche 
Diagnostics: triglycerides/glycerol blanked #11877771 216) and cholesterol (Roche 
Diagnostics: Cholesterol CHOD-PAP #11491458-216) were used. Fresh-EDTA plasma 
(50 µL) was separated by fast protein liquid chromatography (FPLC) using an AKTA 
purifier and a Superose 6 column (Assini et al., 2013). A constant flow rate of 0.4 
mL/min was used to collect 500 µL fractions. An aliquot of each fraction was used to 
measure cholesterol and triglycerides enzymatically in both samples and standards on a 
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microtitre plate with added enzymatic reagents (Triglyceride: Roche Diagnostics, 
triglycerides/glycerol blanked #11877771 216 and total cholesterol: WAKO Diagnostics, 
Richmond, VA, Cholesterol E: (CHOD-DAOS method) #439-17501). Blood glucose was 
measured in whole blood using the Bayer Contour Blood Glucose Monitoring System 
(Bayer Healthcare, Etobicoke, Canada) (Mulvihill et al., 2009). Plasma Insulin (ALPCO 
Diagnostics, Salem, NH: mouse ultrasensitive ELISA #80-INSMSU-E01) was 
determined in EDTA-plasma samples, stored at -80ºC, by a mouse specific ELISA. 
Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using 
the following formula as previously described for mice: HOMA-IR= 26 x fasting insulin 
level (ng/ml) x fasting glucose level (mg/dl)/405 (Murakami et al., 2014).  
2.2.8 Liver Beta Oxidation 
For hepatic fatty acid oxidation, fresh liver (250 mg) was homogenized in 0.1 M 
phosphate buffer, pH 7.2 containing 0.25 M sucrose, 1mM EDTA, 1 mM dithiothreitol, 
and 10 µL/mL of protease inhibitor (Sigma-Aldrich #P8340). Homogenates were 
centrifuged at 1000xg at 4ºC for 10 minutes. 20 µL of supernatant was incubated for 30 
minutes at 37ºC with constant shaking in a 0.1 M phosphate buffer, pH 7.2, containing 
150 mM KCl, 10 mM Hepes, 5 mM Tris malonate, 10 mM MgCl2, 1 mM carnitine, 5 
mM ATP and 2 µCi of [9,10-3H(N)]palmitic acid (PerkinElmer: #NET043001MC)/ 50 
µM unlabeled palmitic acid complexed with 0.15 % fatty acid-free BSA. Reactions were 
stopped with 200 µL of 0.6 N perchloric acid and unreacted fatty acids extracted with 
hexanes. 3H2O in the aqueous phase was measured by liquid scintillation counting (Huss 
et al., 2004; Mulvihill et al., 2009). 
2.2.9 Gene Expression 
RNA was isolated from aliquots of liver, epididymal and inguinal adipose tissue, brown 
adipose tissue and whole aortae using Trizol reagent (Life Technologies, Mississauga, 
Ontario, Canada). Reverse transcription of 1 µg total RNA was performed using the High 
Capacity Reverse Transcription kit (Applied Biosystems, ABI) to yield cDNA. Specific 
mRNA abundances were measured by quantitative real-time PCR (qRT-PCR) on an ABI 
ViiA 7 Sequence Detection System (ABI) according to the manufacturer’s instructions. 
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In the epididymal, inguinal and brown adipose tissue, mRNA quantitation for Tnfa, Ccl2, 
Ccl3, Emr1, Ucp1, Cidea, Pdk4, Ppara, Lipe and Pnpla2 was determined. In liver, 
mRNA quantitation for Cpt1a, Pgc1a, Srepf1c, Ppara, Acox1, Ccl2, Ccl3, and Tnfa was 
determined. In the aorta, mRNA quantitation for Ccl3, Il1b, Ccl2, Tnfa, Emr1, Ccr7, 
Abca1 and Abcg1 was determined. 10 ng samples of cDNA were assayed in triplicate in 
10 µL reactions using a standard curve qRT-PCR protocol to calculate specific mRNA 
concentrations. Expression levels for each gene were normalized to Gapdh expression in 
each tissue. With the exception of Srebf1c, all primer and probe sets used were purchased 
as TaqMan Assays (ABI). The probe and primer sequences for Srebf1c were designed 
from the known murine Srebf1 locus to determine splice junctions. The intervening 
intronic sequence was removed and primers and a probe were designed from the resultant 
Srebp1c exon1c-exon2 sequence using Primer Express 2.0 software (ABI). Primers were 
obtained from Sigma-Genosys and the probes labeled 5’ with 6- carboxyfluorescein 
(FAM) and 3’ with the quencher MGB® were from ABI. TaqMan assay for mouse 
Srebf1c: Forward Primer: CAGGCCCGGGAAGTCACT; Reverse Primer: 
GACCACGGAGCCATGGATT; Probe: FAM-ATTTGAAGACATGCTCCA-MGB®. 
2.2.10 Tissue Histology and Immunohistochemistry 
Histological and morphometric analyses were performed as described previously (Assini 
et al., 2013; Mulvihill et al., 2010). Epididymal white adipose tissue was fixed in 4% 
paraformaldehyde for 24 hours, processed, embedded in paraffin, and sectioned on a 
Microm HM335E microtome (Thermo Fisher Scientific) and stained with hematoxylin 
and eosin. Frozen serial sections (70-100 per heart, 10 µm) of the aortic sinus from hearts 
frozen in OCT, initiating anterior to the origin of the aortic valves, were prepared using a 
Leica CM 3050S cryostat. For quantitation of lesion area in the aortic sinus, sections 
were stained with oil red-O. Immunohistochemistry staining for macrophages by CD68 
(BioRad, Mississauga, Canada: MCA 1957), smooth muscle α-actin (Abcam, Toronto, 
Canada: polyclonal rabbit anti-smooth muscle α-actin, ab5694) and activated caspase-3 
(Abcam, rabbit anti-active caspase-3, ab4051), was performed as described previously 
(Bojic et al., 2014). Slides were fixed in acetone and blocked in 2% bovine serum 
albumin (Sigma-Aldrich). After incubation with primary antibody, a goat biotinylated 
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secondary antibody was used (Vector Laboratories, Burlington, ON). Slides were then 
incubated in peroxidase blocking reagent, followed by incubation with the ABC reagent 
(ABC Elite Standard Kit, Vector Laboratories). Slides were exposed to the DAB 
substrate (Peroxidase substrate kit, Vector Laboratories) followed by counterstain in 
hematoxylin (Sigma-Aldrich). Photomicrographs were obtained using an Olympus BX50 
microscope and a QImaging Retiga EXi FAST camera. Collagen fibrils were assessed 
using circular polarizing microscopy as described previously (Bojic et al., 2014). Aortic 
sinus sections were stained with picrosirius red (Polysciences, Warrington, PA) and 
visualized using an Olympus BX51 microscope (Olympus Canada, Richmond Hill, 
Canada) equipped with circular polarizer/interference filters, a liquid crystal 
compensator, a charge-coupled device video camera and Abrio image-processing 
software (Abrio LC-Polscope, Cambridge Research and Instrumentation, Inc., 
Hopkinton, MA). 
Morphometric analysis of lesion area, necrotic core area, CD68, smooth muscle α-actin 
and collagen in lesions from mice from each group was performed on serial sections. The 
relative area of the atherosclerotic plaque positive for CD68, smooth muscle α-actin or 
collagen was determined as the area of positive staining divided by the area of the 
respective plaque. Quantitation was determined using ImageJ 1.50 software (National 
Institutes of Health) for CD68, smooth muscle α-actin and collagen, or AxioVision 
software for lesion area and necrotic core size. To determine the relative activation of 
caspase-3, the number of cell nuclei immunostained for activated caspase-3 was 
expressed as a percentage of the total lesion area. To ensure that a standard region was 
measured in each mouse, lesion analyses began at the origin of the aortic valves. All 
quantitations were performed independently by three people.  
2.2.11 Flow Cytometry 
Blood and bone marrow cell analyses were performed in a separate experiment in Ldlr-/- 
mice (n=8/group) using the same induction and intervention protocol described above. 
Blood Leukocytes: Monocytes and neutrophils were identified from whole blood. At 
sacrifice, blood was collected by cardiac puncture into EDTA lined tubes and 
immediately placed on ice. For each mouse sample, 100 µL of blood was used. 
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UltraComp eBeads (Affymetrix eBiosciences #01-2222, Cedarlane, Burlington, ON) 
were used as a single positive control, except for the single positive control for the Vital 
Dye, where ArC™ Amine Reactive Compensation Bead Kit was used (A10346, Life 
Technologies, Burlington, ON). Fluorescence minus one (FMO) controls were performed 
on combined blood samples from all mice, 100 µL each. Viability was assessed using 
LIVE/DEAD® Fixable Dead Cell Near-IR Stain Kit (L11019, Invitrogen, Life 
Technologies, Burlington, ON) (Table 2.1) in all samples after incubation for 25 min in 
the dark at room temperature. Cells were stained with a cocktail of antibodies against 
CD45-eFluor®450 (Affymetrix eBiosciences, Cedarlane, Burlington, ON), Ly6-C/G-
PerCP-Cy™5.5 (BD Biosciences, Cedarlane, Burlington, ON) and CD115-APC 
(Affymetrix eBiosciences) on ice for 20 minutes in the dark (Table 2.1), similar to 
previous studies (Murphy et al., 2011). Red blood cells were lysed in 1X PharmLyse (BD 
Biosciences) for 13 minutes at room temperature. The stained white blood cells were 
centrifuged, washed, and re-suspended in flow-buffer (Hank’s buffered salt solution 
(HBSS) + 0.1% BSA, w/v). Cells were fixed by the addition of 4% paraformaldehyde. 
Monocytes were identified as CD45hi CD115hi and further identified into Ly6-Chi and 
Ly6-Clo; neutrophils were identified as CD45hi CD115lo Ly6-C/Ghi (Gr-1), similar to 
previous studies (Figure 2.1A) (Murphy et al., 2011). 
Hematopoietic Stem Cell: Hematopoietic stem and progenitor cells from the bone 
marrow were analyzed by flow cytometry. Bone marrow was harvested from femurs and 
tibias by flushing with HBSS + 0.1% BSA w/v through a 70 µm cell strainer. The cell 
suspension was centrifuged for 5 minutes at 500 g at 6ºC, supernatant aspirated and the 
cells re-suspended in 1X PharmLyse (BD Biosciences) for 5 minutes. Red blood cell 
(RBC) lysis was stopped by the addition of excess HBSS + 0.1% BSA. Cells were once 
again centrifuged at 500 g for 5 min at 6ºC and the supernatant aspirated. Cells were re-
suspended in 1 mL HBSS + 0.1% BSA and blocked with normal goat serum. Cells were 
once again centrifuged at 500 g for 5 min at 6ºC, and the supernatant aspirated. Bone 
marrow was re-suspended in 4 mL of HBSS + 0.1% BSA. For each mouse bone marrow 
sample, 150 µL of suspension was used. UltraComp eBeads (Affymetrix eBiosciences 
#01-2222) were used as a single positive control, except for the single positive control for  
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Table 2.1 Antibodies used for Flow Cytometry 
Antibody
Isotype-
Matched 
Control
Dilution Source Catalogue No.
PerCP-Cy™5.5 Rat Anti-Mouse 
Ly-6G and Ly-6C Rat IgG2b, κ 1/200
BD 
Biosciences 552093
eFluor®450 Anti-Mouse CD45 Rat IgG2b, κ 1/40 Affymetrix eBioscience 48-0451
FITC Mouse Hematopoietic 
Lineage Cocktail
• Anti-mouse CD3 (17A2)
• Anti-mouse CD45R 
(B220)(RA3-6B2)
• Anti-mouse CD11b (M1/70)
• Anti-mouse TER-119
• Anti-mouse Ly-G6 (Gr-1) 
(RB6-8C5)
N/A 20 µl Affymetrix eBioscience 22-7770
Brilliant Violet 421™ Anti-mouse 
CD117 (c-Kit) Rat IgG2b, κ 1/40 Biolegend 105828
Brilliant Violet 605™ anti-mouse 
Ly-6A/E (Sca-1) Rat IgG2a, κ 1/40 Biolegend 108133
Alexa Fluor®700 Anti-mouse 
CD16/32 Rat IgG2a, λ 1/80
Affymetrix, 
eBioscience 56-0161
APC Anti-mouse CD115 (c-fms) Rat IgG2a, κ 1/200 Affymetrix eBioscience 17-1152
PE Anti-mouse CD34 Armenian Hamster IgG 1/80 Biolegend 128610
LIVE/DEAD® Fixable Dead Cell 
Near-IR Stain Kits 1 µl Invitrogen L10119
Table 2.1 Antibodies used for flow cytometry
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. A; Gating 
strategy for blood monocytes and neutrophils. B; Gating strategy for bone marrow 
progenitor populations. 
  
Figure 2.1 Gating Strategy for Peripheral Blood Mononuclear Cells and Bone 
Marrow Progenitor Populations 
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the Vital Dye, where ArC™ Amine Reactive Compensation Bead Kit was used (A10346, 
Life Technologies, Burlington, ON). FMO controls were done on combined samples 
from all mice, 150 µL each. Viability was assessed using LIVE/DEAD® Fixable Dead 
Cell Near-IR Stain Kit (L11019, Invitrogen, Life Technologies, Burlington, ON) (Table 
2.1) in all samples after incubation for 25 min in the dark at room temperature. Cells were 
stained with a cocktail of antibodies against FITC Mouse Hematopoietic Lineage 
Cocktail (CD3 (17A2), CD45R (B220)(RA3-6B2), CD11b (M1/70), TER-119, Ly-G6 
(Gr-1) (RB6-8C5)) (Affymetrix eBiosciences), Brilliant Violet 421™ Anti-mouse CD117 
(c-Kit) (Biolegend, Cedarlane), Brilliant Violet 605™ anti-mouse Ly-6A/E (Sca-1) 
(Biolegend), Alexa Fluor®700 Anti-mouse CD16/32 (Affymetrix eBiosciences) and PE 
Anti-mouse CD34 (Biolegend) on ice for 20 minutes in the dark (Table 2.1) similar to 
previous studies (Murphy et al., 2011). The stained white blood cells were centrifuged, 
washed, and re-suspended in flow-buffer (HBSS + 0.1% BSA, w/v). Cells were fixed by 
the addition of 4% paraformaldehyde. Hematopoietic stem and progenitor cells were 
identified as Lin-, Sca-1+ and ckit+ (LSK) while the hematopoietic progenitor subsets 
were separated using antibodies to CD16/32 (FcγRII/III) and CD34. CMPs were 
identified as lin-, Sca-1-, ckit+, CD34hi, FcγRII/IIIlo, GMPs as lin-, Sca-1-, ckit+, CD34hi, 
FcγRII/IIIhi, MEPs as lin-, Sca-1-, ckit+, CD34lo, FcγRII/IIIlo (Figure 2.1B). 
Flow cytometry was performed using an LSRII (for analysis) running FACS DiVa 
software. All flow cytometry data were analyzed using FlowJo software (Tree Star Inc.) 
2.2.12 Statistical Analysis 
Data is presented as mean ± SEM. Statistical analyses were performed using Sigma Plot 
version 14.0. A One-way ANOVA with post-hoc Tukey’s test was used to test for 
differences between groups except in the case of body weight and adiposity measured 
over time where a 2-way repeated measures ANOVA with post-hoc Tukey’s test was 
used. Significance thresholds were P values less than 0.05. Significance differences are 
indicated by different lowercase letters. A Student’s t-test was used to test for differences 
in ANCOVA-adjusted energy expenditure. Significant differences (P<0.05) are indicated 
by an asterisk. 
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2.3 Results 
2.3.1 Flavonoid Intervention Promotes Weight Loss and Attenuates 
Adiposity.  
Previously, we determined that addition of either naringenin or nobiletin to a HFHC diet 
prevented the development of many of the disorders of the metabolic syndrome and 
prevented atherosclerosis (Mulvihill et al., 2009; Mulvihill et al., 2011; Mulvihill et al., 
2010). To determine the therapeutic utility of these flavonoids, we sought to assess their 
efficacy in an intervention model where these disorders were pre-established. Mice were 
initially fed a HFHC diet over 12 weeks to induce obesity, metabolic syndrome and 
intermediate atherosclerotic lesions, and establish disease baseline to which the efficacy 
of intervention was evaluated (Figure 2.2A). Subsequently, mice were divided among 4 
treatment groups for the subsequent 12 weeks: one group remained on the HFHC diet, a 
second group received intervention with regular mouse chow, a third group received 
intervention with the HFHC diet supplemented with 3% naringenin and the fourth group 
received intervention with the HFHC diet supplemented with 0.3% nobiletin (Figure 
2.2A).  
All mice gained weight over the initial 12-week induction phase (data not shown). 
Subsequently, mice that remained on the HFHC diet increased their body weight a further 
20% (Figure 2.2B). Mice that received intervention with naringenin or nobiletin, while 
also remaining on the same HFHC diet, lost ~13% of the body weight gained during the 
induction phase, a loss similar to that observed in the chow diet intervention group 
(Figure 2.2B). Chow intervention suppressed food intake during the first week, due to the 
abrupt change in food texture, but was rapidly resolved (Figure 2.2C). Intervention with 
the addition of naringenin or nobiletin to the HFHC diet did not significantly reduce 
caloric intake throughout the 12 weeks of intervention, suggesting that there was no 
flavonoid effect on satiety or feeding behavior (Figure 2.2C). 
Epididymal fat depots were increased during induction with the HFHC diet (Figure 
2.2D). Compared to baseline, intervention with naringenin or nobiletin reduced 
epididymal fat by 29% and 44%, respectively, similar to the fat loss in chow-intervened  
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. A; Structure 
of naringenin and nobiletin, and study design. B; Body weight measured weekly 
following intervention after induction (n=6-10/group). C; Caloric intake measured 
weekly during intervention (n=6-10/group). D; Adiposity assessed as epididymal fat pad 
weight/total body weight (n=6-10/group). E; Visceral and subcutaneous fat volume 
assessed by Micro-CT (n=6/group). F; Lean tissue volume assessed by Micro-CT 
(n=6/group). G; Frequency distribution of adipocyte area in mice at the end of 
intervention (n=6/group). Inset shows mean adipocyte area. Representative images of 
epididymal white adipose tissue stained with H&E. Scale bar is 100 µm. Data represent 
the mean±SEM. Different letters are statistically different by two-way ANOVA with 
post-hoc Tukey test (B,C,E,F) and one-way ANOVA with post-hoc Tukey test (D,G) 
(P<0.05). N.S. indicates no significant difference. 
  
Figure 2.2 Intervention with Citrus Flavonoids Promotes Weight Loss and 
Decreases Adiposity 
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mice (Figure 2.2D). By contrast, in mice that remained on the HFHC diet alone, 
epididymal fat mass remained elevated. The same trends were observed for inguinal 
adipose tissue (Figure 2.3A). In a separate study, we confirmed the intervention-induced 
adipose tissue reductions with the flavonoids by Micro-CT (Figure 2.2E and Figure 
2.3B). Micro-CT showed that visceral fat volume was reduced 38-53% and subcutaneous 
fat volume was reduced 23-43% by flavonoid intervention (Figure 2.2E and Figure 2.3B). 
Importantly, lean tissue volume did not significantly change during the 12 weeks of 
intervention (Figure 2.2F), indicating that the intervention-induced weight loss was 
driven by a reduction in adiposity. 
2.3.2 Flavonoid Intervention Reduced Adipose Tissue Inflammation. 
Previous prevention studies demonstrated that naringenin attenuated adipocyte 
hypertrophy and adipose tissue inflammation in HFHC-fed Ldlr-/- mice (Assini et al., 
2013). In the present study, compared to mice that remained on the HFHC-diet, 
intervention by either naringenin, nobiletin or chow induced a shift in epididymal 
adipocyte area towards smaller adipocytes by 19%, 23% and 30%, respectively (Figure 
2.2G). Similarly, flavonoid-treated mice had smaller adipocytes in inguinal adipose tissue 
(Figure 2.3A). We next measured the mRNA expression of inflammatory genes in 
epididymal, inguinal and brown adipose tissues. Consistently, intervention with 
naringenin or nobiletin reduced mean mRNA expressions of Tnfa, Ccl2, and Ccl3, similar 
to reductions observed with chow intervention. Although not statistically significant, 
these reductions suggest a shift to resolution of obesity-associated adipose tissue 
inflammation (Figure 2.4A). To try and understand if the reduction in adiposity was due 
to browning or enhanced lipolysis, the mRNA expression of known markers of adipose 
tissue browning and lipolysis was measured. Treatment with nobiletin, but neither 
naringenin nor chow, increased the mean Ucp1 mRNA expressions in epididymal and 
inguinal adipose tissue (not significant). No intervention altered Ucp1 expression in 
brown adipose tissue (Figure 2.4B). Neither intervention with naringenin, nobiletin nor 
chow, affected mRNA expressions of other browning markers Cidea, Pdk4 and Ppara, or 
the lipolysis associated genes, Lipe and Pnpla2, in inguinal, epididymal or brown adipose  
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently, the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. A; Inguinal 
white adipose tissue weight as a proportion of total body weight (n=6-8/group) and 
representative sections of inguinal adipose tissue stained with hematoxylin and eosin. 
Scale bar is 100µm. B; Representative micro-CT images of the same mice at baseline (12 
weeks HFHC induction) and following intervention (23 weeks); adipose tissue is 
highlighted in red. Data represent the mean±SEM. Different letters are statistically 
different by ANOVA with post-hoc Tukey test (P<0.05).  
  
Figure 2.3 Intervention with Citrus Flavonoids Reduces Adiposity 
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. A; 
Expression of inflammatory genes, Tnfa, Ccl2, Ccl3 and macrophage specific gene, 
Emr1, in epididymal white adipose tissue, inguinal white adipose tissue and brown 
adipose tissue (n=6/group). B; Expression of browning genes, Ucp1, Cidea, Pdk4, Ppara, 
in epididymal white adipose tissue, inguinal white adipose tissue and brown adipose 
tissue (n=6/group). C; Expression of lipolysis genes, Lipe, and Pnpla2, in epididymal 
white adipose tissue, inguinal white adipose tissue and brown adipose tissue (n=6/group). 
D; Representative sections of brown adipose tissue stained with hematoxylin and eosin. 
Scale bar is 100 µm. Data represent the mean±SEM. Different letters are statistically 
different by ANOVA with post-hoc Tukey test (P<0.05).  
 
  
Figure 2.4 Intervention with Citrus Flavonoids Modestly Attenuates Adipose Tissue 
Inflammation, with no Effect on Browning or Lipolysis Gene Expression 
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tissue (Figure 2.4B, C). This suggests that the reduction in adiposity with each 
intervention was not likely mediated directly through browning or enhanced lipolysis 
within white adipose tissue. Histological assessment of brown adipose tissue revealed 
that naringenin or nobiletin intervention reduced tissue lipid accumulation similar to 
intervention with chow (Figure 2.4D).  
2.3.3 Flavonoid Intervention Increases Energy Expenditure.  
Previous prevention studies have shown that the addition of either flavonoid to the HFHC 
diet increased energy expenditure in mice (Assini et al., 2013; Mulvihill et al., 2011). 
Therefore, we assessed whether flavonoid intervention would also correct obesity-
associated suppressed energy expenditure. Following HFHC diet induction, intervention 
with either naringenin or nobiletin increased ANCOVA-adjusted energy expenditure in 
both the light and dark cycles, compared to mice that continued on the HFHC diet alone, 
suggesting a compound-mediated mechanism (Figure 2.5A). The RER, which is 
indicative of metabolic fuel source, was also altered by flavonoid intervention. Mice that 
continued on the HFHC diet alone had a mean RER in the light cycle of 0.82, which 
decreased to 0.75 in the dark cycle, indicative of fat as the primary metabolic fuel source 
over 24hr (Figure 2.5B). Interestingly, intervention with either flavonoid to the HFHC 
diet maintained an RER ~0.8 during the dark cycle, when mice consume the majority of 
their daily caloric intake (Ellacott et al., 2010). This indicates a shift to a combination of 
carbohydrate and fat utilization in the flavonoid-treated mice (Figure 2.5B). Intervention 
with the chow diet increased RER to ≥0.9, over 24 hours, indicating enhanced oxidation 
of carbohydrates. In mice intervened with either flavonoid, food consumption increased 
by 2.5 kcal or ~0.5 grams per day, selectively in the dark cycle (Figure 2.5C), and 
without changes in ambulatory activity (Figure 2.5D). This small increase in food intake 
was not likely detectable when measured every 3 days in standard housing (Figure 2.2C). 
Together, this suggests that flavonoid intervention enhanced energy expenditure and may 
induce a mild starvation response promoting greater food intake. 
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. Between 
weeks 8-12 of intervention, mice were assessed in metabolic cages. A; ANCOVA-
adjusted energy expenditure (kcal/h) over 24 hours and mean ANCOVA-adjusted energy 
expenditure in both the dark and light periods (n=6-8/group).  B; Respiratory exchange 
ratio (RER) over 24 hours and mean RER in both the dark and light periods (n=6-
8/group). C; Accumulated food intake over 24 hours and total food eaten in 24 hours 
(n=6-8/group). D; Ambulatory activity over 24 hours and mean ambulatory activity per 
hour (n=6-8/group). Data represent the mean±SEM. Different letters are statistically 
different by ANOVA with post-hoc Tukey test (P<0.05). N.S. indicates no significant 
difference. * indicates statistical significant by Student’s t-test (P<0.05). 
 
  
Figure 2.5 Intervention with Citrus Flavonoids Increases Energy Expenditure 
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2.3.4 Flavonoid Intervention Normalizes Insulin Sensitivity.  
The ability of intervention with naringenin or nobiletin to reverse established insulin 
resistance was assessed. After induction with the HFHC diet, Ldlr-/- mice developed 
elevated fasting plasma insulin and mild hyperglycemia (Figure 2.6A, B). Intervention 
with chow reversed hyperinsulinemia (-61%) and modestly improved hyperglycemia (-
15%). The addition of either naringenin or nobiletin to the HFHC diet reversed 
hyperinsulinemia at week 24 by 50% and 54%, respectively, suggesting enhanced insulin 
sensitivity, despite the concomitant HFHC diet (Figure 2.6A). These significant 
reductions in fasting insulin levels were accompanied by decreases in fasting glucose by 
intervention with naringenin (-13%, NS) and nobiletin (-35%) (Figure 2.6B). Temporally, 
improvements in fasting glucose were observed at 6 weeks of flavonoid-intervention, and 
were maintained up to 12 weeks (Figure 2.6C). Homeostasis model assessment of insulin 
resistance (HOMA-IR) calculations showed that intervention with either flavonoid 
restored HOMA-IR to similar levels observed in chow-intervened mice (Figure 2.6D). To 
determine if normalized fasting insulin levels resulted in improved insulin or glucose 
tolerance, both tolerance tests at baseline, and after 12 weeks of intervention were 
performed (Figure 2.6E-J). At baseline, all groups had similar insulin tolerance or 
clearance of glucose shown as change in blood glucose concentration over time (Figure 
2.6E) and % change in glucose over time (Figure 2.6F). Following intervention, the lower 
fasting glucose levels in flavonoid-treated mice were accompanied by lower insulin 
tolerance test area under the plasma glucose curve (AUC) (Figure 2.6G), but there was no 
change in the efficiency of glucose clearance over time (Figure 2.6H), suggesting that 
improved insulin tolerance did not enhance glucose clearance. Intervention with chow did 
not affect insulin tolerance (Figure 2.6H). Similar glucose tolerance was observed in all 
groups following 12 weeks of induction (Figure 2.6I). Intervention with the addition of 
either naringenin or nobiletin to HFHC or with chow, improved glucose tolerance 
compared to mice that remained on the HFHC diet alone (Figure 2.6J). To understand 
peripheral insulin sensitivity further, we assessed muscle triglyceride accumulation in 
quadriceps and gastrocnemii, which is known to impair insulin signaling (Kim et al., 
2004) (Figure 2.6K, L). The accumulation of triglyceride in both the quadriceps and 
gastrocnemius muscles was elevated at baseline and increased further by continuation on  
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. A; Fasting (6 
h) plasma insulin levels (n=17-20/group). B; Fasting (6 h) blood glucose (n=10-
32/group). C; Fasting (6 h) blood glucose in the same mice at baseline and 6 weeks and 
12 weeks of intervention (n=11/group). D; Homeostasis model assessment of insulin 
resistance (HOMA-IR) (n=7-12/group). E,F; Insulin tolerance test at baseline shown as 
blood glucose concentrations (n=4-6/group) (E) and % change in glucose from time=0 
(n=6-9/group) (F). G,H; Insulin tolerance test at 12 weeks intervention shown as blood 
glucose concentrations (n=5-6/group) (G) and % change in glucose from time=0 (n=22-
24/group) (H). I; Glucose tolerance test at baseline (n=6-9/group). J; Glucose tolerance 
test at 12 weeks intervention (n=10-11/group). K,L; Muscle triglyceride content in 
quadriceps (n=8/group) (K) and gastrocnemii and solei (n=7-8/group) (L). Data represent 
the mean±SEM. Different letters are statistically different by ANOVA with post-hoc 
Tukey test (P<0.05). N.S. indicates no significant difference.  
  
Figure 2.6 Intervention with Citrus Flavonoids Restores Glucose Homeostasis 
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the HFHC diet (Figure 2.6K, L). In quadriceps, intervention with naringenin, nobiletin or 
chow reversed triglyceride accumulation from baseline (Figure 2.6K). In gastrocnemii, 
intervention with either flavonoid or chow decreased the mean triglyceride levels from 
baseline (trend), but were significantly lower compared to triglyceride levels in HFHC-
fed mice at 24 weeks (Figure 2.6L). 
2.3.5 Flavonoid Intervention Improves Fatty Liver.  
Ldlr-/- mice fed the HFHC induction diet accumulated both hepatic triglycerides and 
cholesterol (Figure 2.7A-C). Compared to baseline, liver triglyceride levels were reversed 
with intervention by either naringenin (-28%), nobiletin (-40%) or chow (-70%) (Figure 
2.7A). Compared to the HFHC diet at 24 weeks, intervention with either flavonoid or 
chow reduced liver triglyceride by 58-82%. Compared to both baseline and HFHC at 24 
weeks, liver cholesteryl ester and free cholesterol were lower with intervention by either 
naringenin (-70%, -40%), nobiletin (-60%, -33%) or chow (-90%, -53%), respectively 
(Figure 2.7B,C). In prevention studies, we reported that a primary mechanism for 
flavonoid-induced reductions in liver lipids and associated metabolic abnormalities was 
enhanced Pgc1a- and Cpt1a-mediated fatty acid oxidation and attenuated Srebp1c-
induced fatty acid synthesis (Mulvihill et al., 2009; Mulvihill et al., 2011). In the present 
study, intervention with the addition of either naringenin or nobiletin to the HFHC diet 
reversed the HFHC diet–induced suppression of hepatic fatty acid oxidation, increasing it 
by 2-fold compared to baseline and by 1.4-fold compared to HFHC-fed mice at 24 weeks 
(Figure 2.7D,E). This was accompanied by enhanced liver mRNA expressions of Cpt1a 
and Pgc1a. Improvements in hepatic lipids with flavonoid or chow intervention were 
associated with a reduction in Srebf1c mRNA expression with naringenin (trend), 
nobiletin and chow (Figure 2.7E), suggesting reduced hepatic de novo lipogenesis. Liver 
weight was reduced with flavonoid treatment and there was no effect on hepatic Acox1 
and Ppara mRNA expression, indicating that the flavonoid effects were independent of 
peroxisome proliferation or activation of PPARa, consistent with our previous prevention 
studies (Figure 2.7F and Figure 2.8A,B) (Mulvihill et al., 2011). Hepatic inflammation is 
also exacerbated by high-fat feeding (Assini et al., 2013). Intervention with either 
flavonoid in addition to HFHC completely normalized the mRNA expression of hepatic  
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. A; Hepatic 
triglycerides (n=7-8/group). B; Hepatic cholesteryl ester (n=7-8/group). C; Hepatic free 
cholesterol (n=7-8/group). D; Ex vivo hepatic fatty acid oxidation (n=7-10/group). E; 
Hepatic gene expression (n=12/group). F; Liver weight (n=22/group). Data represent the 
mean±SEM. Different letters are statistically different by ANOVA with post-hoc Tukey 
test (P<0.05).  
  
Figure 2.7 Intervention with Citrus Flavonoids Increases Hepatic Fatty Acid 
Oxidation and Reduces Liver Steatosis 
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. A; Hepatic 
expression of A; Acox1, B; Ppara C; Ccl2, D; Ccl3, E; Tnfa, and F; Il1b normalized to 
baseline (n=6-12/group). Data represent the mean±SEM. Different letters are statistically 
different by ANOVA with post-hoc Tukey test (P<0.05). N.S. indicates no significant 
difference. 
 
  
Figure 2.8 Flavonoid Intervention Reduces Hepatic Inflammation 
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Ccl2, Ccl3, Tnfa and Il1b, consistent with decreases in hepatic lipids and improvements 
in hepatic function (Figure 2.8C-F). 
2.3.6 Flavonoid Intervention Improves Hyperlipidemia. 
Upon HFHC diet feeding, Ldlr-/- mice developed hypercholesterolemia and 
hypertriglyceridemia (Figure 2.9A-G). Intervention with naringenin or nobiletin 
supplementation to the HFHC diet for 12 weeks reduced plasma cholesterol (>50%) and 
triglycerides (>50%) (Figure 2.9A,B). Flavonoid-mediated plasma lipid lowering was 
confined to VLDL and LDL with no change in HDL cholesterol levels (Figure 2.9C-H). 
Greater VLDL- and LDL-cholesterol reductions were observed with chow intervention 
(Figure 2.9F,G). 
2.3.7 Flavonoid Intervention Does Not Elicit Atherosclerotic Lesion 
Contraction. 
Due to the significant improvement in atherosclerotic risk factors, we sought to determine 
the impact of flavonoid intervention on atherosclerosis regression. Aortic sinus lesions 
were assessed after HFHC induction (baseline) and following flavonoid or chow 
intervention (Figure 2.10A). While intervention with chow did not induce regression of 
aortic sinus lesions, their growth in size was significantly attenuated. Intervention with 
either citrus flavonoid to the HFHC diet did not affect lesion size; the area of sinus 
lesions continued to increase at the same rate as in mice fed the HFHC diet alone for 24 
weeks (Figure 2.10A). Lipid measurements in whole aortae, dissected free from fat, 
revealed that the aorta of HFHC-fed mice continued to accumulate free cholesterol and 
cholesteryl ester (~4-fold) compared to baseline (Figure 2.10B). The addition of either 
flavonoid at intervention slowed, but did not halt, the accumulation of aortic free or 
esterified cholesterol (Figure 2.10B). Chow intervention prevented further increases from 
baseline in aortic cholesterol content. The aortic mRNA expression of the inflammatory 
genes Ccl3, Tnfa and Emr1 increased from baseline with continued HFHC, which was 
not offset by flavonoid intervention (Figure 2.10C). Aortic mRNA of Il1b and Ccl2 were 
not different from baseline in mice continued on HFHC or with flavonoid intervention. 
Chow intervention tended to halt or reverse aortic mRNA expression of all inflammatory  
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. Mice were 
fasted for 6 hours prior to sacrifice. Plasma was subjected to fast protein liquid 
chromatography (FPLC) and lipids were measured in each fraction by enzymatic assay. 
A; Plasma triglycerides (n=19-24/group). B; Plasma cholesterol (n=21-24/group). C; 
Plasma triglyceride FPLC tracing (n=6-7/group). D; Plasma VLDL triglyceride AUC 
calculations (n=6-7/group). E; Plasma cholesterol FPLC tracing (n=6-7/group) F; Plasma 
VLDL cholesterol AUC calculations (n=6-7/group). G; Plasma LDL cholesterol AUC 
calculations (n=6-7/group). H; Plasma HDL cholesterol AUC calculations (n=6-7/group. 
Data represent the mean±SEM. Different letters are statistically different by ANOVA 
with post-hoc Tukey test (P<0.05). N.S. indicates no significant difference. 
  
Figure 2.9 Intervention with Citrus Flavonoids Lowers Plasma Lipids from 
Baseline 
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. Aortae were 
dissected and the aortic sinus sectioned and analyzed histologically. A; Representative 
sections of the aortic sinus stained with oil red-O and hematoxylin and lesion area 
quantitation (n=12-21/group). Scale bar is 500µm. B; Total cholesterol, cholesteryl ester 
and free cholesterol in whole aortae (n=6-8/group). C; Gene expression in whole aortae 
(n=6-8/group). Data represent the mean±SEM. Different letters are statistically different 
by ANOVA with post-hoc Tukey test (P<0.05). N.S. indicates no significant difference. 
 
  
Figure 2.10 Intervention with Citrus Flavonoids does not Attenuate Lesion Size but 
Slows Aortic Cholesterol Accumulation 
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markers examined (Figure 2.10C). Additionally, intervention with either flavonoid did 
not increase the expression of genes linked to regression and chow intervention actually 
decreased the mRNA expression of Ccr7, Abca1, and Abcg1 (Figure 2.10C). 
2.3.8 Flavonoid Intervention Reduces Plaque Macrophages. 
Although there was no change in the plaque size with flavonoid intervention, the decrease 
in aortic cholesterol suggested that lesion composition may have been favorably altered 
(Figure 2.10A,B). After 12 weeks induction, plaques were comprised mainly of 
macrophages (~66%) (Figure 2.11A,H). Lesion macrophage content was reduced with 
intervention by naringenin (-47%), nobiletin (-50%) and chow (-69%) (Figure 2.11A,H), 
consistent with the concept that depletion of macrophages is characteristic of a regressing 
plaque (Burke and Huff, 2018). Although the percent of lesion area occupied by 
macrophages was also less in mice continuing on HFHC (-23%), the decrease was greater 
with flavonoid or chow intervention (Figure 2.11A,H). Compared to lesions at baseline, 
continuation on the HFHC diet enlarged necrotic core area (from 6 to 14%), increased the 
percent of apoptotic cells (from 0.2 to 1.0%), reduced lesion smooth muscle cells (SMCs) 
(from 3.5% to 1.8%) and increased lesion collagen (from 20 to 35%) (Figure 2.11B-F, 
Figure 2.12). Intervention with either naringenin, nobiletin or chow halted the increase in 
necrotic core size, inhibited the increase in apoptosis, attenuated the decrease in SMCs 
and maintained the increase in lesion collagen (Figure 2.11B-F and Figure 2.12). 
Collectively, these intervention-induced changes in lesion composition are characteristic 
of more stable lesions (Figure 2.11G). 
2.3.9 Flavonoid Intervention Prevents Enhanced Monocytosis. 
Reduced plaque macrophage content is phenotypically associated with atherosclerosis 
regression (Burke and Huff, 2018; Distel et al., 2014; Nagareddy et al., 2013; Potteaux et 
al., 2011). Reduced monocyte recruitment from the circulation has been implicated as a 
mechanism contributing to regression (Murphy et al., 2011). In this study, continuation of 
the HFHC diet increased the number of circulating Ly6Chi monocytes (2-fold) (Figure 
2.13A), the monocyte subset known to be the precursor of lesion M1 and M2 
macrophages (Rahman et al., 2017). Intervention with chow or nobiletin completely  
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. Aortae were 
dissected and the aortic sinus sectioned and analyzed histologically. A; Percent of lesion 
area occupied by CD68+ macrophages (n=14-22/group). B; Percent of lesion area 
occupied by the necrotic core (n=14-17). C; Percent of lesion positive for activated 
capase-3 (n=9-20/group). D; Percent of lesion area occupied by smooth muscle cells 
(SMC α-actin) (n=12-23/group). E; Percent of lesion area occupied by collagen 
(picrosirius red) (n=12-19/group). F; Collagen organization measured as mean collagen 
fibril retardation (n=12-19/group). G; Lesion composition for each dietary group. H; 
Representative histological sections of the aortic sinus stained with CD68 (macrophages) 
and counterstained with hematoxylin. Scale bar is 500µm. Data represent the 
mean±SEM. Different letters are statistically different by ANOVA with post-hoc Tukey 
test (P<0.05). N.S. indicates no significant difference. 
  
Figure 2.11 Intervention with Citrus Flavonoids Improves Lesion Morphology 
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for and additional 12 weeks. A; 
Hematoxylin and eosin stained sections of the aortic sinus with outlined necrotic core 
area (>3000µm2). Scale bar is 200 µm. B; Aortic sinus sections immunostained for 
cleaved caspase-3, a marker of cell apoptosis, and counterstained with hematoxylin. Scale 
bar is 200 µm. C; Aortic sinus sections immunostained for smooth muscle α-actin and 
counterstained with hematoxylin. Scale bar is 200 µm. D; Aortic sinus sections stained 
with picrosirius red and imaged using circular polarization microscopy. Scale bar is 250 
µm. Color encoding of light retardation (nm) is depicted in the gradient map (blue: low; 
red: high). Quantitation appears in Figure 2.11. 
 
  
Figure 2.12 Representative Images for Histological Analysis of Aortic Sinus 
Atherosclerotic Lesions 
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. Peripheral 
blood mononuclear cells (PBMCs) were isolated and stained for monocyte and neutrophil 
markers. A; Percent PBMCs that were Ly6Chi monocytes (n=9-10/group). B; Percent of 
PBMCs that were Ly6Clo monocytes (n=9-10/group). C; Percent of PBMCs that were 
both Ly6Chi and Ly6Clo monocytes. D; Percent of PBMCs that were neutrophils. E; 
Representative flow cytometric pseudocolor plots show monocytes and neutrophil 
populations from each dietary group. Data represent the mean±SEM. Different letters are 
statistically different by ANOVA with post-hoc Tukey test (P<0.05). N.S. indicates no 
significant difference. 
 
  
Figure 2.13 Intervention with Citrus Flavonoids Prevents Further Elevation in 
Blood Monocytes 
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prevented the increase in Ly6Chi monocytes, while with naringenin intervention, there 
was a trend to attenuation of the HFHC-induced elevation in Ly6Chi monocytes (Figure 
2.13A). There was no effect on circulating Ly6Clo monocytes or total neutrophil levels 
with continuation of the HFHC diet or with any intervention (Figure 2.13B,D). To 
investigate this trend further, bone marrow progenitor populations were measured (Figure 
2.14). Intervention with chow reduced bone marrow hematopoietic stem and progenitor 
cell populations, whereas the modest reductions with flavonoid intervention were not 
significant (Figure 2.14A,C). A similar trend persisted when looking at bone marrow 
myeloid progenitor cells (Figure 2.14B,C), common myeloid progenitor cells (Figure 
2.14D,G) and granulocyte macrophage progenitor cells (Figure 2.14E,G). There was no 
consistent effect of any treatment group on megakaryocyte and erythrocyte progenitor 
cells (Figure 2.14F,G).  
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Ldlr-/- mice were fed a HFHC diet for 12 weeks. Subsequently the same mice were 
treated with flavonoids added to the HFHC diet for an additional 12 weeks. Bone marrow 
cells were isolated and stained for markers of progenitor populations. A; Percent of bone 
marrow cells that were hematopoietic stem and progenitors (HSPC) (Lin-, Sca-1+, ckit+) 
(n=8-10/group). B; Percent of bone marrow cells that were myeloid progenitors (MPC) 
(Lin-, Sca-1-, ckit+) (n=8-10/group). C; Representative flow cytometric pseudocolor plots 
show HSPCs and MPCs. D; Percent of bone marrow cells that were common myeloid 
progenitors (CMPs) (Lin-, Sca-1-, ckit+, CD16/32-, CD34+) (n=8-10/group). E; Percent of 
bone marrow cells that were granulocyte and macrophage progenitors (GMPs) (Lin-, Sca-
1-, ckit+, CD16/32+, CD34+) (n=8-10/group). F; Percent of bone marrow cells that were 
megakaryocyte and erythrocyte progenitors (MEPs) (Lin-, Sca-1-, ckit+, CD16/32-, CD34-
) (n=8-10/group). G; Representative flow cytometric pseudocolor plots show CMPs, 
GMPs and MEPs. Data represent the mean±SEM. Different letters are statistically 
different by ANOVA with post-hoc Tukey test (P<0.05). N.S. indicates no significant 
difference. 
 
  
Figure 2.14 Intervention with Citrus Flavonoids Modestly Reduces Bone Marrow 
Progenitors 
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2.4 Discussion 
In the present study, we showed that intervention with the citrus-derived flavonoids, 
naringenin or nobiletin, when supplemented to a HFHC diet, reversed diet-induced 
obesity, insulin resistance, improved hyperlipidemia and hepatic steatosis, and favorably 
altered aortic sinus atherosclerotic plaque composition. Flavonoid intervention enhanced 
energy expenditure, despite promoting a modest increase in food consumption during the 
active time and while maintaining similar ambulatory activity. In the liver, fatty acid 
oxidation was increased as were Cpt1a and Pgc1a expressions, suggesting enhanced fat 
mobilization. In white adipose tissue, there were no consistent effects on browning genes 
in visceral or subcutaneous depots and no enhancement of browning genes in brown 
adipose tissue, suggesting a non-browning mechanism of enhanced energy expenditure 
and reduced adiposity. Although atherosclerotic lesion size was unaffected, the 
improvements in metabolic parameters with flavonoid intervention correlated with a 
reduction in circulating monocytes and reduced macrophage content in established 
atherosclerotic lesions, characteristics consistent with atherosclerosis regression (Basu et 
al., 2018).  
Changes in food consumption can result from the effects of dietary components or drugs 
on behavior, satiety or energy balance, which in turn alter metabolic regulation, including 
adipose tissue metabolism (Ellacott et al., 2010). Consistent with previously reported 
prevention studies, addition of flavonoids to the HFHC diet did not decrease caloric 
intake as measured in standard caging (Assini et al., 2015; Assini et al., 2013; Mulvihill 
et al., 2009; Mulvihill et al., 2011). Studies from other laboratories have reported reduced 
caloric intake in high fat-fed mice with naringenin intervention, leading to decreased 
body weight and adiposity (Ke et al., 2015), an effect likely attributed to a taste aversion 
to the compound when administered in the food. In the present study, taste aversion was 
mitigated by starting intervention at a low flavonoid dose, which was slowly increased to 
the final dose over the first week of intervention. Thus, food intake did not drop 
precipitously, which would in itself cause weight loss. In metabolic cage studies, we 
unexpectedly identified a small (~0.5 grams/day) but significant increase in caloric 
consumption during the dark cycle in both naringenin and nobiletin treated mice, at 
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weeks 21-23, near the end of the intervention. Despite this small increase, intervention 
with both flavonoids induced weight loss, decreased adiposity and improved metabolic 
indices, implying the molecular mechanism for the flavonoid effects was not related to 
suppressed food intake (Ellacott et al., 2010). The reasons underlying the flavonoid-
induced increase in caloric intake during the dark cycle is not well understood, but may 
be related to a mild starvation response resulting from increased energy expenditure. 
Pair-feeding experiments would help to confirm and further understand this observation.  
Naringenin intervention has previously been studied in ovarectomised female C57BL/6J 
mice to assess its impact on post-menopausal metabolic dysfunction (Ke et al., 2016; Ke 
et al., 2015). In chow-fed ovarectomised mice at a normal body weight, intervention by 
the addition of naringenin to chow prevented weight gain while promoting modest weight 
loss, reduced adiposity and improved glucose homeostasis, accompanied by a reduction 
in caloric intake (Ke et al., 2015). When the same ovarectomised mice were fed a high-fat 
diet, intervention with the addition of naringenin to the high-fat diet prevented further 
weight gain and adiposity, while increasing ambulatory activity, with no change in 
energy expenditure (Ke et al., 2016). In our male Ldlr-/- mice fed a high-fat diet, 
intervention with either flavonoid also decreased body weight and adiposity, but was due 
to an increase in ANCOVA-adjusted energy expenditure, with no change in ambulatory 
activity and despite a small increase in caloric intake. Ambulatory activity was lower in 
treated post-menopausal mice compared to our flavonoid-intervention Ldlr-/- mice, which 
might be attributed to post-menopausal sarcopenia. It is possible that the discrepancy in 
activity results could be due to differences in age and sex of the two models. The lack of 
effect of flavonoid intervention on activity is consistent with our previous prevention 
studies in high-fat fed Ldlr-/- mice treated with both naringenin and nobiletin (Mulvihill et 
al., 2009; Mulvihill et al., 2011). Experiments in age-matched female Ldlr-/- mice would 
help further understand this observation. 
Hypercholesterolemia, hyperglycemia, obesity, and more specifically adipose tissue 
inflammation are all independent risk factors for leukocytosis, which can contribute to 
accelerated atherosclerosis (Nagareddy et al., 2014; Nagareddy et al., 2013; Tolani et al., 
2013). In the present study, intervention with either naringenin or nobiletin reduced 
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atherosclerotic lesion macrophage content, consistent with plaque regression. Reduced 
monocyte recruitment to atherosclerotic plaques is characteristic of atherosclerosis 
regression (Burke and Huff, 2018; Potteaux et al., 2011). While trafficking kinetics to 
determine the contribution of monocyte recruitment to the reduced lesion macrophage 
content were not performed, leukocyte levels in the circulation were quantitated. 
Intervention with naringenin or nobiletin prevented any further increase in circulating 
Ly6Chi monocytes, known to be the precursor of lesion macrophages (Rahman et al., 
2017). We also showed that intervention with chow induced a more notable, but not 
significant, reduction from baseline in blood Ly6Chi monocytes compared to flavonoid 
intervention, but this did not translate into a reduction in circulating total monocytes. This 
chow-alone intervention effect is consistent with previous regression studies in high fat-
fed Ldlr-/- mice (Nagareddy et al., 2013), but not studies in high fat-fed Ldlr-/- mice in 
which the chow intervention was coupled to hepatic Mttp deletion, which resulted in 
more rapid regression and a large reduction in circulating monocytes (Distel et al., 2014). 
It is possible that interventions with dietary flavonoids plus HFHC or chow-alone were 
not strong enough or long enough in duration to achieve larger significant reductions in 
circulating monocytes (Distel et al., 2014; Nagareddy et al., 2013). In addition, neither 
flavonoid nor chow intervention completely corrected hypercholesterolemia thereby 
restricting a more robust reduction in myelopoiesis (Tolani et al., 2013). Furthermore, we 
used Ldlr-/- mice, which develop more modest monocytosis compared to Apoe-/- mice in 
response to a high fat diet, which would make the effects of naringenin or nobiletin 
intervention more subtle, especially considering the incomplete correction of metabolic 
dysfunction (Murphy et al., 2011).  
The mechanism(s) through which either naringenin or nobiletin regulates energy 
expenditure, lipid metabolism and insulin sensitivity are not completely understood. 
Previous in vitro studies demonstrated that both naringenin and nobiletin activate insulin 
signaling independent of the insulin receptor or insulin receptor substrate (Allister et al., 
2008; Mulvihill et al., 2011). Additionally, in high-fat fed Ldlr-/- mice, both naringenin 
and nobiletin upregulated Pcg1a- and Cpt1a-mediated hepatic fatty acid oxidation, 
independent of peroxisomal proliferation, and suppressed Srebp1c-mediated fatty acid 
synthesis (Mulvihill et al., 2009; Mulvihill et al., 2011). The upstream mechanism(s) 
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governing these effects have remained somewhat elusive. The hormone-like fibroblast 
growth factor 21 elicits similar metabolic improvements as naringenin when given 
exogenously to mice, but naringenin prevented metabolic dysfunction and obesity in high 
fat-fed Fgf21-/- mice to the same extent as in wild type mice (Assini et al., 2015). In 
short-term treatment of Ob/Ob mice, naringenin supplementation to a low fat diet 
reversed hyperlipidemia, attenuated body weight and improved hepatic steatosis and 
insulin sensitivity, indicating that the naringenin effect was independent of leptin-
deficiency (Assini et al., 2015). This suggests that unlike other natural compounds, 
celastrol and withaferin A, naringenin does not work through enhancing leptin sensitivity 
(Lee et al., 2016; Liu et al., 2015). Alternatively, celastrol has also been shown to prevent 
weight gain and improve metabolic dysfunction through activation of the heat shock 
factor 1-PGC1a axis in adipose tissue and muscle, but not liver (Ma et al., 2015), more 
similar to, but not identical to, the hepatic effects of naringenin or nobiletin.  
Recent studies revealed that the addition of naringenin plus apigenin (a related flavonoid) 
to a high-fat diet, prevented the exacerbated rebound in body weight in mice, when re-
challenged with a high-fat diet following a period of chow-induced weight loss (Thaiss et 
al., 2016). Celastrol or a leptin-sensitizing antagonist did not mitigate weight rebound. 
Flavonoid treatment replaced the persistent high fat diet-induced loss of microbiome-
derived flavonoid availability, resulting in increased energy expenditure and upregulation 
of Ucp1 expression in brown adipose tissue (Thaiss et al., 2016). In prevention models, 
we have shown that naringenin modestly increases Ucp1 expression in inguinal white 
adipose tissue (Assini et al., 2015), but in the present study we saw no effect with either 
naringenin or nobiletin on inguinal or brown adipose tissue Ucp1 expression. 
Additionally, we reported no change with nobiletin treatment on non-shivering 
thermogenesis, however experiments were not conducted at thermoneutrality (Mulvihill 
et al., 2011). This suggests that flavonoid-mediated enhanced browning may not be the 
mechanism through which citrus flavonoids exert their anti-obesity effects. It is possible 
that the browning effect of flavonoids in the weight cycling mouse model was apigenin 
specific. Nobiletin, but not naringenin, has been shown to enhance the amplitude of 
circadian rhythms, specifically in obese mice (He et al., 2016). In our previous studies, 
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we have not observed any differences in the effects of either naringenin or nobiletin 
treatment aside from potency. Nobiletin is ~10-times more potent than naringenin, which 
is reflected in its lower effective dose (0.3% vs 3% of diet) (Mulvihill et al., 2009; 
Mulvihill et al., 2011). It is possible that naringenin may also enhance clock sensitivity 
and that differences in dosing and administration may be responsible for the discrepancy 
in results between naringenin and nobiletin (He et al., 2016; Mulvihill et al., 2009).  
In the present study, we tested one protocol of induction and intervention times, 12 weeks 
induction with a HFHC diet followed by 12 weeks intervention with either citrus 
flavonoid supplemented to the HFHC diet. These timelines were chosen based on 
atherosclerosis regression models in the literature and are similar to other dietary 
flavonoid-intervention timelines (Burke and Huff, 2018; Ke et al., 2016; Ke et al., 2015). 
Twelve weeks of HFHC induction was sufficient time to induce moderate obesity, 
significant hyperlipidemia, moderate insulin resistance, hepatic steatosis and intermediate 
atherosclerosis. Twelve weeks intervention was sufficient to completely improve obesity 
and insulin resistance, but moderate hyperlipidemia and hepatic steatosis persisted, 
resulting in improvements in lesion morphology but no regression of plaque size. This 
raises the intriguing possibility that a longer duration of flavonoid intervention would 
result in greater resolution of these disorders. It would be of interest to test different 
intervention durations and potentially longer induction periods to test the limits of 
flavonoid intervention on the resolution of diet-induced obesity, metabolic syndrome and 
atherosclerosis.  
A number of human studies using purified citrus flavonoids have demonstrated 
improvements in plasma lipids, glucose metabolism and obesity (reviewed in (Mulvihill 
et al., 2016)). However, results were modest and inconsistencies between studies, and 
considerable inter-patient variation were observed. Bioavailability of flavonoids is low, 
especially in humans, metabolism of flavonoids differs between subjects, and differences 
in the enteric microflora may be responsible for considerable inter-individual variability 
in absorption and pharmacokinetic parameters (Mulvihill et al., 2016). Larger controlled 
human studies are required to assess dose, bioavailability, efficacy and safety for 
therapeutic development. 
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In summary, we have shown that intervention by the addition of either of the citrus 
flavonoids, naringenin or nobiletin, to a high-fat diet in obese mice, reverses weight gain 
and adiposity similar to intervention with chow, without reducing food intake. Mice 
treated with naringenin or nobiletin consume more calories, but expend more energy 
without increased ambulatory activity. Flavonoid-treated mice regain insulin sensitivity 
and reverse hyperinsulinemia completely. Plasma lipids are decreased and hepatic fatty 
acid oxidation is increased resulting in reduced hepatic lipids. Collectively these 
improvements in atherogenic risk factors did not result in lesion contraction but improved 
lesion morphology, most notably reduced lesion macrophage content, consistent with 
early stages of atherosclerosis regression. These studies highlight the potential 
therapeutic utility of either naringenin or nobiletin, especially in the context of existing 
obesity and metabolic dysfunction, and further underscore their importance in future 
therapeutic development.  
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Chapter 3  
3 Naringenin enhances the regression of atherosclerosis 
induced by a chow diet in Ldlr-/- mice 
3.1 Introduction 
Atherosclerosis is a progressive, lipid and inflammatory-driven disease characterized by 
the growth of fatty plaques within the arterial wall (Moore and Tabas, 2011). It is a major 
contributor to myocardial infarction and stroke, contributing to cardiovascular disease 
being the most common cause of morbidity and mortality in western society (Go et al., 
2014). Metabolic syndrome is a collection of disorders that increase risk for the 
development of atherosclerosis including, obesity, insulin resistance, hepatic steatosis, 
hyperlipidemia, and hypertension. Many of these disorders also increase inflammation 
and potentiate myelopoiesis, resulting in increased monocytes in the circulation, another 
independent risk factor for atherosclerosis (Moore and Tabas, 2011). The majority of 
patients with atherosclerosis present without overt clinical symptoms during the majority 
of disease progression and therefore, greater than 50% of patients die without knowledge 
of prior disease (Go et al., 2014). This also results in a delay in administration of 
treatment and therefore, most patients are treated after extensive disease is established. 
Cholesterol-lowering statins have irrefutably reduced cardiovascular disease, but there 
remain unmet clinical needs in cardiovascular disease treatment (Hegele et al., 2015). 
Despite many promising therapeutic studies in animal models, there is often a lack of 
translatability into humans. The majority of pre-clinical therapeutic studies have been 
performed in animal models of disease progression, whereby the treatment is started at 
the same time as disease initiation. This suggests that investigation of therapeutics should 
be attempted in models of reversal or atherosclerosis regression (Burke and Huff, 2018; 
Gleissner, 2016). 
The majority of pre-clinical cardiovascular therapeutic studies have been conducted in a 
progression or prevention mouse model, whereby the therapeutic is added at the same 
time as the disease initiator, the high-fat diet (Burke and Huff, 2018; Gleissner, 2016). 
Efficacy has been measured as the ability of the knockout or therapeutic to prevent or 
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slow the development of atherosclerosis, compared to the pro-atherogenic model. 
Recently, clinically-relevant models have been developed and characterized to study 
cardiovascular drugs in an intervention model to assess atherosclerosis regression (Burke 
and Huff, 2018; Feig et al., 2011a; Hewing et al., 2013; Rayner et al., 2011). These 
mouse models have established atherosclerosis and metabolic disease prior to treatment, 
similar to how humans would present when starting a therapy or treatment. In this way, 
we can test the ability of drugs to regress or reverse disease, which may help with success 
in translatability (Gleissner, 2016).  
Epidemiological evidence suggests an inverse correlation between the consumption of 
flavonoids, a class of plant-derived polyphenols, and cardiovascular and metabolic 
disease (Mulvihill et al., 2016). Naringenin is a grapefruit-derived flavonoid that has 
significant lipid-lowering and insulin-sensitizing effects (Allister et al., 2005; Borradaile 
et al., 2003). Previously, we have shown in the Ldlr-/- mouse, that naringenin attenuates 
obesity, insulin resistance, hyperlipidemia, hepatic steatosis and atherosclerosis (Assini et 
al., 2015; Assini et al., 2013; Mulvihill et al., 2009; Mulvihill et al., 2010). When 
investigated in an intervention model, naringenin supplemented to a high-fat diet was 
able to correct many metabolic indices including obesity, adipose tissue accumulation 
and inflammation, and glucose tolerance (Chapter 2). However, when supplemented to a 
high-fat diet, naringenin reversed, but did not completely correct hyperlipidemia, hepatic 
steatosis, or insulin intolerance, leading to an improvement in atherosclerotic lesion 
morphology, but no lesion regression (Chapter 2). With the exception of one report 
(Zimmer et al., 2016), mouse atherosclerosis intervention studies that have achieved 
regression of lesion size in addition to improvements in plaque morphology, required a 
transfer from the high-fat induction diet to a low fat, cholesterol-free diet (usually chow) 
with or without genetic manipulation to amplify plasma lipid lowering (Basu et al., 2018; 
Feig et al., 2011a; Potteaux et al., 2011) (e.g. deletion of hepatic Mttp or reconstitution 
with Apoe or the Ldlr).  
In the present study, we assessed the ability of naringenin to enhance regression of high-
fat diet-induced atherosclerosis in Ldlr-/- mice, in which the intervention consisted of a 
chow diet. The addition of naringenin to a chow diet completely halted atherosclerotic 
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plaque growth and significantly improved the composition of atherosclerotic plaques 
compared to intervention with the chow diet alone. Plaque morphology improvements 
were accompanied by a reduction in circulating blood monocytes and reduced 
myelopoietic progenitor populations in the bone marrow of naringenin-treated mice. 
Metabolically, naringenin enhanced the improvements of hyperlipidemia, insulin 
sensitivity and weight loss compared to intervention with chow alone, thereby 
contributing to atherosclerosis regression in this model.  
3.2 Materials and Methods 
3.2.1 Animals and Diets 
Male Ldlr-/- mice on a C57BL/6 background (Jackson Laboratory, Bar Harbor, MA), 
were housed in pairs in standard cages at 23ºC on a 12 h light and dark cycle. The 
animals were cared for in accordance with the Canadian Guide for the Care and Use of 
Laboratory Animals. All experimental procedures were approved by the Animal Care 
Committee at the University of Western Ontario (protocol # AUP-2016-057). Mice (10-
12 weeks of age, n=40; 10/group) were fed ad libitum a high-fat, cholesterol containing 
(HFHC; 42% of calories from fat, 0.2% cholesterol, Teklad TD09268, Envigo, Madison 
WI) diet for 12 weeks. One subgroup of these mice was sacrificed to provide baseline 
data (n=10). The remaining mice were divided amongst 3 different groups. For the 
subsequent 12 weeks, one group remained on the same HFHC diet (n=6), one group 
switched to isoflavone-free standard rodent chow (12% of calories from fat, Teklad 
Global 16% Protein Rodent Diet 2016, Envigo, Madison WI) (n=10), and one group 
switched to the same chow supplemented with 3% (wt/wt) naringenin (#N5893, 
Millipore-Sigma) (n=10). Food intake was measured daily and body weight was 
measured weekly. Caloric intake was calculated as weight of food eaten (g) per day by 
multiplied by the caloric content of each diet (chow 3.0 kcal/g; HFHC 4.5 kcal/g). 
3.2.2 Blood and Tissue Collection 
Mice were fasted for 6 hours at the start of the light cycle prior to sacrifice. At sacrifice, 
animals were anesthetized with Ketamine-Xylazine (100µg/g Ketamine hydrochloride, 
Bioniche Animal Health Canada Inc., Belleville, ON and 10µg/g Xylazine, Bayer 
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Healthcare, Animal Health Division, Bayer Inc., Toronto ON) and tissue dissections were 
performed via midline incision. Blood was collected via cardiac puncture in syringes 
containing 80 µl of 7% Na2-EDTA. Blood was centrifuged at 12,000 rpm for 10 minutes 
at 4ºC to separate the plasma, which was stored at -20ºC for further use. To dissect the 
heart for histological analysis, the left ventricle was perfused with phosphate buffered 
saline (PBS) containing heparin (10 units/mL) and the right atrium cut to drain the 
perfusate. The heart and full-length aorta were dissected together. Aortae were rinsed and 
cleaned using a dissecting microscope to remove any adipose tissue. Aortae were snap 
frozen in liquid N2 and stored at -80ºC for lipid measurements. The top half of the heart 
was placed in optimum cutting temperature (OCT) medium, frozen on dry ice and stored 
at -80ºC for histological analyses. The liver was removed, weighed and a piece of liver 
was placed in OCT medium, frozen on dry ice and stored at -80ºC for histological 
analyses. The remainder of the livers was snap frozen in liquid N2 and stored at -80ºC for 
further analyses. 
3.2.3 Glucose Tolerance and Insulin Tolerance Tests 
A glucose tolerance test (GTT) was performed following a 6 h fast by i.p. injection with 
15% glucose in 0.9% NaCl (1g/kg body weight) (Mulvihill et al., 2009). Blood samples 
for glucose measurements (Bayer Contour Blood Glucose Monitoring System) were 
taken up to 120 minutes post-injection. An insulin tolerance test (ITT) was conducted 
following a 5 h fast by i.p. injection with insulin (0.6 IU/kg body weight; Novolin GE 
Toronto, Novo Nordsik, Cooksville, ON) (Mulvihill et al., 2009). Blood samples for 
glucose measurements were obtained up to 60 minutes post-injection. Glucose tolerance 
and insulin sensitivity were calculated as a percent change in blood glucose from 
baseline. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated 
using the following formula as previously described for mice: HOMA-IR= 26 x fasting 
insulin level (ng/ml) x fasting glucose level (mg/dl)/405 (Murakami et al., 2014). 
3.2.4 Tissue Lipids 
Lipids from liver and full-length aortae dissected free of fat and connective tissue were 
extracted using the method of Folch et al. from samples stored at -80ºC, as described 
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previously (Assini et al., 2013; Folch et al., 1957). [Cholesteryl-1,2-3H(N)]Cholesteryl 
oleate (PerkinElmer, Guelph, Canada: #NET746L) was added to assess recovery. A 
combined 200 µg/mL triolein and 200 µg/mL cholesterol standard (0-64µg) was prepared 
in isopropanol and aliquoted for standard curves. Samples and standards were dried under 
N2 and a 1% Triton X-100 solution in chloroform added. Following solubilization, 
samples and standards were capped, left at room temperature for 1 hour, and dried under 
N2. Deionized water was added and incubated at 37ºC for 15 minutes. Samples were 
analyzed using enzymatic reagents for triglyceride (Roche Diagnostics: 
Triglycerides/glycerol blanked, #11877771 216), total cholesterol (WAKO Diagnostics: 
Cholesterol E (CHOD-DAOS method) #439-17501) and free cholesterol (WAKO 
Diagnostics: Free cholesterol (COD-DAOS) method #435-35801) as per manufacturer’s 
instructions. Cholesteryl ester was determined as the difference between total cholesterol 
and free cholesterol. 
3.2.5 Plasma Measurements 
Plasma triglyceride and total cholesterol were measured on a Cobas Mira S autoanalyzer 
(Roche Diagnostics, Laval, Canada) using calibrators and controls from Roche 
Diagnostics (Mulvihill et al., 2009). Enzymatic reagents for triglyceride (Roche 
Diagnostics: triglycerides/glycerol blanked #11877771 216) and cholesterol (Roche 
Diagnostics: Cholesterol CHOD-PAP #11491458-216) were used. Fresh-EDTA plasma 
(50 µL) was separated by fast protein liquid chromatography (FPLC) using an AKTA 
purifier and a Superose 6 column (Assini et al., 2013). A constant flow rate of 0.4 
mL/min was used to collect 500 µL fractions. An aliquot of each fraction was used to 
measure cholesterol and triglycerides enzymatically in both samples and standards on a 
microtitre plate with added enzymatic reagents (Triglyceride: Roche Diagnostics, 
triglycerides/glycerol blanked #11877771 216 and total cholesterol: WAKO Diagnostics, 
Burlington, Canada Cholesterol E (CHOD-DAOS method) #439-17501). Blood glucose 
was measured in whole blood using the Bayer Contour Blood Glucose Monitoring 
System (Bayer Healthcare, Etobicoke, Canada) (Mulvihill et al., 2009). Plasma Insulin 
(ALPCO Diagnostics, Salem, NH: mouse ultrasensitive ELISA #80-INSMSU-E01) was 
determined in frozen EDTA-plasma samples by mouse specific ELISA as per 
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manufacturer’s instructions. Plasma non-esterified fatty acids (NEFAs) were determined 
enzymatically as per manufacturer’s instructions (Wako Chemicals, VWR, Mississauga, 
Canada). 
3.2.6 Tissue Histology and Immunohistochemistry 
Histological and morphometric analyses were performed as described previously (Assini 
et al., 2013; Mulvihill et al., 2010). Pieces of liver were placed in OCT, frozen and 
sectioned at 8 µm using a Leica CM 3050S cryostat. Liver sections were stained with oil 
red O (ORO, Sigma-Aldrich) and visualized using brightfield microscopy. Frozen serial 
sections of the aortic sinus from hearts frozen in OCT (70-100 per heart, 10 µm), 
initiating anterior to the origin of the aortic valves, were prepared using a Leica CM 
3050S cryostat. For quantitation of lesion area in the aortic sinus, sections were stained 
with ORO. Immunohistochemistry staining for macrophages by CD68 (BioRad, 
Mississauga, Canada: MCA 1957), smooth muscle α-actin (Abcam, Toronto, Canada: 
polyclonal rabbit anti-smooth muscle α-actin, ab5694,) and activated caspase-3 (Abcam: 
rabbit anti-active caspase-3, ab4051), was performed as described previously (Bojic et 
al., 2014; Samsoondar et al., 2017). Slides were fixed in acetone and blocked in 2% 
bovine serum albumin (Sigma-Aldrich). After incubation with primary antibody, a goat 
biotinylated secondary antibody was used (Vector Laboratories, Burlington, ON). Slides 
were then incubated in peroxidase blocking reagent, followed by incubation with the 
ABC reagent (ABC Elite Standard Kit, Vector Laboratories). Slides were exposed to the 
DAB substrate (Peroxidase substrate kit, Vector Laboratories) followed by counterstain 
in hematoxylin (Sigma-Aldrich). Photomicrographs were obtained using an Olympus 
BX50 microscope and a QImaging Retiga EXi FAST camera. Collagen fibrils were 
assessed using circular polarizing microscopy as described previously (Bojic et al., 2014; 
Samsoondar et al., 2017). Aortic sinus sections were stained with picrosirius red 
(Polysciences, Warrington, PA) and visualized using an Olympus BX50 microscope 
(Olympus Canada, Richmond Hill, Canada) equipped with circular polarizer/interference 
filters, a liquid crystal compensator, a charge-coupled device video camera and Abrio 
image-processing software (Abrio LC-Polscope, Cambridge Research and 
Instrumentation, Inc., Hopkinton, MA). 
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3.2.7 Flow Cytometry 
In a separate experiment, mice (10-12 weeks of age, n=10/group) were fed ad libitum a 
high-fat, cholesterol containing (HFHC; 42% of calories from fat, 0.2% cholesterol, 
Teklad TD09268, Envigo) for 12 weeks. For an additional 12 weeks, these mice were 
divided amongst 3 different groups: one group remained on the same HFHC diet, one 
group switched to standard a standard rodent chow (12% of calories from fat, Teklad 
Global 16% Protein Rodent Diet 2016, Envigo), and one group switched to the same 
standard chow supplemented with 3% naringenin (#N5893, Millipore-Sigma).  
Blood Leukocytes: Monocytes and neutrophils were identified from whole blood. Blood 
was collected by cardiac puncture into EDTA lined tubes and immediately placed on ice. 
For each mouse sample, 100 ul of blood was used. UltraComp eBeads (Affymetrix 
eBiosciences #01-2222, Cedarlane, Burlington, ON) were used as a single positive 
control, except for the single positive control for the Vital Dye, we used ArC™ Amine 
Reactive Compensation Bead Kit (A10346, Life Technologies, Burlington, ON). 
Fluorescence mine one (FMO) controls were done on combined blood samples from all 
mice, 100 µl each. Viability was assessed using LIVE/DEAD® Fixable Dead Cell Near-
IR Stain Kit (L11019, Invitrogen, Life Technologies, Burlington, ON) (Table 2.1) in all 
samples after incubation for 25 min in the dark at room temperature. Cells were stained 
with a cocktail of antibodies against CD45-eFluor®450 (Affymetrix eBiosciences, 
Cedarlane, Burlington, ON), Ly6-C/G-PerCP-Cy™5.5 (BD Biosciences, Cedarlane, 
Burlington, ON) and CD115-APC (Affymetrix eBiosciences, Cedarlane, Burlington, ON) 
on ice for 20 minutes in the dark (Table 2.1), similar to previous studies (Murphy et al., 
2011) (Chapter 2). Red blood cells were lysed in 1X PharmLyse (BD Biosciences, 
Cedarlane, Burlington, ON) for 13 minutes at room temperature. The stained white blood 
cells were centrifuged, washed, and resuspended in flow-buffer (Hank’s buffered salt 
solution +0.1% BSA, w/v). Cells were fixed by the addition of 4% paraformaldehyde. 
Monocytes were identified as CD45hi CD115hi and further identified into Ly6-Chi and 
Ly6-Clo; neutrophils were identified as CD45hi CD115lo Ly6-C/Ghi (Gr-1), similar to 
previous studies (Murphy et al., 2011). 
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Hematopoietic Stem Cells: Hematopoietic stem and progenitor cells from the bone 
marrow were analyzed by flow cytometry. Bone marrow was harvested from femurs and 
tibias by flushing with HBSS +0.1% BSA w/v through a 70µm cell strainer. The cell 
suspension was centrifuged for 5 minutes at 500 g at 6ºC, supernatant aspirated and the 
cells re-suspended in 1X PharmLyse (BD Biosciences, Cedarlane, Burlington, ON) for 5 
minutes. RBC lysis was stopped by the addition of excess HBSS + 0.1% BSA. Cells were 
once again centrifuged at 500 g for 5 min at 6ºC and the supernatant aspirated. Cells were 
re-suspended in 1 mL HBSS + 0.1% BSA and blocked with normal goat serum. Cells 
were once again centrifuged at 500 g for 5 min at 6ºC, and the supernatant aspirated. 
Bone marrow was resuspended in 4mL of HBSS +0.1% BSA. For each mouse bone 
marrow sample, 150 ul of suspension was used. UltraComp eBeads (Affymetrix 
eBiosciences #01-2222, Cedarlane, Burlington, ON) were used as a single positive 
control, except for the single positive control for the Vital Dye, we used ArC™ Amine 
Reactive Compensation Bead Kit (A10346, Life Technologies, Burlington, ON). FMO 
controls were done on combined samples from all mice, 150 µl each. Viability was 
assessed using LIVE/DEAD® Fixable Dead Cell Near-IR Stain Kit (L11019, Invitrogen, 
Life Technologies, Burlington, ON) (Table 2.1) in all samples after incubation for 25 min 
in the dark at room temperature. Cells were stained with a cocktail of antibodies against 
FITC Mouse Hematopoietic Lineage Cocktail (CD3 (17A2), CD45R (B220)(RA3-6B2), 
CD11b (M1/70), TER-119, Ly-G6 (Gr-1) (RB6-8C5)) (Affymetrix eBiosciences, 
Cedarlane, Burlington, ON), Brilliant Violet 421™ Anti-mouse CD117 (c-Kit) 
(Biolegend, Cedarlane, Burlington, ON), Brilliant Violet 605™ anti-mouse Ly-6A/E 
(Sca-1) (Biolegend, Cedarlane, Burlington, ON), Alexa Fluor®700 Anti-mouse CD16/32 
(Affymetrix eBiosciences, Cedarlane, Burlington, ON) and PE Anti-mouse CD34 
(Biolegend, Cedarlane, Burlington, ON) on ice for 20 minutes in the dark (Table 2.1) 
similar to previous studies (Murphy et al., 2011)(Chapter 2). The stained white blood 
cells were centrifuged, washed, and resuspended in flow-buffer (HBSS+0.1% BSA, w/v). 
Cells were fixed by the addition of 4% paraformaldehyde. HSPCs were identified as Lin-, 
Sca-1+ and ckit+ (LSK) while the hematopoietic progenitor subsets were separated using 
antibodies to CD16/32 (FcγRII/III) and CD34. CMPs were identified as lin-, Sca-1-, ckit+, 
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CD34hi, FcγRII/IIIlo, GMPs as lin-, Sca-1-, ckit+, CD34hi, FcγRII/IIIhi, MEPs as lin-, Sca-
1-, ckit+, CD34lo, FcγRII/IIIlo. 
Flow cytometry was performed using an LSRII (for analysis) running FACS DiVa 
software. All flow cytometry data were analyzed using FlowJo software (Tree Star Inc.) 
3.2.8 Statistical Analysis 
Data is presented as mean ± SEM. Statistical analyses were performed using Sigma Plot 
version 14.0. A One-way ANOVA was used to test for differences between groups. 
Significance thresholds were P values less than 0.05. Significance differences are 
indicated by different lowercase letters. 
3.3 Results 
3.3.1 Naringenin Enhances Lipid Lowering Observed with Chow 
Intervention 
Previous results in our laboratory showed that naringenin was able to improve established 
atherosclerotic lesion pathology when supplemented to a high-fat diet, but did not induce 
lesion regression in part due to the persistence of elevated plasma lipids (Chapter 2). In 
the present study, we sought to achieve atherosclerosis regression with naringenin 
intervention in the setting of low plasma lipids. To accomplish this, we designed an 
intervention study in which intermediate atherosclerotic lesions were induced in Ldlr-/- 
mice by a high-fat diet for 12 weeks, similar to other regression study protocols (Hewing 
et al., 2013; Rayner et al., 2011). One group was sacrificed to provide baseline data. 
Subsequently, the remaining mice either remained on the HFHC diet, or received an 
intervention with isoflavone-free standard chow supplemented with 3% naringenin or the 
chow alone for 12 weeks. Intervention with chow reduced plasma cholesterol and 
triglyceride levels (Figure 3.1), while continuation on the HFHC maintained elevated 
plasma cholesterol and triglycerides (Figure 3.1). Intervention with naringenin in addition 
to a chow diet potentiated the reduction in plasma cholesterol (-83.2% vs -76.6%) and 
triglycerides (-79.4% vs -65.6%) (Figure 3.1). FPLC separation of plasma revealed that 
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naringenin plus chow decreased VLDL-cholesterol, LDL-cholesterol and VLDL-
triglycerides to a greater extent than chow alone (Figure 3.1).  
3.3.2 Naringenin Completely Halts Atherosclerosis  
To assess whether the enhanced lipid-lowering effects of naringenin resulted in 
atherosclerosis regression, we measured aortic lipids and plaque size in the aortic sinus. 
Unlike continuation on the HFHC diet, intervention with chow diet slowed the 
accumulation of aortic free and esterified cholesterol (Figure 3.2A, B). Intervention with 
naringenin in addition to the chow diet further slowed the accumulation of aortic 
cholesterol (Figure 3.2A, B) and reduced aortic triglycerides compared to all other 
treatment groups (Figure 3.2C). Together, this suggests an effect of naringenin 
intervention on atherosclerosis compared to chow intervention alone. To investigate this 
further, we measured lesion size in the aortic sinus (Figure 3.2D). Induction with the 
HFHC diet promoted intermediate lesion development. Continuation on the HFHC diet 
for an additional 12 weeks increased lesion size more than 2-fold (Figure 3.2D). 
Intervention with chow alone slowed lesion growth by 66%, whereas the addition of 
naringenin to chow completely halted lesion growth (-92%) in the aortic sinus (Figure 
3.2D). 
3.3.3 Naringenin Improves Aortic Sinus Atherosclerosis Lesion 
Pathology 
The reduction in aortic lipids (Figure 3.2) also suggested that the smaller lesions in 
naringenin-treated mice, may be accompanied by distinct changes in lesion morphology 
consistent with atherosclerosis regression. Therefore, we assessed plaque composition 
histologically. Macrophages comprise most of the cells within early to intermediate 
atherosclerotic lesions, which is consistent with observations in HFHC-induced plaques 
at baseline (Figure 3.3A,B). Continuation on the HFHC diet for an additional 12 weeks 
reduced the contribution of macrophages to lesion cellularity (-33%) as the size and 
complexity of the lesion increased (Figure 3.3A,B). Following intervention with the chow 
diet, macrophage content was significantly reduced from baseline by 63%, and 
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Ldlr-/- mice were fed a HFHC diet for 12 weeks (Baseline). Subsequently the same mice 
were intervened with a chow diet or a chow diet supplemented with 3 % naringenin 
(Nar). At the end of intervention plasma lipids were measured. A; Total plasma 
cholesterol and FPLC separated plasma cholesterol (n=6-10/group). B; Plasma 
triglycerides and FPLC separated plasma triglycerides (n=6-10/group). Data represent the 
mean±SEM. Different letters are statistically different by ANOVA with post-hoc Tukey 
test (P<0.05).  
  
Figure 3.1 Naringenin Supplementation Enhances the Reduction in Plasma Lipids 
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Ldlr-/- mice were fed a HFHC diet for 12 weeks (Baseline). Subsequently the same mice 
were intervened with a chow diet or a chow diet supplemented with 3 % naringenin 
(Nar). At baseline and at the end of intervention aortae were dissected free from fat and 
lipids were measured enzymatically. A; Aortic free cholesterol (FC) (n=6-10.group). B; 
Aortic cholesteryl ester (CE) (n=6-10). Aortic triglycerides (TGs) (n=6-10). Lesion area 
in the aortic root and representative sections stained with oil-red O and counterstained 
with haematoxylin (n=6-10/group). Data represent the mean±SEM. Different letters are 
statistically different by ANOVA with post-hoc Tukey test (P<0.05). N.S indicates non-
significance. 
  
Figure 3.2 Naringenin Supplementation Completely Halts Atherosclerotic Lesion 
Growth 
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Ldlr-/- mice were fed a HFHC diet for 12 weeks (Baseline). Subsequently the same mice 
were intervened with a chow diet or a chow diet supplemented with 3 % naringenin 
(Nar). At baseline and at the end of intervention aortae were dissected free from fat and 
the sinus was sectioned for histological analyses. A; Representative sections for each 
stain in the aortic sinus. B; Per cent of lesion area occupied by CD68+ macrophages 
(n=6-10.group). C; Per cent of lesion area occupied by SM α-actin (n=6-10/group). D; 
Per cent of lesion occupied by collagen (n=6-10). E; Mean collagen retardation (nm) in 
atherosclerotic lesions in aortic sinus (n=6-10/group). F; Per cent of lesion positive for 
activated capsase-3 (n=10-20). G; Per cent of lesion comprised of the necrotic core (n=9-
25). Data represent the mean±SEM. Different letters are statistically different by 
ANOVA with post-hoc Tukey test (P<0.05). N.S indicates non-significance. 
  
Figure 3.3 Naringenin Supplementation Improves Atherosclerotic Plaque 
Morphology 
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macrophages were luminally located. This reduction was magnified (-75%) by the 
addition of naringenin to the chow diet (Figure 3.3A,B). Previous studies have 
established that reductions of lesion macrophage content from baseline is a feature of 
regressing atherosclerotic plaques (Feig et al., 2011a; Feig et al., 2012). To further 
characterize these plaques, features of stability, including smooth muscle α-actin, acting 
as a marker of smooth muscle cells (SMC), as well as collagen content, were assessed 
(Figure 3.3A-D). SMC content in sinus lesions at baseline was ~4.2% of total plaque area 
(Figure 3.3A,C). Continuation of the HFHC diet for an additional 12 weeks, decreased 
SMC content to ~2% of plaque area (Figure 3.3A,C). While intervention with chow alone 
slowed the reduction in SMC content (~3% of plaque area), intervention with naringenin 
plus chow appeared to halt the reduction in lesion SMCs (~4% of plaque area) (Figure 
3.3A,C). Examination of lesion collagen content and organization using picrosirius red 
staining revealed a strong correlation between the two parameters. Collagen content tends 
to increase with lesion complexity as evidenced by the increase in collagen content and 
organization in mice continuing on HFHC (Figure 3.3A,D,E). Intervention with chow 
alone or chow supplemented with naringenin increased collagen content and organization 
from baseline, which were moderately higher compared to mice remaining on the HFHC 
diet (Figure 3.3A,D,E). Analyses of necrotic core size and apoptotic cell accumulation, 
both markers of advanced plaques, revealed that both parameters were increased from 
baseline in mice continuing on the HFHC diet, although increases were not significant 
(Figure 3.3A,F,G). Intervention with both chow alone or chow plus naringenin tended to 
slow necrotic core growth and to reverse apoptotic cell accumulation to a similar extent, 
suggesting improved lesion morphology (Figure 3.3A,F,G).  
3.3.4 Naringenin Reduces Blood Monocytes 
The significant reduction in lesion macrophages with naringenin treatment is 
characteristic of atherosclerosis regression (Burke and Huff, 2018). A number of studies 
have shown that reduced recruitment of monocytes into plaques as well as reduced 
proliferation of macrophages within the plaque contribute to reduced macrophage content 
and enhanced regression. Therefore, we measured blood monocytes after 12 weeks 
intervention. Following induction with the HFHC diet, blood leukocytes were increased 
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and remained elevated with continuation of the HFHC diet (Figure 3.4A-E). Intervention 
with chow alone reduced both neutrophils (-18%) and total monocytes (-36%) from 
baseline, with a greater reduction in Ly6Chi monocytes compared to Ly6Clo monocytes 
(Figure 3.4A-E). Intervention with the addition of naringenin to chow, reduced 
neutrophils a further 19% and total monocytes a further 38%, with the further reduction 
in Ly6Chi monocytes (-62%) being of greater magnitude than the further reduction in 
Ly6Clo monocytes (-12%) (Figure 3.4A-E).  
3.3.5 Naringenin Reduces Bone Marrow Progenitor Proliferation 
In our previous study, the modest reductions in circulating peripheral blood monocytes 
with intervention by the addition of naringenin to HFHC were not associated with any 
effect on bone marrow progenitor cells (HSPCs) (Chapter 2). In the present study, the 
much greater magnitude of reduction in circulating peripheral blood mononuclear cells 
with naringenin plus chow intervention suggests that it may result from suppressed bone 
marrow progenitor cells. Consistent with previous studies, hematopoietic stem and 
progenitor cells (HSPCs) were elevated in the bone marrow of Ldlr-/- mice during 
induction with the HFHC diet (Figure 3.4F) (Murphy et al., 2011). Intervention with 
chow alone reduced HSPCs by 33% from baseline (Figure 3.4F). With the addition of 
naringenin to chow, the magnitude of reduction was slightly enhanced (trend), reducing 
HSPCs by 37% from baseline (Figure 3.4F). This suggests that reduced bone marrow 
myelopoiesis contributed to reduced circulating monocytes with both intervention diets. 
Looking further down the differentiation lineage, we assessed bone marrow monocyte 
progenitor cells (MPCs) (Figure 3.4G). A similar trend emerged with reduced bone 
marrow MPCs with chow intervention (-17%) and a slight enhancement in the magnitude 
reduction with naringenin plus chow (Figure 3.4G). Assessment of the common 
macrophage progenitor CMP and granulocyte macrophage progenitor (GMP) populations 
with both interventions, showed a trend towards reduction in CMPs but no effect was 
observed for GMPs (Figure 3.4H,I). There was no effect on erythrocyte progenitor pools 
(MEPs) (Figure 3.4J). 
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Ldlr-/- mice were fed a HFHC diet for 12 weeks (Baseline). Subsequently the same mice 
were intervened with a chow diet or a chow diet supplemented with 3 % naringenin 
(Nar). At baseline and at the end of intervention blood and bone marrow cells were 
isolated, stained and analyzed by flow cytometry. A; Representative dot plots depicting 
gating of blood peripheral blood mononuclear cells. B; Per cent of blood PBMCs that are 
neutrophils (n=6-9/group). C; Per cent of PBMCs that are monocytes (n=9-10/group). D; 
Per cent of monocytes that are Ly6Chi (n=8-10/group). E; Per cent of monocytes that are 
Ly6Clo (n=9-10/group). F; Per cent of bone marrow (BM) cells that are hematopoietic 
stem and progenitor cells (HSPCs) (n=8-10/group). G; Percent of BM cells that are 
myeloid progenitor cells (MPCs) (n=9-10/group). H; Percent of BM cells that are 
common myeloid progenitor cells (CMPs) (n=9-10/group). I; Percent of BM cells that are 
granulocyte and macrophage progenitor cells (GMPs) (n=10/group). J; Percent of BM 
cells that are megakaryocyte and erythrocyte progenitor cells (MEPs) (n=8-10/group). 
Data represent the mean±SEM. Different letters are statistically different by ANOVA 
with post-hoc Tukey test (P<0.05). N.S indicates non-significance. 
  
Figure 3.4 Naringenin Supplementation Reduces Blood Monocytes 
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3.3.6 Naringenin Enhances Insulin Sensitivity 
Insulin resistance in mice has been correlated with worsening atherosclerosis and 
enhanced monocytosis and myelopoiesis (Bornfeldt and Tabas, 2011). The HFHC diet 
induced hyperinsulinemia and impaired insulin tolerance at 12 weeks (Figure 3.5A, B). 
Continuation on the HFHC diet maintained hyperinsulinemia and a suppressed insulin 
tolerance test response (Figure 3.5A, B). Intervention with chow improved 
hyperinsulinemia (-38%), while addition of naringenin enhanced this improvement, 
reducing hyperinsulinemia by 85% (Figure 3.5A). Insulin tolerance was unaffected by 
intervention with chow alone, however naringenin plus chow enhanced glucose clearance 
in response to insulin by 38% (Figure 3.5B). Assessment of glucose homeostasis in 
HFHC-fed Ldlr-/- mice confirmed the development of a moderate hyperglycemia, which 
persisted with continuation of HFHC for 24 weeks (Figure 3.5C). Compared to baseline 
values, intervention with chow alone did not change levels of fasting blood glucose, 
whereas intervention with naringenin supplemented chow significantly reduced fasting 
blood glucose by 38% (Figure 3.5C). To assess if the changes in insulin tolerance were 
reflected by alterations in glucose homeostasis, glucose tolerance tests were performed at 
baseline and following 12 weeks intervention (Figure 3.5D). At baseline, glucose 
tolerance was impaired and continuation on the HFHC diet or intervention with chow 
alone had no effect on glucose clearance after a glucose challenge (Figure 3.5D). In 
contrast, supplementation of naringenin to the chow diet significantly enhanced glucose 
tolerance (Figure 3.5D). Furthermore, homeostasis model assessment of insulin resistance 
(HOMA-IR) calculations showed that intervention with naringenin supplemented to 
chow reduced HOMA-IR to a greater extent than intervention with chow alone (Figure 
3.5E). Obesity and insulin resistance are characterized by an elevation in NEFAs, 
therefore we measured NEFAs after induction and intervention. At baseline, NEFAs were 
elevated and remained elevated with continuation of the HFHC diet (Figure 3.5F). 
Following intervention with chow alone or chow supplemented with naringenin, NEFAs 
were reduced to a similar extent (-47% and -35%, respectively) (Figure 3.5F). 
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Ldlr-/- mice were fed a HFHC diet for 12 weeks (Baseline). Subsequently the same mice 
were intervened with a chow diet or a chow diet supplemented with 3 % naringenin 
(Nar). At baseline and at the end of intervention insulin sensitivity was measured. A; 
Plasma insulin levels (n=6-10). B; Insulin tolerance test as a percent of baseline glucose 
(n=4-14/group). C; Fasting blood glucose levels (n=6-10/group). D; Glucose tolerance 
test (n=4-14/group). E; Homeostasis model assessment of insulin resistance (HOMA-IR) 
(n=5-6/group). F; Plasma non-esterified fatty acids (n=6-10/group). Data represent the 
mean±SEM. Different letters are statistically different by ANOVA with post-hoc Tukey 
test (P<0.05).  
  
Figure 3.5 Naringenin Supplementation Enhances Insulin Sensitivity 
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3.3.7 Naringenin Improves Liver Lipids and Body Weight 
Metabolic disturbances contribute to atherosclerosis in mice and their resolution have 
been linked to lesion regression (Burke and Huff, 2018). Therefore, we measured 
parameters of hepatic steatosis and obesity. Hepatic triglycerides and cholesterol were 
increased at baseline and remained elevated in mice that continued on the HFHC diet 
(Figure 3.6A-C). Liver sections were characterized by the accumulation of large lipid 
droplets (Figure 3.6C). Intervention with chow alone completely reversed hepatic lipid 
accumulation (Figure 3.6A-C). The addition of naringenin to the chow diet slightly 
enhanced the reduction in liver triglycerides (-75% vs -68%) (Figure 3.6A), whereas the 
reductions in free and cholesteryl ester were the same as with the chow alone intervention 
(Figure 3.6B). Lipid droplets in liver sections appeared smaller with intervention by 
naringenin plus chow, compared to intervention with chow alone (Figure 3.6C). To 
investigate whether the modest reduction in hepatic lipids was due to enhanced 
mobilization and oxidation of fatty acids by the liver, we measured the expression of 
genes in the liver. The addition of naringenin to chow increased the expression of Pnpla2 
(1.73-fold), Cpt1a (1.24-fold) and Pgc1a (1.88-fold) compared to chow alone, suggesting 
augmented fatty acid oxidation (Figure 3.6D-F).  
The impact of intervention on body weight and adiposity was assessed. On the HFHC 
diet, mice rapidly gained weight during the 12-week induction phase, which continued in 
HFHC-fed mice throughout the subsequent 12 weeks (Figure 3.6G). Intervention with 
chow alone promoted rapid weight loss over the first 6 weeks, which tapered off for the 
last 6 weeks of intervention (Figure 3.6G). Similarly, the addition of naringenin to chow 
induced rapid weight loss in the first 6 weeks, followed by a plateau, although body 
weights at sacrifice were 20% lower than in mice intervened with chow alone, however 
this was not significant (Figure 3.6G). Assessment of epididymal adiposity showed that 
the modest enhancement in weight loss by naringenin was due to a significant reduction 
in adiposity compared to intervention with chow alone (Figure 3.6H). Importantly, during 
the intervention phase, caloric intake was similar between all groups (Figure 3.6E).  
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Ldlr-/- mice were fed a HFHC diet for 12 weeks (Baseline). Subsequently the same mice 
were intervened with a chow diet or a chow diet supplemented with 3 % naringenin 
(Nar). At baseline and at the end of intervention analyses were performed. A; Hepatic 
triglycerides determined by extraction followed by enzymatic assay (n=6-8/group). B; 
Hepatic cholesteryl ester and free cholesterol determined by enzymatic assay (n=6-
8/group). C; Representative liver sections stained with oil red-O. D; Hepatic expression 
of Pnpla2 expressed as a fold change of baseline (n=5-10/group). E; Hepatic expression 
of Pgc1a expressed as a fold change of baseline (n=5-10/group). F; Hepatic expression of 
Cpt1a expressed as fold change of baseline (n=5-10/group). G; Biweekly body weights 
during the study (n=6-10/group). H; Adiposity assessed as epididymal fat pad 
weight/total body weight (n=6-10/group). I; Biweekly daily caloric intake and average 
caloric intake during the study (n=6-10/group). Data represent the mean±SEM. Different 
letters are statistically different by ANOVA with post-hoc Tukey test (P<0.05). 
  
Figure 3.6 Naringenin Supplementation Enhances Weight Loss and Reduces 
Hepatic Lipids 
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3.4 Discussion 
Regression of atherosclerosis has become an important clinical objective and therefore, 
studies into the underlying mechanisms and therapeutics that induce atherosclerosis 
regression have become increasingly relevant. In the majority of published mouse 
regression studies, the intervention involves genetic modulation, whereas studies of 
intervention with novel therapeutics are limited. The data presented herein demonstrates 
that in Ldlr-/- mice with established diet-induced atherosclerosis, intervention with the 
citrus flavonoid naringenin enhances the regression of atherosclerosis compared to 
regression induced with intervention by a chow diet alone. The growth in size of aortic 
sinus plaques was completely halted and plaques were characterized by a significant 
reduction in macrophages, attenuation in the reduction of smooth muscle cells and with 
similar amounts of collagen, apoptotic cells and necrotic core sizes. Together, this 
suggests improved lesion morphology. The naringenin intervention amplified the 
reduction in circulating monocytes, due to an attenuation of myelopoiesis in the bone 
marrow. Furthermore, naringenin improved hyperlipidemia, insulin resistance and 
adiposity to a greater extent than the chow intervention alone, which collectively 
contributed to the enhanced atherosclerosis regression in naringenin-treated mice. 
The most well characterized cell type in atherosclerosis regression is the macrophage 
(Burke and Huff, 2018; Peled and Fisher, 2014). Similar to a number of other regression 
studies, we observed reduced macrophage content within plaques of naringenin-treated 
mice. These macrophages tended to be located at the luminal periphery of the plaque, 
consistent with other intervention studies in mice (Feig et al., 2011a; Potteaux et al., 
2011; Rayner et al., 2011). Monocyte dynamics are intrinsically involved in 
atherosclerosis regression, including reduced recruitment of monocytes from the 
circulation, egress of macrophages out of the plaque or attenuated proliferation within the 
plaque (Burke and Huff, 2018). In this study, naringenin intervention reduced 
macrophages within regressing plaques and decreased monocytes (Ly6chi and Ly6clo) in 
the circulation, which was accompanied by a reduction in progenitor populations in the 
bone marrow. Similar results have been observed in the context of reversed 
hyperlipidemia, obesity and hyperglycemia (Murphy et al., 2011; Nagareddy et al., 2014; 
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Nagareddy et al., 2013), suggesting that the metabolic improvements with naringenin 
treatment attenuated myelopoiesis, thereby contributing to atherosclerosis regression. We 
cannot exclude a direct effect naringenin on myelopoiesis with naringenin treatment or 
the contribution of hyperlipidemia, hyperglycemia or adiposity. Although the reversal of 
hyperlipidemia, hyperglycemia or adiposity with naringenin intervention likely resulted 
in a reduction in the recruitment of circulating monocytes to the regressing plaque, we 
did not perform trafficking studies to confirm the contribution of monocyte recruitment, 
proliferation or macrophages egress to the suppression of lesion macrophages. 
Although less well characterized during atherosclerosis regression, some of the 
morphological changes in the plaque involve other cell types. Some studies show 
enhanced smooth muscle cell content and increased collagen content and organization 
associated with a stable fibrous cap (Bojic et al., 2014; Foks et al., 2013; Huang et al., 
2017). Although both interventions appeared to stabilize lesion smooth muscle cell 
content, which trended to be more effective with naringenin, this did not correlate with an 
increase in collagen content or organization, as observed previously in other studies of 
atherosclerosis regression in mice (Bojic et al., 2014; Foks et al., 2013; Huang et al., 
2017; Willecke et al., 2015). It is possible that naringenin intervention prevented loss of 
smooth muscle α-actin expression, known to occur during the transition of SMCs into 
foam cells (Gomez and Owens, 2012; Pidkovka et al., 2007), but these SMCs retained 
their inability to lay down collagen matrix in the milieu of more advanced lesions 
(Frontini et al., 2009). Thus, it would be important in future studies to determine the 
origin of smooth muscle α-actin expressing cells during regression, which could be 
determined using lineage-tracing technology (Shankman et al., 2015). Although not often 
investigated, regression of necrotic core size is an important indicator of plaque stability 
(Moore and Tabas, 2011). Necrotic core contraction appears to be rare in regression 
studies (Van Craeyveld et al., 2011), but many interventions stabilize necrotic core 
growth to levels measured at baseline (Huang et al., 2017). In the present study, necrotic 
core growth was halted to a similar extent with both naringenin plus chow and chow 
alone interventions. Additionally, both interventions reduced the accumulation of 
apoptotic cells in the plaque. During regression, macrophage phenotype shifts towards 
M2, which are more efficient at efferocytosis, or the clearance of apoptotic cells (Bojic et 
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al., 2014; Feig et al., 2011b; Van Vre et al., 2012). Although we did not examine 
macrophage phenotype, it is possible that naringenin intervention enhanced macrophage 
polarization towards an M2 phenotype, consistent with the other features of regression. 
Furthermore, enhanced or improved efferocytosis, as well as inhibition of apoptosis, 
could contribute to reduced apoptotic cell accumulation within lesions and halt the 
growth of the necrotic core (Van Vre et al., 2012). 
The majority of mouse intervention studies that have achieved lesion regression involve 
genetic inhibition of hepatic lipoprotein production or genetic restoration of lipoprotein 
clearance (Apoe or Ldlr-/-), thereby resulting in robust lowering of plasma lipids. Fewer 
studies have successfully achieved regression with anti-atherosclerotic agents added to 
dietary interventions. Rayner et al. used a HFD-induction Ldlr-/- mouse intervention 
model to show that a 4-week intervention with a mir-33 antagonist, in addition to a chow 
diet, decreased lesion size and macrophage content, compared to chow alone (Rayner et 
al., 2011). However, in the Ldlr-/- Reversa mouse model, this additive effect of the mir-33 
antagonist intervention was not observed (Distel et al., 2014). Hewing et al. demonstrated 
in the HFD-induction Ldlr-/- model, that the addition of an MTP inhibitor to the chow diet 
intervention did not decrease lesion size but reduced plaque macrophage content, 
compared to chow alone (Hewing et al., 2013). Using the Reversa model, the addition of 
the PPARγ agonist, pioglitazone to the chow intervention, had no additive effect on 
regressing lesions (Feig et al., 2011a). In the present study, intervention with the addition 
of naringenin to the chow intervention consistently reduced lesion size and reversed 
plaque macrophage content, compared to chow alone. Notably, in addition to lipid 
lowering, naringenin has a significant systemic effect on metabolic atherosclerotic risk 
factors, whereas mir33 antagonism and MTP inhibition specifically target reverse 
cholesterol transport and hepatic lipoprotein production, respectively (Hewing et al., 
2013; Rayner et al., 2011).  
Naringenin intervention completely halted lesion growth and reduced macrophage 
content, consistent with lesion regression. Although naringenin enhanced the reversal of 
obesity, insulin insensitivity, hepatic steatosis and hyperlipidemia, all factors that could 
affect atherosclerosis regression (Feig et al., 2011a; Nagareddy et al., 2014; Nagareddy et 
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al., 2013), we could not exclude additional effects of naringenin on plaque components 
contributing to regression. Previous mouse intervention studies administered treatments 
that directly targeted lesions, without effect on plasma lipids or metabolic indices. For 
example, in the Ldlr-/- model, intervention with small molecule inhibitors of ER stress 
signaling did not affect lesion area, but reduced necrotic core size and increased SMC 
and collagen content, features consistent with more stable plaques (Huang et al., 2017). 
In high-fat-fed Apoe-/- mice, an intervention consisting of lesion-targeted simvastatin 
nanoparticles had no effect on plaque size, but the intervention attenuated macrophage 
proliferation, reduced plaque inflammation and increased markers of plaque stabilization 
(Tang et al., 2015) It is possible that naringenin has pleiotropic effects on lesional cells 
aside from its metabolic effects. Experiments in cell culture have demonstrated that 
naringenin treatment of vascular smooth muscle cells reduced proliferation and migration 
via heme oxygenase-1 (Chen et al., 2012) and in THP-1 macrophages, naringenin 
enhanced the expression of genes involved in cholesterol efflux via LXRa (Saenz et al., 
2018). Context-dependently, both these effects could significantly enhance lesion 
regression. Future experiments could address these pleiotropic effects by evaluating the 
ability of naringenin to regress lesions in Apoe-/- mice, which can develop atherosclerosis 
spontaneously on a chow-based diet or in Apoe-/- mice fed a high-fat diet, which do not 
develop as severe metabolic dysfunction as in the high-fat fed Ldlr-/- model (Chanet et al., 
2012; Getz and Reardon, 2016). Prevention studies in Apoe-/- mice fed a semi-synthetic 
diet demonstrated that naringin, the glycosylated form of naringenin at 0.02% had no 
effect on lesion development (Chanet et al., 2012). With a naringin dose 10-fold lower 
than that of naringenin in the present study, it is difficult to conclude whether no 
pleiotropic effects occurred or if the dose used was insufficient to elicit them. 
The mechanism(s) through which naringenin regulates lipid metabolism, adiposity and 
insulin sensitivity are not completely understood. Previous in vitro studies demonstrated 
that naringenin activated insulin signaling independent of the insulin receptor or insulin 
receptor substrate (Allister et al., 2005) and does not activate PPARα, PPARδ or PPARγ 
(Mulvihill et al., 2009). In mice, naringenin upregulated hepatic fatty acid oxidation, 
independent of peroxisomal proliferation (Mulvihill et al., 2009). The upstream 
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mechanism(s) governing these effects have remained somewhat elusive. The hormone-
like fibroblast growth factor 21 elicits similar metabolic improvements as naringenin 
when given exogenously to mice, but naringenin treatment of Fgf21-/- mice, prevented 
metabolic dysfunction and obesity as effectively as in wildtype mice (Assini et al., 2015). 
Short-term treatment of Ob/Ob mice with naringenin corrected hyperlipidemia and 
insulin sensitivity and decreased body weight (Assini et al., 2015), suggesting that the 
effect of naringenin intervention was independent of leptin deficiency. Treatment of 
weight cycling C57BL6/J mice with the combination of apigenin and naringenin 
increased brown adipose tissue Ucp1 expression (Thaiss et al., 2016), however, studies in 
Chapter 2 suggest naringenin intervention had no effect on the expression in white 
adipose tissue of Ucp1 or other genes linked to browning. Metabolic protection by the 
flavonoid nobiletin has been linked to enhanced amplitude of circadian rhythms, 
specifically in obese mice (He et al., 2016), however the effect of naringenin at the doses 
used in the present study have not been examined. 
In conclusion, we have shown that intervention with naringenin supplemented to chow 
enhanced atherosclerosis regression compared to intervention with chow alone. Lesions 
were characterized by reduced macrophages and improved morphology, in part due to 
reduced circulating monocytes and myelopoiesis in the bone marrow, and enhanced 
improvements in metabolic indices. These studies highlight the therapeutic utility of the 
citrus flavonoid, naringenin, especially in the context of existing atherosclerosis. 
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Chapter 4  
4 Naringenin supplementation to a chow diet enhances 
energy expenditure and fatty acid oxidation, and 
reduced adiposity in lean, pair-fed Ldlr-/- mice 
4.1 Introduction 
Epidemiological evidence shows an inverse correlation between the consumption of fruits 
and vegetables, and the risk for developing obesity, metabolic syndrome and 
cardiovascular disease (Aune et al., 2017). Flavonoids, a class of secondary plant 
metabolites, are widely distributed in fruits and vegetables, are present in our daily diet, 
and may confer potential health benefits (Peterson et al., 2012). Naringenin is a citrus-
derived flavonoid that is found abundantly in grapefruits and tomatoes and exhibits a 
diverse range of biological functions such as anti-cancer, anti-inflammation and anti-
atherosclerotic activities (Mir and Tiku, 2015; Mulvihill et al., 2016). It has been studied 
in humans and mice and although its bioavailability is low, it accumulates in the liver, 
with lesser amounts in adipose tissue, muscle and plasma of mice fed naringenin (Ke et 
al., 2016; Mulvihill et al., 2016). Therefore, the health benefits of grapefruit consumption 
may be due in part to the molecular effects of naringenin. 
Previous studies in our laboratory have shown that naringenin has lipid-lowering and 
insulin sensitizing properties in cultured hepatocytes (Allister et al., 2005; Borradaile et 
al., 2003a; Borradaile et al., 2003b). In an animal model of obesity and metabolic 
dysfunction, the C57BL/6 or the Ldlr-/- mouse fed a high-fat diet, supplementation of the 
high-fat diet with naringenin prevents weight gain, adiposity, hyperlipidemia, hepatic 
steatosis and insulin resistance, with no effect on caloric intake (Assini et al., 2015; 
Mulvihill et al., 2009). Furthermore, naringenin-supplementation of a high-fat, or a low-
fat, high-sucrose diet was able to prevent cholesterol-induced systemic inflammation, 
metabolic dysregulation and atherosclerosis in Ldlr-/- mice (Assini et al., 2013). These 
studies showed that naringenin increased energy expenditure, enhanced insulin sensitivity 
and increased hepatic fatty acid oxidation, which contributed to reduced adiposity and 
improved metabolic function (Assini et al., 2013; Mulvihill et al., 2009). However, a 
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significant effect of naringenin was prevention of weight gain, which in itself would 
confer metabolic protection. Furthermore, it was unknown if the metabolic protection 
afforded by naringenin only occurred in the context of a high-fat or high sucrose diet. 
Therefore, in the studies described herein we sought to assess the metabolic effects of 
naringenin supplementation in the absence of diet-induced obesity and weight gain. 
Increasing metabolic rate represents a therapeutic strategy for weight loss, reduced 
adiposity and improving other metabolic parameters (Crowley et al., 2002). Analysis of 
body weight allows for an indirect measure of energy expenditure if food consumption is 
unchanged. Caloric intake can be artificially matched by a procedure called “pair-
feeding” (Ellacott et al., 2010; Tschop et al., 2011). In a pair-fed study design, each 
mouse in the experimental group is paired to a mouse in the control group (Ellacott et al., 
2010). The mouse in the group that consumes less food is fed ad libitum and their pair is 
offered the same amount of food the following day, such that caloric intake is identical 
between the two groups. This protocol allows for the dissection of mechanisms 
contributing to reduced body weight and obesity as well as improved metabolic indices 
and whether these are due to reduced caloric intake or enhanced energy expenditure 
(Tschop et al., 2011). 
In the present study, we assessed the effects of naringenin supplementation in a lean 
mouse model, namely Ldlr-/- mice fed a chow diet. Initial experiments showed that 
naringenin supplementation reduced body weight, which was associated with reduced 
food consumption. Subsequent investigation using a pair-feeding protocol revealed that 
naringenin-treated mice still maintained lower body weight, but this was independent of 
caloric intake. Naringenin-treatment decreased adipose tissue mass, reduced plasma 
lipids, and maintained lower blood glucose with reduced plasma insulin. Metabolic cage 
studies, during which mice were fed ad libitum, revealed that naringenin-treated mice had 
increased energy expenditure with no change in ambulatory activity. During the dark 
cycle, the respiratory exchange ratio (RER) was increased, accompanied by increased 
food consumption. Plasma β-hydroxybutyrate and other markers of hepatic fatty acid 
oxidation were increased, indicating that one of the mechanisms underlying the effect of 
naringenin, independent of caloric intake, was increased hepatic fatty acid oxidation.  
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4.2 Materials and Methods 
4.2.1 Animals and Diets 
Male Ldlr-/- mice on a C57BL/6 background (Jackson Laboratory, Bar Harbor, MA), 
were housed in standard cages at 23ºC on a 12 h light and dark cycle. The animals were 
cared for in accordance with the Canadian Guide for the Care and Use of Laboratory 
Animals. All experimental procedures were approved by the Animal Care Committee at 
the University of Western Ontario (protocol # AUP-2016-057). For the initial study, mice 
(10-12 weeks of age, n=12/group) were fed ad libitum a purified rodent chow diet (12% 
of calories from fat, Teklad Global 16% Protein Rodent Diet 2016, Envigo, Madison WI) 
or the same purified rodent chow supplemented with 3% (wt/wt) naringenin (#N5893, 
Millipore-Sigma) for 8 weeks. For the subsequent pair-feeding study, littermate mice, 10-
12 weeks of age (n=12/group), were weighed and paired according to body weight. One 
mouse of each pair was fed ad libitum, the purified rodent chow diet supplemented with 
3% (wt/wt) naringenin for 8 weeks. Body weight and food consumption was measured 
daily. The second mouse of each pair commenced the feeding study 3 days later and was 
fed an identical amount of rodent chow alone as that consumed by its naringenin-treated 
pair. Caloric intake was calculated as weight of food eaten (g) per day multiplied by the 
caloric content of each diet (3.0 kcal/g).  
4.2.2 Blood and Tissue Collection 
Mice were fasted for 6 hours at the start of the light cycle prior to blood taking or 
sacrifice. At sacrifice, animals were anesthetized with Ketamine-Xylazine (100µg/g 
Ketamine hydrochloride, Bioniche Animal Health Canada Inc., Belleville, ON, and 
10µg/g Xylazine, Bayer Healthcare, Animal Health Division, Bayer Inc., Toronto, ON). 
Blood was collected via cardiac puncture in syringes containing 80 µL of 7% Na2-EDTA. 
Blood was centrifuged at 12,000 rpm for 10 minutes at 4ºC to separate the plasma, which 
was stored at -20ºC for further use. Tissue dissections were performed via midline 
incision. Liver, epididymal white adipose tissue (eWAT) and inguinal white adipose 
tissue (iWAT) were removed, weighed and snap frozen in liquid N2 and stored at -80ºC. 
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4.2.3 Metabolic Cage Studies 
Between weeks 6 and 8, energy expenditure, RER, food consumption and locomotor 
activity were assessed using the Comprehensive Laboratory Animal Monitoring System 
(CLAMS; Columbus Instruments, Columbus, OH). Mice were housed in metabolic cages 
with free access to food and water and acclimatized for 24 hours. For the subsequent 48 
hours, every 10 minutes, data on O2 consumption (VO2; mL/h) and CO2 production 
(VCO2; mL/h) were collected. The RER was derived from the ratio of VCO2 to VO2, and 
energy expenditure was determined as (3.815 + 1.232 X RER) X VO2 and expressed as 
kcal/h. Ambulatory activity was measured as infrared beam breaks in the X, Y, and Z 
axis per hour. Accumulated food consumption was measured in grams. Regression plots 
and statistical analyses for metabolic studies were performed in the R programming 
language with CalR, a custom package for analysis of indirect calorimetry using a 
generalized linear model with a graphical user interface (Mina et al., 2018). Total body 
weight was used as the covariate in the analysis. 
4.2.4 Glucose Tolerance and Insulin Tolerance Tests 
A glucose tolerance test was performed following a 6 hour fast by i.p. injection with 15% 
glucose in 0.9% NaCl (1g/kg body weight) (Mulvihill et al., 2009). Blood samples for 
glucose measurements (Bayer Contour Blood Glucose Monitoring System, Bayer 
Healthcare) were taken up to 120 minutes post-injection. An insulin tolerance test was 
conducted following a 5 hour fast by i.p. injection with insulin (0.6 IU/kg body weight; 
Novolin GE Toronto, Novo Nordsik, Cooksville, ON) (Mulvihill et al., 2009). Blood 
samples for glucose measurements were obtained up to 60 minutes post-injection. 
Glucose tolerance was measured as change in blood glucose from baseline and insulin 
tolerance was calculated as a percent change in blood glucose from baseline.  
4.2.5 Tissue Lipids 
Lipids from liver were extracted using the method of Folch et al. from samples stored at -
80ºC, as described previously (Assini et al., 2013; Folch et al., 1957). [Cholesteryl-1,2-
3H(N)]Cholesteryl oleate (PerkinElmer, Guelph, Canada: #NET746L) was added to 
assess recovery. A combined 200 µg/mL triolein and 200 µg/mL cholesterol standard 
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was prepared in isopropanol and aliquoted for standard curves (0-20µg). Samples and 
standards were dried under N2, and a 1% Triton X-100 solution in chloroform was added 
and left at room temperature for 1 hour to solubilize. Samples and standards were dried 
under N2, followed by the addition of deionized water and incubation at 37ºC for 15 
minutes. Samples were analyzed using enzymatic reagents for triglyceride (Roche 
Diagnostics (Laval, Canada): Triglycerides/glycerol blanked, #11877771 216), total 
cholesterol (WAKO Diagnostics (Richmond, VA): Cholesterol E (CHOD-DAOS 
method) #439-17501) and free cholesterol (WAKO Diagnostics: Free cholesterol (COD-
DAOS) method #435-35801). Cholesteryl ester was determined as the difference between 
total cholesterol and free cholesterol. 
4.2.6 Plasma Measurements 
Plasma triglyceride and total cholesterol were measured on a Cobas Mira S autoanalyzer 
(Roche Diagnostics) using calibrators and controls from Roche Diagnostics.(Mulvihill et 
al., 2009) Enzymatic reagents for triglyceride (Roche Diagnostics: triglycerides/glycerol 
blanked #11877771 216) and cholesterol (Roche Diagnostics: Cholesterol CHOD-PAP 
#11491458-216) were used. Fresh-EDTA plasma (50 µL) was separated by fast protein 
liquid chromatography (FPLC) using an AKTA purifier and a Superose 6 column (Assini 
et al., 2013). A constant flow rate of 0.4 mL/min was used to collect 500 µL fractions. An 
aliquot of each fraction was used to measure cholesterol and triglycerides enzymatically 
in both samples and standards on a microtitre plate with added enzymatic reagents 
(Triglyceride: Roche Diagnostics, triglycerides/glycerol blanked #11877771 216 and 
total cholesterol: WAKO Diagnostics, Cholesterol E: (CHOD-DAOS method) #439-
17501). Blood glucose was measured in whole blood using the Bayer Contour Blood 
Glucose Monitoring System (Bayer Healthcare, Etobicoke, Canada) (Mulvihill et al., 
2009). Plasma Insulin (ALPCO Diagnostics, Salem, NH: mouse ultrasensitive ELISA 
#80-INSMSU-E01) was determined in EDTA-plasma samples, stored at -80ºC, by a 
mouse specific ELISA. Homeostasis model assessment of insulin resistance (HOMA-IR) 
was calculated using the following formula as previously described for mice: HOMA-
IR= 26 x fasting insulin level (ng/mL) x fasting glucose level (mg/dL)/405 (Murakami et 
al., 2014). β-hydroxybutyrate (Cayman Chemical #700190, Cedarlane, Burlington, 
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Canada) was measured in EDTA-plasma samples, stored at -80ºC, by colorimetric assay 
as per manufacturer’s instructions. 
4.2.7 Liver Beta Oxidation 
For hepatic fatty acid oxidation, fresh liver (250 mg) was homogenized in 0.1 M 
phosphate buffer, pH 7.2 containing 0.25 M sucrose, 1mM EDTA, 1 mM dithiothreitol, 
and 10 µL/mL of protease inhibitor (Sigma-Aldrich #P8340). Homogenates were 
centrifuged at 1000xg at 4ºC for 10 minutes. 20 µL of supernatant was incubated for 30 
minutes at 37ºC with constant shaking in a 0.1 M phosphate buffer, pH 7.2, containing 
150 mM KCl, 10 mM Hepes, 5 mM Tris malonate, 10 mM MgCl2, 1 mM carnitine, 5 
mM ATP and 2 µCi of [9,10-3H(N)]palmitic acid (PerkinElmer: #NET043001MC)/ 50 
µM unlabeled palmitic acid complexed with 0.15 % fatty acid-free BSA. Reactions were 
stopped with 200 µL of 0.6 N perchloric acid and unreacted fatty acids extracted with 
hexanes. 3H2O in the aqueous phase was measured by liquid scintillation counting (Huss 
et al., 2004; Mulvihill et al., 2009). 
4.2.8 Gene Expression 
RNA was isolated from aliquots of liver using Trizol reagent (Life Technologies, 
Mississauga, Ontario, Canada). Reverse transcription of 1 µg total RNA was performed 
using the High Capacity Reverse Transcription kit (Applied Biosystems, ABI) to yield 
cDNA. Specific mRNA abundances were measured by quantitative real-time PCR (qRT-
PCR) on an ABI ViiA 7 Sequence Detection System (ABI) according to the 
manufacturer’s instructions. In liver, mRNA quantitation for Cpt1a, Pgc1a, and Pnpla2 
was determined. 10 ng samples of cDNA were assayed in triplicate in 10 µL reactions 
using a standard curve qRT-PCR protocol to calculate specific mRNA concentrations. 
Expression levels for each gene were normalized to Gapdh expression in each tissue. All 
primer and probe sets were purchased as TaqMan Assays (ABI).  
4.2.9 Statistical Analysis 
Data is presented as mean ± SEM. Statistical analyses were performed using GraphPad 
Prism version 7.0. A Student’s t-test was used to test for differences between groups in 
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the initial study. Significance thresholds were P values less than 0.05. Significant 
differences are indicated by an asterisk. In pair-fed mice, a paired t-test was used to test 
for differences between groups. Significance thresholds were P values less than 0.05. 
Significant differences are indicated by an asterisk. 
4.3 Results 
4.3.1 Lean Mice Treated with Naringenin Maintain Less Adiposity. 
Previous studies from our laboratory showed that supplementation of a high-fat diet with 
naringenin prevented obesity, insulin resistance, hyperlipidemia and atherosclerosis in 
high-fat fed Ldlr-/- mice (Mulvihill et al., 2009; Mulvihill et al., 2010). To understand the 
metabolic effects of naringenin, we assessed the impact of naringenin supplementation in 
the absence of obesity and metabolic dysfunction. Ldlr-/- mice were fed a regular mouse 
chow or the same chow supplemented with 3% naringenin for 8 weeks (Figure 4.1A). 
Within one week of treatment, mice fed chow supplemented with naringenin had reduced 
body weight (~8%) compared to mice fed chow alone, and this weight differential 
persisted during the 8 weeks of study (Figure 4.1A). Furthermore, after 8 weeks, 
naringenin-treatment had reduced eWAT weight, lower plasma triglycerides, cholesterol 
and insulin, and increased plasma β-hydroxybutyrate (Figure 4.1B-F), indicating that 
naringenin was targeting metabolic indices. However, measurement of caloric intake 
revealed that supplementation of the chow diet with naringenin resulted in a significant 
14% reduction in caloric intake during the initial 3 weeks of study, compared to mice fed 
chow alone (Figure 4.1G). Reduced food consumption persisted for four weeks before 
becoming isocaloric thereafter, resulting in non-different overall food consumption 
between the two groups over 8 weeks (Figure 4.1G). In previous disease regression 
studies in mice, we observed a taste aversion during the transfer of mice from a high-fat 
diet to a naringenin supplemented chow diet (Chapter 3), but not with a naringenin 
supplemented high-fat diet, (Chapter 2; Mulvihill et al., 2009) providing a likely 
explanation for the initial 4-week decrease in caloric intake (Figure 4.1G).  
As metabolic indices can be improved significantly by decreased caloric intake leading to 
weight loss, we attempted to mitigate the difference in food consumption by conducting a  
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Ldlr-/- mice were fed a chow diet with or without 3% naringenin (Nar) for 8 weeks. A; 
Body weight during the 8 weeks of naringenin treatment (n=11-12/group). B; Epididymal 
fat pad (eWAT) weight (n=12/group). C; Plasma triglycerides (TGs; n=11-12/group). D; 
Plasma cholesterol (n=12/group). E; Plasma β-hydroxybutyrate, a ketone body produced 
through fatty acid oxidation (n=10-12/group). F; Fasting plasma insulin (6 h fast) 
(n=11/group). G; Caloric intake over 8 weeks of naringenin treatment and average caloric 
intake (n=11-12/group). Data represent the mean±SEM. * indicates significant difference 
by Student’s t-test (P<0.05).  
  
Figure 4.1 Naringenin Induces Weight Loss and Reduced Caloric Intake in Lean 
Ldlr-/- Mice 
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pair-feeding study. Mice fed chow supplemented with naringenin were fed ad libitum. 
Each mouse was paired by weight with a littermate, who received the same amount of 
chow consumed by their naringenin-treated pair. Food consumption between the two 
groups was essentially isocaloric over 8 weeks (Figure 4.2A). Interestingly, although 
intake was isocaloric, the naringenin-treated mice still achieved a ~10% lower body 
weight by week 3, which was maintained for 8 weeks (Figure 4.2B). The reduction in 
body weight in naringenin-treated mice was associated with a reduction in eWAT by 
69% and iWAT by 71% (Figure 4.2C), suggesting that the majority of weight loss was 
due to a reduction in adiposity. The expression of Ucp1 in brown adipose tissue was 
unaffected, (0.590±0.056 vs. 0.485±0.030, P=0.121) indicating that naringenin 
supplementation did not enhance brown adipose tissue function. 
4.3.2 Naringenin-treated lean mice maintain glucose homeostasis 
with lower plasma insulin 
Naringenin has previously been shown to enhance insulin sensitivity and improve 
glucose homeostasis in high-fat fed Ldlr-/- mice (Assini et al., 2015; Mulvihill et al., 
2009). Therefore, we measured fasting plasma insulin and glucose, and conducted insulin 
and glucose tolerance tests (Figure 4.3). Treatment with naringenin significantly reduced 
fasting plasma glucose by 37% and fasting plasma insulin by 59%, suggesting that treated 
mice were able to maintain lower blood glucose with less insulin (Figure 4.3A,B). 
HOMA-IR calculations showed that naringenin supplementation reduced HOMA-IR 
compared to pair-fed controls (Figure 4.3C). In the glucose tolerance tests, the addition of 
naringenin decreased the area under the blood glucose curves by 25% (Figure 4.3D). The 
insulin tolerance tests demonstrated that naringenin had little additive effect compared to 
chow alone showing that with either diet insulin tolerance remained normal (Figure 
4.3E). 
4.3.3 Naringenin reduces plasma lipids in lean mice 
In addition to its insulin sensitizing effects, naringenin has previously been shown to have 
lipid-lowering effects in vitro and in high-fat diet fed mice in vivo (Borradaile et al., 
2003a; Mulvihill et al., 2009; Mulvihill et al., 2010). Therefore, we measured fasting  
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Littermate Ldlr-/- pairs were separated into two groups. One pair was fed a low-fat chow 
with 3% naringenin (Chow+Nar) and its pair was fed an identical amount of low-fat 
chow alone (Chow) for 8 weeks. A; Caloric intake over 8 weeks and average caloric 
intake (n=12/group). B; Body weight over the 8 weeks of pair feeding (n=12/group). C; 
Weight of the epididymal (eWAT) and inguinal (iWAT) fat pads after 8 weeks of feeding 
(n=12/group). Data represent the mean±SEM. * indicates significant difference by paired 
t-test (P<0.05).  
  
Figure 4.2 Naringenin-Treated Mice Maintain Lower Body Weight Despite 
Isocaloric Intake 
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Littermate Ldlr-/- pairs were separated into two groups. One pair was fed a low-fat chow 
with 3% naringenin (Chow+Nar) and its pair was fed an identical amount of low-fat 
chow alone (Chow) for 8 weeks. A; Fasting blood glucose (6 h fast; n=9-10/group). B; 
Fasting plasma insulin (6 h fast; n=8-10/group). C; Homeostasis model assessment of 
insulin resistance (HOMA-IR) (n=9/group). D; Glucose tolerance test and area under the 
curve calculation (n=8-10/group). E; Insulin tolerance test and area under the curve 
calculation (n=7-9/group). Data represent the mean±SEM. * indicates significant 
difference by paired t-test (P<0.05). N.S indicates non-significance. 
 
  
Figure 4.3 Naringenin-Treated Lean Mice Have Improved Insulin Sensitivity 
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plasma triglycerides and cholesterol as well as their lipoprotein distribution. Treatment 
with naringenin reduced plasma triglycerides by 46% and cholesterol by 23% (Figure 
4.4A,B). This reduction in plasma lipids was within the VLDL fraction for triglycerides 
and the LDL fraction for cholesterol (Figure 4.4A,B), indicating that naringenin reduces 
apoB-containing lipoproteins in the setting of a chow diet. 
4.3.4 Naringenin enhances energy expenditure in lean mice 
In order to understand the mechanisms contributing to reduced adiposity, decreased 
plasma lipids and improved glucose homeostasis in the naringenin-treated pair-fed mice, 
metabolic cage studies were performed. Both groups were fed ad libitum, during the 
metabolic cage studies. Mice consuming chow supplemented with naringenin had 
elevated energy expenditure compared to mice fed chow alone (Figure 4.5A and Figure 
4.6A). Energy expenditure was significantly increased by naringenin only during the light 
cycle, but not the dark cycle, indicating that energy expenditure was significantly 
increased during the sleeping hours of the mice (Figure 4.5A and Figure 4.6B-D). 
Regression curves and generalized linear model analysis generated by CalR that were 
used to correct energy expenditure for differences in body weight are shown in Figure 
4.6. Assessment of ambulatory activity showed no change between naringenin or chow-
fed mice (Figure 4.5B), revealing that the increased energy expenditure was 
metabolically driven during the light cycle. Mice treated with naringenin had 
significantly elevated RER (1.00 vs 0.96), specifically in the dark cycle, the time period 
in which mice are more active (Figure 4.5C). Although we observed no difference in 
ambulatory activity (Figure 4.5B), we did observe a 10% increase in food consumption 
with naringenin supplementation compared to mice fed chow alone, while mice were fed 
ad libitum in the metabolic cages (Figure 4.5D). The increase in food consumption was 
observed primarily in the dark cycle (Figure 4.6D). It is possible that naringenin induced 
a mild starvation response, driving mice to increase caloric consumption. 
4.3.5 Naringenin enhances hepatic fatty acid oxidation  
To assess the underpinnings of the naringenin-induced improvement in metabolic 
parameters, hepatic lipid content and fatty acid oxidation were assessed. The liver of  
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Littermate Ldlr-/- pairs were separated into two groups. One pair was fed a low-fat chow 
with 3% naringenin (Chow+Nar) and its pair was fed an identical amount of low-fat 
chow alone (Chow) for 8 weeks. A; Fasting plasma triglycerides (TGs) and their 
distribution amongst circulating lipoproteins as determined by FPLC (n=12/group). B; 
Fasting plasma cholesterol and its distribution amongst circulating lipoproteins (n=8-
10/group). VLDL; very low-density lipoproteins, LDL; low-density lipoproteins, HDL; 
high density lipoproteins. Data represent the mean±SEM. * indicates significant 
difference by paired t-test (P<0.05).  
  
Figure 4.4 Naringenin-Treated Lean Mice Have Reduced Plasma Lipids 
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Littermate Ldlr-/- pairs were separated into two groups. One pair was fed a low-fat chow 
with 3% naringenin (Chow+Nar) and its pair was fed an identical amount of low-fat 
chow alone (Chow) for 8 weeks. Mice were put in metabolic cages from weeks 6-8 and 
indirect calorimetry was performed. A; Energy expenditure and average energy 
expenditure in both the light and dark cycles (n=7/group) as determined by the 
generalized linear model (GLM) using total body mass as a covariate; * indicates 
significant difference (P<0.05). Regression curves and GLM analysis generated by CalR 
are shown in Figure 4.6. B; Ambulatory activity and average ambulatory activity in both 
the light and dark cycles (n=8/group). C; Respiratory exchange ratio (RER) and average 
RER in both the light and dark cycles (n=8/group). D; Accumulated food intake in mice 
fed ad libitum and average daily food intake (n=8/group). Data represent the mean±SEM. 
* indicates significant difference by paired t-test (P<0.05). N.S indicates non-
significance. 
  
Figure 4.5 Naringenin-Treated Lean Mice Have Enhanced Energy Expenditure 
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Littermate Ldlr-/- pairs were separated into two groups. One pair was fed a low-fat chow 
with 3% naringenin (Chow+Nar) and its pair was fed an identical amount of low-fat 
chow alone (Chow) for 8 weeks. Mice were put in metabolic cages from weeks 6-8 and 
indirect calorimetry was performed. A; Regression curve showing relationship between 
full day average energy expenditure and total body weight. B; Regression curve showing 
relationship between light cycle average energy expenditure and total body weight. C; 
Regression curve showing relationship between dark cycle average energy expenditure 
and total body weight. D; Generalized linear model (GLM) analysis results. Values 
shown are P values. * indicates P<0.05. Mass indicates an interaction of total mass. 
Group indicates an interaction of treatment group (Chow vs. Chow+Nar). 
  
Figure 4.6 Regression Curves for Generalized Linear Model Analysis of Energy 
Expenditure 
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naringenin-treated mice weighed less (7%) (Figure 4.7A). Compared to mice fed chow 
alone, naringenin-treated mice had similar hepatic cholesterol, but showed a trend to 
reduced hepatic triglyceride content (12%) (Figure 4.7B,C). This may account for the 
modest reduction in liver weight. Previously, in the setting of a high-fat or a high-sucrose 
diet, we demonstrated that naringenin enhanced hepatic fatty acid oxidation (Mulvihill et 
al., 2009). Therefore, we measured plasma β-hydroxybutyrate and assessed hepatic fatty 
acid oxidation ex vivo (Figure 4.7D,E). Plasma β-hydroxybutyrate was increased 38% in 
mice fed chow supplemented with naringenin compared to mice fed chow alone, 
suggesting enhanced hepatic fatty acid oxidation (Figure 4.7D). Alternatively, there was 
no effect of naringenin supplementation on hepatic fatty acid oxidation measured ex vivo 
(Figure 4.7E). To try and understand this discrepancy in results, we examined the 
expression of genes involved in hepatic fatty acid oxidation. In liver, the mRNA 
expression of Pgc1a and Cpt1a, were increased 47% and 15% (trend), respectively in 
naringenin-treated mice (Figure 4.7F,G). Furthermore, the expression of the lipolysis and 
fatty acid mobilization gene Pnpla2 (adipose triglyceride lipase (ATGL)), was increased 
33% by naringenin treatment (Figure 4.7H). Collectively, this suggests that naringenin 
enhanced hepatic fatty acid oxidation in this lean mouse model.  
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Littermate Ldlr-/- pairs were separated into two groups. One pair was fed a low-fat chow 
with 3% naringenin (Chow+Nar) and its pair was fed an identical amount of low-fat 
chow alone (Chow) for 8 weeks. A; Liver weight at sacrifice (n=12/group). B; Hepatic 
total cholesterol (n=9-10/group). C; Hepatic triglycerides (n=12/group). D; Plasma β-
hydroxybutyrate, a ketone body produced through fatty acid oxidation (n=10-11/group). 
E; Liver fatty acid oxidation determined ex vivo (n=12/group). F-H; Hepatic gene 
expression normalized to Gapdh for (F) Pgc1a (n=11/group) (G) Cpt1a (n=11/group) and 
Pnpla2 (n=11-12/group). Data represent the mean±SEM. * indicates significant 
difference by paired t-test (P<0.05). N.S indicates non-significance. 
  
Figure 4.7 Naringenin-Treated Lean Mice Have Increased Hepatic Fatty Acid 
Oxidation 
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4.4 Discussion 
The majority of weight-loss and metabolism-targeted drugs are investigated in the setting 
of diet-induced obesity. When a primary effect of the drug is identified as weight loss, it 
is important to determine if this is a consequence of decreased caloric intake, increased 
activity, enhanced metabolism or a combination of these factors. The data described in 
the present study demonstrates that naringenin supplementation in lean, pair-fed Ldlr-/- 
mice induced lower adiposity, reduced plasma lipids, and enhanced insulin sensitivity 
with isocaloric food intake and unchanged physical activity. In lean mice fed ad libitum, 
naringenin supplementation increased energy expenditure and promoted a mild starvation 
response resulting in increased food consumption. Naringenin had no effect on hepatic 
lipids, but increased plasma β-hydroxybutyrate, and the hepatic expression of Pgc1a and 
Pnpla2 suggesting enhanced fatty acid mobilization and oxidation, which may underlie 
the increased energy expenditure and decreased adiposity. 
Several studies have characterized the effects and mechanism of therapeutic compounds 
in both lean and obese models. Nobiletin is another citrus-derived flavonoid that has been 
examined in animal models of obesity and metabolic dysfunction, showing similar effects 
to naringenin in preventing obesity and metabolic syndrome (He et al., 2016; Mulvihill et 
al., 2011). Although very similar to naringenin in obese models, nobiletin had no effect 
on body weight or glucose metabolism when supplemented to a chow diet in lean mice 
(He et al., 2016), suggesting the metabolic effects of nobiletin were dependent on the 
consumption of a high-fat diet. Another study investigating a polyphenol-rich cranberry 
extract supplemented to both a high-fat or regular chow diet in C57Bl/6J mice revealed 
that the outcome differed, depending on the background diet (Anhe et al., 2017). The 
polyphenol extract had no effect in chow-intervened mice but reversed hepatic steatosis 
and improved insulin resistance in high-fat fed mice, again suggesting that the effects of 
the cranberry extract were dependent on high-fat feeding. These reports contrast the 
observations described in the present study. In lean mice, naringenin maintained the 
majority of its metabolic effects that were observed previously in obese mouse models, 
demonstrating that naringenin has the ability to improve metabolic parameters, even in 
the absence of adiposity or a high-fat diet. 
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The effects of naringenin in pair-fed mice were similar to those fed a high-fat diet, albeit 
of a smaller magnitude. Mice fed the high-fat diet supplemented with naringenin had a 
significantly reduced rate of body weight gain compared to mice fed the high-fat diet 
alone (Assini et al., 2015; Mulvihill et al., 2009). Although pair-fed mice had isocaloric 
intake, naringenin-treatment maintained a lower body weight compared to lean mice fed 
chow alone. In both models, naringenin treatment reduced plasma triglycerides and 
cholesterol, and maintained lower blood glucose with reduced plasma insulin. In 
metabolic cage studies, baseline energy expenditure and RER was lower in the high-fat 
fed mice compared to the chow fed mice (Assini et al., 2013; Mulvihill et al., 2009). 
However, irrespective of the baseline diet, supplementation of naringenin elevated energy 
expenditure and RER in both lean (present study) and obese models (Mulvihill et al., 
2009). In the high-fat fed mice, the RER results suggested that mice increased the 
proportion of carbohydrate compared to fat utilized for energy production and in the 
present study the increase in RER was associated with an increase in consumption of 
carbohydrate-rich chow. The only major difference detected was in the hepatic effects of 
naringenin. In the high-fat fed mice, naringenin increased hepatic fatty acid oxidation and 
significantly reduced hepatic triglycerides and cholesterol (Mulvihill et al., 2009). In the 
present study, liver lipids were not significantly changed and we were unable to detect a 
difference in fatty acid oxidation measured ex vivo. Interestingly, we did detect a 
significant increase in plasma β-hydroxybutyrate, a ketone produced through fatty acid 
oxidation, in response to naringenin treatment in the lean mice. Furthermore, hepatic 
expression of Pgc1 and Pnpla2 were elevated with naringenin treatment, suggestive of 
fatty acid mobilization and oxidation. It is possible that liver lipid levels were below a 
critical threshold in lean mice whereby hepatic lipid stores were not further affected by 
naringenin, but dietary or adipose tissue lipids were oxidized, increasing the production 
of ketones. Furthermore, this could explain the significantly smaller inguinal and 
epididymal adipose tissue depots. Lipid flux from adipose tissue is increased during 
fasting or starvation and could fuel naringenin-induced hepatic fatty acid oxidation 
(Degrace et al., 2007). Previous studies have shown that muscle can ‘substrate steal’ to 
fuel enhanced fatty acid oxidation and this may also be possible in the liver (Weinstock et 
al., 1997). This would result in less substrate for hepatic VLDL production leading to 
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decreased plasma lipids, consistent with the hepatic effects of naringenin observed in the 
setting of a high-fat diet (Assini et al., 2013; Mulvihill et al., 2009). Similar to these 
differential hepatic effects, a study investigating green tea extract reduced hepatic 
steatosis in a mouse model of obesity, but not in a lean model suggesting that there might 
be a minimum hepatic triglyceride content, independent of changes in hepatic fatty acid 
oxidation (Bruno et al., 2008).  
This is the second study in which we observed an increase in food consumption, detected 
via metabolic cages, in naringenin-treated mice.(Chapter 2) In both studies, the increase 
in food consumption was undetectable in standard caging because it was small 
(~0.5g/day), although it was statistically significant. Over time, this could lead to excess 
caloric accumulation. However, the increased caloric intake was more than compensated 
for by elevated hepatic oxidation and enhanced energy expenditure, without change in 
physical activity and argues for a molecular mechanism that targets hepatic metabolism, 
rather than a neuroendocrine or satiety mechanism for weight loss and metabolic 
improvements. This appears to be an uncommon mechanism for a weight-loss 
therapeutic. Many drugs that target metabolism and weight-reduction promote appetite 
suppression and reduced food intake through altering hypothalamic, leptin, and 
mesocorticolimbic dopamine system signaling (Saltiel, 2016). Furthermore, other 
therapeutics that work by promoting increased energy expenditure do so by enhancing the 
thermogenic capacity of brown or beige adipose tissue without effect on food intake. The 
results of the present studies and our previous studies suggest that it is unlikely that 
naringenin works through either of these mechanisms.(Chapter 2; Mulvihill et al., 2009) 
In lean chow-fed mice, naringenin stimulated a small increase in food intake, rather than 
appetite suppression and no evidence of adipose tissue browning has been consistently 
detected. Collectively, this suggests an alternative and novel mechanism by which 
naringenin enhances weight loss and improves metabolic function. 
In conclusion, we have shown that in lean, pair-fed Ldlr-/- mice, naringenin 
supplementation causes mice to maintain a lower body weight due to reduced adiposity. 
Furthermore, naringenin reduces plasma triglycerides and cholesterol, enhances insulin 
sensitivity, and increases energy expenditure, while promoting a mild increase in caloric 
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consumption. Mechanistically, naringenin increased the hepatic expression of Pgc1a and 
Pnpla2, and increased plasma levels of β-hydroxybutyrate, suggesting increased hepatic 
fatty acid mobilization and oxidation, a response central to metabolic protection. These 
studies highlight the therapeutic potential of naringenin and suggest that this flavonoid 
maintains significant metabolic properties in the absence of obesity or a high-fat diet.  
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Chapter 5  
5 Discussion 
5.1 Summary 
Cardiovascular disease due to accelerated atherosclerosis is the primary cause of death in 
patients with metabolic syndrome and type 2 diabetes, and represents the leading cause of 
morbidity and mortality worldwide (Olshansky et al., 2005). Despite many successes in 
risk reduction due to the development of pharmacological therapies, most notably statins, 
cardiovascular disease in Canadians continues to rise (Lee et al., 2009). Many patients are 
unable to meet cholesterol-lowering targets, and statins are ineffective against other 
atherogenic dyslipidemias and in mitigating additional atherosclerosis risk factors such as 
obesity, insulin resistance and monocytosis (Musunuru, 2010). Therefore, novel 
therapeutics are highly sought after.  
In this thesis, I investigated two naturally-derived citrus flavonoids, naringenin and 
nobiletin, as novel therapeutics for metabolic syndrome and cardiovascular disease. 
Previous work in our laboratory had shown that these compounds have significant lipid-
lowering and insulin sensitizing properties in vitro and in vivo, leading to 
atheroprotection in vivo (Allister et al., 2005; Borradaile et al., 2003a; Borradaile et al., 
2003b; Mulvihill et al., 2009; Mulvihill et al., 2011; Mulvihill et al., 2010). However, the 
ability of citrus flavonoids to reverse existing metabolic dysfunction and atherosclerosis 
had not been investigated. In Chapter 2 of this thesis, I investigated the capacity of 
naringenin or nobiletin, when supplemented to a high-fat diet, to reverse existing obesity, 
insulin resistance, dyslipidemia and atherosclerosis in Ldlr-/- mice with pre-existing 
metabolic dysfunction and intermediate atherosclerosis. For the first time, I demonstrated 
that both flavonoids completely corrected obesity and insulin resistance, and improved 
lipid parameters by more than 50%. Although metabolic parameters were improved, they 
were not completely corrected and atherosclerotic plaques in the aortic sinus continued to 
grow. Although plaques in flavonoid-treated mice were the same size as controls, they 
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were characterized by beneficial changes in morphology and increased stability, 
consistent with regression. 
The capacity of naringenin to improve atherosclerotic plaque morphology lead me to 
investigate the ability of naringenin to reverse metabolic dysfunction and to induce 
plaque remodelling in a more aggressive model of atherosclerosis regression in Chapter 
3. Ldlr-/- mice with diet-induced obesity, metabolic syndrome and atherosclerosis were 
switched to a chow diet supplemented with naringenin. In this model of regression, I 
showed for the first time that intervention by the addition of naringenin to chow resulted 
in an enhancement in the correction of dyslipidemia, insulin resistance, obesity and 
monocytosis. Furthermore, naringenin reduced lesion size, decreased lesion macrophage 
content and increased markers of lesion stability such as smooth muscle cells, compared 
to intervention with chow alone, characteristics consistent with lesion regression. Lesion 
regression was attributed to enhanced correction of metabolic indices, a reduction in 
blood monocytes and attenuated bone marrow myelopoiesis, all of which could be 
causative in enhancing atherosclerosis regression compared to intervention with the chow 
diet alone.  
The metabolic improvements with naringenin compared to chow intervention alone in 
Chapter 3 suggested that naringenin may have metabolic effects in the absence of high-
fat feeding or obesity. Therefore, in Chapter 4 I investigated the effects of naringenin 
supplementation in lean, chow-fed mice. I found that despite isocaloric intake, lean mice 
treated with naringenin maintained lower body weight, reduced adiposity, enhanced 
insulin sensitivity and lowered plasma lipids. Investigating this mechanistically, I found 
that naringenin enhanced hepatic fatty acid oxidation and increased energy expenditure 
during both the light and dark cycles, which were not associated with increased 
ambulatory activity. Furthermore, the mice treated with naringenin had significantly 
elevated RER and food intake during the dark cycle, when mice are more active. Coupled 
with the increase in energy expenditure, this suggests that the mice treated with 
naringenin may have consumed more to try and compensate for a mild starvation 
response induced by naringenin supplementation. In spite of increased caloric intake in 
naringenin-treated mice, these mice still displayed improved metabolic indices.  
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Collectively, the results described in this thesis add to the growing body of evidence that 
citrus flavonoids have marked lipid-lowering and insulin-sensitising effects (Table 5.1). 
Additionally, these citrus compounds are efficacious enough such that treatment with 
either naringenin or nobiletin is able improve or reverse existing metabolic disease and 
atherosclerosis in two dietary intervention models. Furthermore, they retain metabolic 
effects in the absence of obesity or high-fat feeding. The studies outlined in this thesis 
underscore the potential therapeutic utility of naringenin and nobiletin in the treatment of 
obesity, metabolic syndrome, and atherosclerosis.  
5.2 Effects of Naringenin or Nobiletin on Plaque Cells 
In both models of intervention (Chapter 2 and Chapter 3), flavonoid treatment resulted in 
varying levels of improvement in aortic sinus atherosclerosis. In Chapter 2, where 
flavonoids were added to the HFHC diet, lesions were characterized by continued 
growth, but changes in the composition were readily apparent, including reduced 
macrophage content, diminished necrotic core size and attenuated apoptosis. However, 
there was no effect on lesion smooth muscle cells or collagen content in this model. In 
Chapter 3, where flavonoids were added to the chow diet, lesions were smaller compared 
to intervention with chow alone, with more robust improvements in morphology 
including reduced lesion macrophages and increased smooth muscle cell content. The 
reduction in plaque size and the favourable changes in lesion morphology and 
composition could be due to metabolic improvements, direct effects on cells within the 
lesion or both. The studies described in this thesis were not designed to determine the 
mechanistic contribution of each of these aspects of flavonoid treatment on 
atherosclerotic lesion improvement. Both studies showed correction or reversal of 
metabolic indices, but this does not negate the possibility of flavonoid-mediated effects 
on vascular and plaque cells. 
Studies in tissue culture have shown that citrus flavonoids can have an effect on lesional 
cells such as macrophage and smooth muscle cells. In elicited peritoneal macrophages 
from Ldlr-/- mice fed a high-fat, high cholesterol diet, supplementation with naringenin 
reduced macrophage cholesteryl ester content and significantly reduced the expression of 
Tnfa, Ccl2 and Ccl3 (Assini et al., 2013). In cultured J774A.1, incubation with nobiletin  
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HFHC Intervention Chow Intervention Lean Pair-Fed
Reduced Weight Reduced Weight Reduced Weight
Reduced Adiposity Reduced Adiposity Reduced Adiposity
Enhanced Insulin 
Sensitivity
Enhanced Insulin 
Sensitivity
Enhanced Insulin 
Sensitivity
Improved Plasma 
Lipids
Reversed Plasma 
Lipids
Improved Plasma 
Lipids
Improved Hepatic 
Steatosis
Reversed Hepatic 
Steatosis
Hepatic Lipids 
Maintained
Increased Energy 
Expenditure --
Increased Energy 
Expenditure
Improved 
Atherosclerosis
Regressed 
Atherosclerosis --
Table 5.1 Summary of Thesis Findings 
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significantly reduced the uptake and degradation of acetylated LDL, as shown by reduced 
cholesteryl ester mass and cholesterol esterification (Whitman et al., 2005). In 
lipopolysaccharide-stimulated J774A.1 macrophage, treatment with nobiletin reduced 
inflammatory cytokine expression (Lin et al., 2003). The incubation of vascular smooth 
muscle cells isolated from thoracic aortas of mice with naringenin reduced TNFα-
stimulated migration and proliferation (Chen et al., 2012). Collectively, these studies 
suggest that there may be a beneficial effect of naringenin or nobiletin directly on plaque 
and vascular cells in vivo in the context of atherosclerosis. 
The studies described in this thesis were not able to dissect the relative contributions of 
flavonoid-mediated metabolic reversal compared to direct plaque cell improvements to 
atherosclerosis regression. Future studies could address the effects of citrus flavonoid-
treatment on plaque cells in vivo in Apoe-/- mice fed a chow diet, which develop lesions 
spontaneously, or Apoe-/- mice fed the high-fat diet because these mice do not develop as 
severe metabolic dysfunction as Ldlr-/- mice fed the high-fat diet (Getz and Reardon, 
2016). Citrus flavonoid intervention in these models may yield novel insight into the 
effects of flavonoids on lesion cells or metabolic indices contributing to atherosclerosis 
plaque regression. 
5.3 Naringenin Supplementation and Atherosclerosis 
Regression 
Atherosclerosis regression is process by which established atherosclerotic plaques are 
remodelled, leading to contraction in plaque size and increased features of plaque 
stability (Moore et al., 2013). Recent advances in the development of murine models of 
atherosclerosis regression have expanded our understanding of processes that govern 
atherosclerosis regression. The majority of studies that have investigated processes that 
direct atherosclerosis regression have been done in surgical models and models with 
some form of genetic manipulation altering lipoprotein metabolism (Feig et al., 2011; 
Potteaux et al., 2011; Reis et al., 2001; Van Craeyveld et al., 2011). Importantly, these 
models used aggressive plasma lipid-lowering to drive atherosclerosis regression in the 
mouse. Few atherosclerosis studies have been carried out assessing pharmacological 
methods for inducing atherosclerosis regression. Furthermore, even fewer 
207 
 
pharmacological regression studies have been conducted on the background of dietary 
intervention (Hewing et al., 2013; Huang et al., 2017; Zimmer et al., 2016).The studies 
described in this thesis investigated the capacity of citrus flavonoids to induce regression 
in two different dietary intervention mouse models. In Chapter 2, I investigated the 
ability of naringenin and nobiletin to induce regression of established lesions in Ldlr-/- 
mice that continued to consume a high-fat diet. I showed that citrus flavonoids had no 
significant effect on lesion size, but significant reduced lesion macrophages, maintained 
more smooth muscle cells in the plaque and reduced necrotic core size, suggesting 
enhanced plaque stability. In Chapter 3, I investigated the ability of naringenin to 
enhance regression of established lesions in Ldlr-/- mice that had switched to a chow diet. 
The addition of naringenin to a chow diet reduced lesion size, reduced macrophage 
content, and increase lesion smooth muscle cells compared to intervention with chow 
alone, suggesting enhanced atherosclerosis regression.  
The results from both these studies suggest that certain metabolic effects of flavonoid 
supplementation are more critical to atherosclerosis regression. In the high-fat 
intervention model, insulin resistance and obesity were completely corrected by twelve 
weeks intervention, however modest hyperlipidemia, hepatic steatosis and monocytosis 
persisted. In the chow intervention model, improvements in obesity, insulin resistance, 
hyperlipidemia and monocytosis were enhanced by naringenin compared to chow 
intervention alone. Thus, hyperlipidemia and monocytosis were corrected to a greater 
extent in the chow intervened model compared to the high-fat intervened model. This 
suggests that complete correction of hyperlipidemia and reduced monocytosis is critical 
to atherosclerosis regression. In Chapter 2, after 12 weeks flavonoid-intervention, 
hyperlipidemia and hepatic steatosis were only corrected by ~50%, and monocytosis was 
maintained at baseline levels. These incomplete corrections may have slowed 
atherosclerosis lesion regression. It is possible that a longer intervention time is needed to 
completely correct hyperlipidemia and reduce monocytosis, which may significantly 
enhance the regression of plaques in the high-fat fed intervention model. Studies with 
longer intervention times would help address this question. 
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5.4 Effect of Naringenin and Nobiletin on Macrophage 
Polarization 
Macrophages are a heterogeneous and plastic population of cells that exist across a 
spectrum, but can be basically classified into M1 and M2 macrophages (Moore et al., 
2013). Simplistically, M1 macrophages are pro-inflammatory and associated with plaque 
progression and M2 macrophages are thought to be anti-inflammatory and involved in 
wound-healing, repair and atherosclerosis regression. In Chapter 2, I measured the 
expression of genes associated with macrophage polarization in the whole aorta. Aortic 
inflammatory markers were reduced in flavonoid-treated mice, although there was no 
effect on markers of regression such as Ccr7 and Abca1expression with naringenin or 
nobiletin treatment. This suggests a reduction in M1 pro-inflammatory macrophages but 
the results are inconclusive in terms of enrichment of lesions with M2 macrophages. It is 
possible that because gene expression was measured in the whole aorta, which 
encompasses plaque cells as well as unaffected vascular cells, that small effects in plaque 
macrophage phenotype were masked by gene expression of other cells in the 
homogenate. Many studies in atherosclerosis regression have characterized macrophages 
during atherosclerosis regression using laser capture microdissection to assess 
macrophage phenotype (Feig et al., 2011; Feig et al., 2012; Trogan et al., 2006). Future 
experiments could address macrophage polarization in the flavonoid-treated mice, 
confirming that the molecular changes in the plaque are consistent with the 
morphological changes characteristic of plaque regression. 
5.5 Limitations of Murine Atherosclerosis 
In both Chapter 2 and Chapter 3 of this thesis, the morphology of the atherosclerotic 
plaques was characterized histologically in the aortic sinus of mice. This is a site of 
significant atherosclerosis development in mice and using the leaflets of the aortic valves 
as anatomical landmarks, allows for the consistent assessment of lesion morphology 
(Whitman, 2004). However, this analysis presents several limitations. Firstly, this is not 
the same anatomical location of atherosclerosis development in humans and therefore 
may present some limitations regarding translatability of these results to humans. In 
humans, atherosclerosis predominantly develops in the coronary arteries, where complete 
209 
 
artery occlusion or plaque rupture can result in myocardial infarction (Liao et al., 2015). 
Larger animal models can develop coronary atherosclerosis such as pig or rabbit models, 
however these models are expensive and require specific expertise and handling (Burke 
et al., 2018; Liao et al., 2015). A few new models of coronary atherosclerosis have been 
established, which may be useful in studying flavonoid-treatment on coronary 
atherosclerosis. SR-B1 deficient mice on either an Apoe-/- or Ldlr-/- background develop 
occlusive coronary atherosclerosis and have recently been used to evaluate 
pharmacological therapies (Braun et al., 2002; Fuller et al., 2014; Yu et al., 2018).  
A second limitation in the analysis of atherosclerosis in the aortic sinus is that plaque 
cells lose and gain expression markers within the developing lesion, resulting in the 
misidentification of the origin of cells within the plaque (Allahverdian et al., 2018). 
Smooth muscle cells can lose expression of smooth muscle α-actin and acquire the 
expression of CD68, meaning they can be misidentified as macrophages using 
immunohistochemistry. It will be important to define changes in plaque composition in 
order to confirm the capacity of flavonoids to induce regression and enhance plaque 
stability for translatability to humans and to further elucidate the in vivo effects of 
flavonoid-treatment on specific plaque cells. A mouse model has recently been developed 
that employs lineage-tracing technology to fluorescently tag SMCs so that SMCs within 
the plaque can be identified, even if they lose expression of smooth muscle α-actin or 
gain expression of CD68 (Shankman et al., 2015). Intervention studies in this lineage-
tracing model would allow us to confirm and further elucidate the flavonoid-induced cell-
specific improvements in plaque morphology. 
Mice are inherently resistant to atherosclerosis because they have high HDL cholesterol 
and no CETP activity (Guyard-Dangremont et al., 1998). Therefore, to study 
atherosclerosis, genetic manipulation is required. Ldlr-/- and Apoe-/- mice are the most 
common mouse models of atherogenesis. These mice have either delayed clearance of 
VLDL/LDL or delayed clearance of chylomicron remnants resulting in an accumulation 
of atherogenic lipoproteins in the circulation (Getz and Reardon, 2016). This presents a 
limitation in studying drugs that target CETP activity and LDLR activity. Naringenin has 
previously been shown to increase LDLR expression in cultured human hepatocytes, 
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which may facilitate increased clearance of apoB-containing lipoproteins (Borradaile et 
al., 2003b). The studies described in this thesis were unable to test this effect and novel 
mouse models of atherosclerosis are required to test this effect in vivo. 
5.6 Naringenin and Monocytosis 
Monocytosis and increased inflammation are independent risk factors for atherosclerosis 
(Hilgendorf et al., 2015). Therefore, in the context of atherosclerosis regression, reducing 
monocytosis and myelopoiesis has therapeutic implications. In Chapter 2 of this thesis, I 
showed that the citrus flavonoids, naringenin, prevented any further increase in blood 
monocytes, specifically Ly6Chi monocytes, driven by continued high-fat diet feeding. 
There was no effect on Ly6Clo monocytes or neutrophils. In the bone marrow, there was a 
trend to reduced hematopoietic progenitor populations, which could contribute to the 
reduced monocyte levels in the circulation. In Chapter 3 of this thesis, I showed that 
naringenin reduced blood monocytes, both Ly6Chi and Ly6Clo monocytes, as well as 
neutrophils in the circulation compared to mice intervened with a chow diet alone. In the 
bone marrow, there was a significant reduction in hematopoietic progenitor populations 
and monocyte and myeloid progenitor cells, which likely contributed to the reduced 
circulating levels.  
The results from these two chapters provide some new insights into the effects of 
flavonoids on monocytosis and atherosclerosis regression. Firstly, the differences in 
effect between flavonoid supplementation to a high-fat diet or to a chow diet, highlight 
the concept that the reduction in monocytosis appears to be driven by changes in 
metabolic risk factors for monocytosis. Hyperlipidemia, hyperglycemia and obesity have 
all been shown to induce myelopoiesis and elevate blood monocytes, potentiating their 
atherogenic risk (Murphy et al., 2011; Nagareddy et al., 2014; Nagareddy et al., 2013). 
The impact of naringenin intervention on monocytosis and myelopoiesis were much 
greater in the chow-fed model, reflecting the more significant reductions of 
hyperlipidemia, hyperglycemia and obesity compared to the naringenin-HFHC model.  
In order to support flavonoid therapeutic utility, the investigation of monocytosis and 
myelopoiesis in the pair-fed mice described in Chapter 4 may provide further mechanistic 
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insight. Pair-feeding studies of monocytosis in chow-fed mice supplemented with 
naringenin could confirm whether naringenin’s effects on monocytosis is due to a direct 
effect on myelopoiesis or is secondary to improvements in myelopoietic risk factors. This 
could be achieved because there is no metabolic stimulus for monocytosis in the pair-feed 
mice because these mice lack hyperglycemia, dyslipidemia and obesity. Furthermore, 
Ldlr-/- mice fed chow have previously been shown to have lower blood monocytes 
compared to mice fed the high-fat diet (Murphy et al., 2011). This experiment would also 
be important in assessing the safety of the mechanism through which naringenin reduces 
blood monocytes as a basal level of circulating monocytes and neutrophils is required to 
elicit an immune response (Karsunky et al., 2002). It might also be advantageous to 
examine naringenin supplementation in the Apoe-/- mouse model of atherosclerosis on 
both a chow and high-fat diet. Apoe-/- mice develop more severe monocytosis, in part due 
to the deficiency of ApoE in the myeloid cells (Murphy et al., 2011). Studies in Apoe-/- 
mice may also allow for the dissection of naringenin’s direct effect on monocytosis, 
compared to its effect through improved adiposity and/or and insulin resistance. 
However, the results from this proposed study would have to be interpreted carefully 
because Apoe-/- mice on a chow diet have increased plasma cholesterol compared to Ldlr-
/- mice fed a chow diet (Getz and Reardon, 2016; Murphy et al., 2011). 
Secondly, the results from Chapter 2 and 3 suggest that reduced circulating monocytes 
are contributing to the reduction in macrophage content within the plaques in both 
models of intervention. However, we have not completed monocyte trafficking 
experiments in flavonoid-treated mice to elucidate the contribution of monocyte 
recruitment, macrophage egress, or macrophage proliferation within the plaques, which 
would help to validate this hypothesis (Llodra et al., 2004; Potteaux et al., 2011; Robbins 
et al., 2013; Tang et al., 2015). Future experiments could determine the effect of 
flavonoids on parameters of monocyte/macrophage trafficking, as well as proliferation, 
within the plaque. 
5.7 Mechanism of Action of Naringenin or Nobiletin 
Both naringenin and nobiletin have biologically significant metabolic effects. Studies 
have identified that both naringenin and nobiletin are insulin sensitizers and stimulate 
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insulin signalling in cultured hepatocytes, but activation is independent of insulin 
receptor, or insulin receptor substrate phosphorylation (Allister et al., 2005; Borradaile et 
al., 2003b; Mulvihill et al., 2011). Furthermore, naringenin and nobiletin increase Pgc1- 
and Cpt1-induced hepatic fatty acid oxidation and reduce Srebp1c-medicated hepatic 
lipogenesis, mechanisms confirmed in Chapters 2, 3 and 4 of this thesis. However, the 
upstream mechanism governing these effects has remained elusive. Experiments in 
cultured hepatocytes suggests that naringenin or nobiletin do not activate PPARα, 
PPARγ, or PPARβ/δ. Furthermore, although exogenous Fgf21 has similar effects to 
naringenin when administered to mice, the effects of naringenin are not mediated through 
Fgf21, as evidenced by significant metabolic protection in high-fat fed Fgf21-/- mice 
treated with naringenin (Assini et al., 2015). Additionally, the effects of naringenin are 
not likely mediated through leptin, as naringenin maintains efficacy in the leptin-deficient 
Ob/Ob mouse model of obesity (Assini et al., 2015). In terms of nobiletin’s mechanism 
of action, recent studies in our laboratory have investigated the activation of the energy 
sensor, AMP-activated protein kinase by nobiletin in high fat diet-fed AMPK β1 
knockout mice (essentially liver-specific AMPK-deletion), acetyl-CoA carboxylase 1 and 
2 double knock-in mice (prevents ACC activation by AMPK) and adipose tissue-specific 
knockout of AMPK β1 and β2 (prevents β-adrenergic stimulation of adipose tissue fatty 
acid mobilization). Studies in all three models demonstrated that nobiletin still protects 
against metabolic dysregulation and obesity, despite AMPK deficiency (unpublished 
observations).  
One possible mechanism that was investigated in Chapter 2 of this thesis was the 
browning of white adipose tissue as an explanation for the prevention of obesity as well 
as metabolic dysregulation. We measured the expression of genes associated with 
browning in the inguinal white adipose tissue, epididymal adipose tissue and brown 
adipose tissue. In both studies, no consistent change was observed in the expression of 
Ucp1, Pdk4, Cidea and Ppara, which are markers that have previously been shown to be 
responsive to beta-adrenergic stimulated browning of white adipose tissue (Mottillo et al., 
2016). In weight-cycling mice, treatment with a combination of apigenin and naringenin 
prevented the exacerbated rebound in body weight in mice re-challenged with a high-fat 
diet after a period of chow-induced weight loss (Thaiss et al., 2016). These effects were 
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attributed to an increase in Ucp1 expression in brown adipose tissue and an increase in 
energy expenditure. Although I did observe an increase in energy expenditure in 
naringenin-treated mice in Chapter 2 and 4, I did not observe an increase in brown 
adipose tissue Ucp1 in either model. It is possible that the increase in Ucp1 expression 
was specific to apigenin in the weight-cycling studies.  
Another possible target or regulator of the flavonoids effect in the liver is ATGL. ATGL 
is the first lipase in the hydrolysis of triglycerides and is the rate limiting step in the 
catabolism of triglycerides to diacylglycerides (Lass et al., 2011). An interesting role for 
ATGL in the liver has been recently characterized (Ong et al., 2011). Increased ATGL 
activity increased hepatic fatty acid oxidation, through increased expression of Ppara and 
its target genes, and this effect was independent of PPARα agonism. Alternatively, sirtuin 
1 (SIRT1) deacetylase activity is positively regulated by ATGL resulting in increased 
expression of Pgc1a and PPARα regulated target genes (Khan et al., 2015). In Chapter 3 
and 4, I showed that naringenin increases hepatic mRNA levels of ATGL (Pnpla2). 
Furthermore, other polyphenolic compounds such as resveratrol have been shown to 
increase SIRT1 activity (Allard et al., 2009). This suggests that it may be possible that 
naringenin or nobiletin increase the mobilization and oxidation of fatty acids through 
ATGL activity. Future experiments in mice using an adenovirus encoding mouse ATGL 
short hairpin RNA to knockdown the expression of ATGL in the liver would help to 
address this hypothesis.  
5.8 Naringenin-Mediated Increase in Food Consumption 
An unexpected but consistent result in Chapter 2 and Chapter 4 was that in metabolic 
cage studies, nobiletin (Chapter 2) and naringenin (Chapter 2 and 4) promoted a modest 
increase in food consumption. The increase in food consumption was small (~0.5 g/day) 
but significant, and was observed in the setting of both a high-fat diet and a chow diet. 
Over time, this could accumulate to become significant caloric excess, however this was 
mitigated by a concomitant increase in energy expenditure and hepatic fatty acid 
oxidation. Food consumption can be influenced by changes in behaviour, energy balance 
and satiety (Ellacott et al., 2010). Evidence in this thesis suggests that citrus flavonoids 
do not affect behaviour or satiety. The prevention of weight gain coupled with increased 
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food intake and no change in ambulatory movement points towards a molecular 
mechanism that targets metabolism. One possibility is that the addition of naringenin may 
promote a mild starvation response in response to increased hepatic fatty acid oxidation 
(Cahill, 2006). In order to mitigate this mild starvation response, the mice consume more 
calories, specifically in the dark cycle when they are active. 
5.9 Intervention Models for Studying Drugs 
The large majority of pre-clinical studies designed to investigate novel drugs and 
compounds to treat obesity, metabolic dysfunction and atherosclerosis have been tested in 
prevention models (Baylis et al., 2017). Fewer studies have investigated therapeutics in 
an intervention model. The majority of atherosclerosis studies in mice are designed so 
that the therapeutic is administered at the same time as the disease stimulus, the high-fat 
diet in the case of metabolic dysfunction and atherogenesis. However, this does not 
model how these diseases would be treated clinically, and this may partially explain the 
lack of translatability for many therapeutics developed in this pre-clinical model. The 
protocol of intervention studies in this thesis were modelled after studies in the literature 
(Anhe et al., 2017; Ke et al., 2016; Ke et al., 2015). A 12-week high-fat, high cholesterol 
induction period was followed by a 12-week period of intervention with flavonoid 
supplementation. In Chapter 2, twelve weeks intervention with the addition of flavonoids 
to a high-fat diet was sufficient to attenuate weight gain, reverse obesity and normalize 
insulin tolerance, but moderate hyperlipidemia and hepatic steatosis persisted, and there 
was no attenuation of atherosclerotic plaque size. In Chapter 3, twelve weeks intervention 
with the addition of naringenin to a chow diet rapidly reversed weight gain and metabolic 
improvements were enhanced compared to chow alone, leading to significant 
atherosclerosis regression. Specifically, in the chow intervention model, obesity, 
hyperlipidemia and hepatic steatosis were corrected to a greater extent than in the high-
fat-fed intervention model. This suggests that a longer intervention time may be required 
to achieve reversal of these disorders in the background of continue high-fat feeding. 
Future studies with different induction and intervention durations would be able to test 
the therapeutic limits of the flavonoids on metabolic disorders in intervention models.  
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5.10 Final Conclusions 
A substantial amount of preclinical work shows that citrus flavonoids significantly 
prevent hyperlipidemia and metabolic dysregulation thereby contributing to the 
prevention of atherosclerosis. However, their ability to correct established obesity, 
metabolic dysfunction and induce atherosclerosis regression had not yet been 
investigated. The studies described in this thesis have addressed this gap in knowledge by 
providing evidence and molecular insight into how treatment with citrus flavonoids can 
reverse metabolic dysfunction, and contribute to the regression of atherosclerosis. 
Specifically, studies in Chapters 2-4 of this thesis demonstrate the capacity of naringenin 
or nobiletin to: 1) reverse established obesity, attenuate metabolic dysregulation and 
promote plaque remodelling in an intervention model in which mice continued on a high-
fat diet; 2) induce atherosclerosis regression and enhance metabolic improvements to a 
greater extent in mice with established atherosclerosis intervened with a chow diet 
supplemented with naringenin, compared to chow alone, and 3) to enhance metabolic 
improvements in lean, pair-fed mice, independent of a high fat diet or obesity. 
Collectively, the studies in this thesis highlight the therapeutic utility of the citrus 
flavonoids, naringenin and nobiletin, and provide novel insights into the treatment of 
obesity, dyslipidemia, insulin resistance, hepatic steatosis and atherosclerosis. 
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